Theranostic applications of fluorescent liquid crystalline nanoparticles by Meli, Valeria
Università degli Studi di Cagliari 
DOTTORATO DI RICERCA 
Scienze e Tecnologie Chimiche 
Ciclo XXVIII 
TITOLO TESI 
THERANOSTIC APPLICATIONS OF  
FLUORESCENT LIQUID CRYSTALLINE NANOPARTICLES 
Settore/i scientifico disciplinari di afferenza 
CHIM/02 
Presentata da: Valeria Meli 
Coordinatore Dottorato:  Prof. Mariano Casu 
Tutor: Dott. Sergio Murgia 
Esame finale anno accademico 2014 – 2015 
List of articles 
This thesis is based on the following papers, referred to by Roman numerals in the text. The papers are appended at the end of the thesis. 
I. Drug-Loaded Fluorescent Cubosomes: Versatile Nanoparticles for Potential Theranostic Applications. S. Murgia, S. Bonacchi, A. M. Falchi, S. Lampis, V. Lippolis, V. Meli, M. Monduzzi, L. Prodi, J. Schmidt, Y. Talmon, C. Caltagirone, Langmuir, 2013, 29, 6673-6679. 
II. Cancer-Cell-Targeted Theranostic Cubosomes. C. Caltagirone, A.M. Falchi, S. Lampis, V. Lippolis, V. Meli, M. Monduzzi, L. Prodi, J. Schmidt, M. Sgarzi, Y. Talmon, R. Bizzarri, S. Murgia, Langmuir 2014, 30 (21), 6228–6236. 
III. Cubosome formulations stabilized by a dansyl-conjugated blockcopolymer for possible nanomedicine applications. S. Murgia,  A. M. Falchi, V. Meli, K. Schillén, V. Lippolis, M. Monduzzi, A. Rosa, J. Schmidt, Y. Talmon, R. Bizzarri, C. Caltagirone,  Colloids and Surf. B: Biointerfaces, 2015, 129, 87–94. 
IV. Docetaxel loaded fluorescent liquid crystalline nanoparticles for cancer theranostics. V. Meli, C. Caltagirone,  A. M. Falchi, V. Lippolis, M. Monduzzi, M. Obiols-Rabasa, A. Rosa, J. Schmidt, Y. Talmon, S. Murgia,  Langmuir, 2015, 31 (35), 9566-9575. 
V. Solvatochromic fluorescent BODIPY derivative as imaging agent in camptothecin loaded hexosomes for possible theranostic applications. C. Caltagirone, M. Arca, A. M. Falchi, V. Lippolis, V. Meli, M. Monduzzi, T. Nylander, A. Rosa, J. Schmidt, Y. Talmon, Sergio Murgia, RSC Adv., 2015, 5, 23443–23449. 
VI. Effects of monoolein-based cubosome formulations on lipid droplets and mitochondriaof HeLa cells. A. M. Falchi, A. Rosa, A. Atzeri, A. Incani, S. Lampis, V. Meli, S. Murgia, Toxicol. Res., 2015, 4, 1025-1036. 
VII. Monoolein-based cubosomes affect lipid profile in HeLa cells. Rosa, S. Murgia, D. Putzu, V. Meli, A. M. Falchi, Chem. Phys. Lipids, 2015, 191, 96-105.  VIII. Near infra-red fluorescent cubic liquid crystalline nanoparticles for optical imaging applications in vivo. S. Biffi, L. Andolfi, C. Caltagirone, C. Garrovo, A. M. Falchi, V. Lippolis, A. Lorenzon, P. Macor, V. Meli, M. Monduzzi, M. Obiols-Rabasa, L. 
Petrizza, L. Prodi, A. Rosa, J. Schmidt, Y. Talmon, S. Murgia, submitted to Langmuir, 2016. 
  
  
 
TABLE OF CONTENS 
ABSTRACT .............................................................................................................. 1 
1. SURFACTANTS AND SELF-ASSEMBLY .................................................. 2 
1.1. THE PACKING PARAMETER (P) .................................................................. 4 
2. LIQUID CRYSTALLINE PHASES ............................................................... 5 
2.1. LAMELLAR PHASES (L) .............................................................................. 6 2.2. HEXAGONAL PHASES (H) ........................................................................... 7 2.3. CUBIC PHASES (I,V) ................................................................................... 7 2.4. SPONGE PHASES (L3) .................................................................................. 8 
3. LIQUID CRYSTALLINE NANOPARTICLES ............................................ 9 
4. MONOOLEIN ................................................................................................ 10 
4.1. MO/W PHASE DIAGRAM........................................................................... 11 4.2. APPLICATIONS OF MO ............................................................................. 13 
5. SOFT MATTER AND DRUG DELIVERY ................................................ 13 
6. THERANOSTIC ............................................................................................ 17 
6.1. IMAGING MODALITIES .............................................................................. 18 6.1.1. Magnetic Resonance Imaging (MRI) .............................................. 18 6.1.2. Radionuclide-based imaging (PET and SPECT) ............................ 19 6.1.3. Computed tomography (CT) ........................................................... 19 6.1.4. Ultrasound imaging (US) ............................................................... 19 6.1.5. Optical imaging (OI) ...................................................................... 20 6.2. TARGETING STRATEGIES .......................................................................... 21 6.2.1. Passive targeting ............................................................................ 21 6.2.2. Active targeting .............................................................................. 22 
7. CUBOSOMES AND HEXOSOMES: A STATE-OF-ART ........................ 24 
CONCLUSIONS ..................................................................................................... 32 
REFERENCES ....................................................................................................... 34 
ACKNOWLEDGMENTS ...................................................................................... 44 
 
 
Introduction 
Valeria Meli PhD Thesis A.Y. 2014-2015  1 
 
Abstract 
Lipid liquid crystalline nanoparticles can find application as nanocarriers in several 
fields of the daily life but, very likely,  the pharmaceutical arena is the most relevant. 
Indeed, several problems encountered in drugs administration (e.g. critical side-
effects from antitumor drugs) require alternative, less invasive, but simultaneously 
efficient therapeutic routes to be explored. Novel fields of personalized 
nanomedicine are developing in this direction. One of the most interesting is 
theranostic, which calls for the design of platforms capable of combining therapeutic 
and diagnostic functionalities. 
In this optic, we explored the potential of monoolein-based cubosomes and 
hexosomes as nanocarriers for theranostic purposes. Our work focussed on the 
design of lipid nanoparticles able to deliver antineoplastic drugs and imaging probes 
for fluorescent optical in vitro and in vivo imaging. We developed cubosome 
formulations loaded with antineoplastic drugs and useful for the fluorescence 
imaging of cells. Such formulations were also actively targeted to cancer cells and 
coupled with a NIR-emitting fluorophore, which was the promise for in vivo 
applications. We also investigated hexosomes with encouraging results 
encapsulating in their lipid matrix a BODIPY derivative with solvatochromic 
properties, helpful for the understanding of the dye localization. 
Importantly, we reported (manuscript submitted) the first proof-of-principle for in 
vivo fluorescence optical imaging application using monoolein-based cubosomes in 
a healthy mouse animal model.  
Finally, since relatively little is known about the interaction of cubosomes with 
biological systems, their effects on lipid droplets, mitochondria and lipid profile of 
HeLa cells were deeply studied. 
This thesis is divided in two main parts. The introduction section reports on the 
essential background of the research field, and it is followed by the publications 
(published or submitted) resulting from these three years of work. 
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1. Surfactants and self-assembly 
Surfactants are among the most versatile products of the chemical industry. They 
appear in a wide variety of everyday products such as the motor oils used in 
automobiles, pharmaceuticals, cosmetics, detergents or in industrial products, such 
as drilling muds used in prospecting for petroleum, or flotation agents used in 
beneficiation of ores. 
The ability of surfactant molecules to act as detergents was known for centuries, but 
the mechanism through which they remove the dirt was clarified in the last century 
only when scientists started to become aware of surfactant self-assembly. Indeed, the 
first idea of a surfactant aggregate dates back to the work of J.W. McBain who, in 
1913, suggested the existence of colloidal ions in sodium palmitate solutions.1 
The word surfactant derives from the contraction of the term surface-active agent 
and indicates a substance that, if present at low concentration in a system, is able to 
modify to a certain degree its surface or interfacial free energy by simply adsorption.  
Molecularly and structurally speaking surfactants consist of two different moieties: 
the lyophobic (hydrophobic) one, with very little attraction for the solvent (water), 
and the lyophilic (hydrophilic) one, with strong attraction for the solvent (water). 
This peculiar molecular organization is known as amphiphilic structure, and a 
practice way to quantify this duality is the hydrophilic-lipophilic balance (HLB), a 
number ranging between 1 and 40: the larger this number, the higher the 
hydrophilicity of the surfactant considered. Usually the hydrophobic group is a 
long-chain hydrocarbon residue, and less often a halogenated or oxygenated 
hydrocarbon, or siloxane chain, while the hydrophilic group is an ionic or a highly 
polar neutral group. 
Depending on the nature of the polar group the surfactants can be classified as 
anionic, cationic, zwitterionic and non-ionic.2 Some examples of each class are 
reported in figure 1. 
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Figure 1.  Examples of surfactant molecules. 
The amphiphilic nature of these molecules gives them a range of properties strongly 
connected with two key phenomena: adsorption at interfaces and self-assembly in 
solution. 
The adsorption at interfaces is responsible for applications in processes such as 
detergency, wetting, spreading and stabilization of particles, droplets and bubbles in 
dispersions, emulsions, and foams. The self-assembly in solution underpins the 
formation of nanoscale structures like micelles, microemulsions, and liquid crystals 
and molecular organizations easily found in biological contexts. The driving force 
for this phenomenon is the hydrophobic effect, which acts to minimize the interface 
between the hydrocarbon tails of the amphiphile, and the surrounding polar solvent.  
For most surfactants aggregation occurs at a specific concentration known as the 
Critical Micelle Concentration (CMC), which is the lowest concentration at which 
aggregation in bulk solution can take place. The reason for such phenomenon is that 
at some critical level (related primarily to the hydrophobicity of the surfactant tail 
groups), it is more favourable for the surfactant tails cluster together, thus 
minimizing unfavourable contacts with solvent molecules. Upon reaching CMC a 
clear break in properties such as adsorption, surface tension or conductivity, occurs, 
and any further addition of surfactants will just increase the number of micelles.3 An 
opposite situation should also be considered, that is the reverse self-assembly in an 
apolar solvent. In this case the polar heads are buried inside the aggregate thus 
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avoiding any contact with the bulk, while the hydrophobic tails protrude outwards of 
the aggregate.    
1.1. The Packing Parameter (P) 
Micelles are the simplest self-assembled structures but, at concentration higher than 
the CMC, other and more topologically/morphologically complex aggregate 
structures may become favoured, such as elongated micelles (termed “rodlike” or 
“wormlike” depending on the length, see figure 2c), and other liquid crystalline 
phases. The interplay of weak interactions (between surfactant head groups, tail 
groups, and the solvent), and geometric factors, drives the propensity to form 
different phases and structures in solution.3  
 
Figure 2. Structure of direct (a), inverted (b) and rod-shaped (c) micelles. 
Concerning the geometric factor, between the 70s and the 80s was introduced by B. 
Ninham and J. Israelachvili the first conceptual idea of the surfactant shape 
parameter, known as  packing parameter  P:4,5 
ܲ =  ௩௔௟                                   Eq. 1.1 
where v and l are respectively the volume and the length of the tail group, while a is 
the cross-sectional area of the head group. This simple factor represents the driving 
input for the spontaneous curvature of the polar-apolar interface (H) and allows 
predicting, with certain precision, which type of self-assembled aggregate will be 
formed (see table 1.1). 
 
 
(a) (b) (c)
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Table 1.1 Molecular shapes and relative association structures of surfactants. 
Packing shape Packing parameter (P) Phase formed Lipid examples CONE         
 
<1/3 (spheres) 
 
Lysophospholipids (e.g. LPC, LPE, etc.)   
TRUNCATED CONE 
 
1/3 – 1/2 (rods, lamellar, flexible bilayers, vesicles)  
Free fatty acids (e.g. oleate, stearate, etc) and double-chained lipids with large head group areas and fluid chains    
CYLINDER 
 
~ 1 (lamellar, planar bilayers)  
Double-chained lipids with small head group areas, anionic lipids and saturated chains   
INVERTED TRUNCATED CONE 
 
>1 (hexagonal HII,micellar reverse) 
 
Double-chained lipids with small head group areas, non-ionic lipids and polyunsaturated chains   
 
H is strictly correlated to P: for P < 1 the curvature H will be positive, for P = 1 H 
will be equal to zero, and for P > 1 H will be negative and inverted phases are 
favoured. 
2. Liquid crystalline phases 
When a sufficient number of micelles is formed in solution, they start to pack 
together (in spite of the loss of entropy) in a number of geometric arrangements 
strongly dependent upon the shape of the surfactant involved. The result of these 
arrangements are mesophases characterized by long-range orientation or translation 
a
l v
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order typical of solid crystals, and by a mobility typical of liquids. Such mesophases 
are known as liquid crystalline phases. The short-range disordered arrangement of 
the molecules confers to liquid crystals a viscosity sometimes pretty considerable.2 
Liquid crystals can be grouped into two subclasses: the thermotropics and the 
lyotropics. In both cases molecular shapes and mutual interactions between 
molecules are the driving forces for self-assembly process, but, in the thermotropic 
liquid crystals, the phase transitions are dependent solely from temperature, while, in 
the lyotropic liquid crystals, the concentration of the surfactant (and hence the 
presence of the solvent) is also strictly crucial.  
An overview of lyotropic liquid crystals polymorphism is given below. 
2.1. Lamellar phases (L) 
The lamellar phase consists of planar surfactant bilayers stacked in a 1D lattice 
separated by layers of water (figure 3). They constitute the basic building block of 
all biological membranes. These phases are optically anisotropic and birefringent 
and in the polarizing microscope they show mosaic-like patterns.6 Different types of 
lamellar phases, such as Lα, Lβ, Lc have been observed in lyotropic mixtures. The Lβ 
phase differs from the Lα phase for the state of the carbonic chains. Indeed, in the Lα 
phase the hydrocarbon chains are molten, while in the Lβ they are arranged parallel 
to the layer normal. Consequently, the latter looks like a gel, while the former is a 
more fluid phase. The Lc phase presents the chains of the surfactant molecules 
“frozen” into specific lattice sites, making this phase the most ordered of the three 
lamellar phases.7 
 
Figure 3. Schematic representation of a lamellar phase (image from the web). 
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2.2. Hexagonal phases (H) 
The hexagonal liquid crystalline phases consist of a dense packing of cylindrical 
micelles arranged on a 2D hexagonal lattice. Normal (oil-in-water) hexagonal phases 
are denoted by HI, while inverse (water-in-oil) hexagonal phases are denoted by HII. 
In HII phases water is contained within the cylindrical reversed micelles (figure 4). 
The remaining space is occupied by the non-polar chains overlapped in order to 
leave the cylinders close together as much as possible.6 The opposite configuration 
characterizes the HI phases. Under a polarized light microscope hexagonal phases 
exhibit birefringence and their typical optical textures are smoke-like, fan-like or 
mosaic in appearance. 
Figure 4. Schematic representation of an inverted hexagonal phase HII (image from the web). 
2.3. Cubic phases (I,V) 
Two distinct families of cubic phases can be defined: the discrete micellar (I) and 
the bicontinuous (V) both having a 3D lattice arrangement. In the discrete micellar 
phase, micelles are packed on a cubic lattice (face-centered or body-centered), while 
in bicontinuous phase a curved lipid bilayer is extended in the three dimensions. 
Both types may be normal or inverse (II, III, VI, VII).  
Figure 5. The three IPMS surfaces: CG (a), CD (b) and CP (c). Thanks to Prof. Stefano 
Montaldo for the images. 
(a) (b) (c)
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In bicontinuous cubic phase the curved, triply periodic non-intersecting bilayer is 
folded on an infinite periodic minimal surface (IPMS) having an average curvature 
equal to zero everywhere. Such special organization leads to the formation of two 
interpenetrated and disjointed continuous water networks.   
To date, three cubic bicontinuous phases based on three IPMS surfaces have been 
identified: the CP (primitive, Im3m), the CD (diamond, Pn3m) and the CG (gyroid, 
Ia3d), showed in figure 5. The lipid bilayer is centred on the IPMS with the polar 
heads pointing outwards, while the water fills the labyrinth systems on each side of 
the surface. These phases are extremely viscous and optically isotropic, therefore no 
texture is visible through polarized light. The high viscosity is a consequence of the 
lack of shear planes within the structure that would allow a sliding movement.  
2.4. Sponge phases (L3) 
As the bicontinuous cubic phases, the sponge phase (L3) is constituted by a 3D lipid 
bilayer surrounded by two different water channels, with the only difference that the 
sponge phase is less ordered and can be considered to be a melt of the bicontinuous 
one. Figure 6 allows appreciating this difference. 8,9 
With respect to bicontinuous cubic phases, the interface in sponge phases is highly 
flexible and thermal excitations lead to the break-down of the long-range order of 
the channel network so that the interface is no longer arranged on a lattice. Sponge 
phases are characterized by flow birefringence (giving anisotropic optical textures) 
but they are isotropic at rest.6 
 
 
Figure 6. (a) Fragments of a disordered sponge and (b) the ordered Im3m surface morphology.8 
(a) (b)
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2.5. Intermediate phases
The existence of lyotropic phases with lower symmetry than those previously 
described has been widely proved. These phases are sometimes called “intermediate 
phases” and are in the middle of lamellar and bicontinuous phases. They are 
characterized by a smectic stack of “punctured” bilayers, together with an ordered 
arrangement of punctures within each bilayer, giving, like discrete micellar and 
bicontinuous mesophases, 3D lattices. Two polymorphs are known, the “R” 
(rhombohedral, space group R3m), containing a hexagonally close-packed array of 
punctures, and the (body-centred) “T” (tetragonal, space group I422) with a square 
array of punctures. Both mesophases are optically anisotropic.8  
3. Liquid crystalline nanoparticles
The bulk liquid crystalline phases can be fragmented (sometimes literally and 
sometimes just figuratively) in submicron particles thus forming liquid crystalline 
nanoparticles dispersions in excess of water. The result of this process are diluted 
non-viscous aqueous dispersions with internal nanostructure.10  
The simplest and most studied of such structures are the lamellar phase dispersions, 
which include liposomes or, more in general, vescicles. Liposomes consist of 
spherically concentric lipid bilayers (two or more) alternating with water layers, and 
they can be considered as dispersed particles of a Lα phase.11 Liposomes have been 
extensively studied since they were identified and characterized by electron 
microscopy by Bangham in the1960s.12 They are still widely used as a model for cell 
membranes thanks to their 1D lamellar flat structure, which is the most commonly 
observed system in cellular contests. 
Similarly to liposomes, hexosomes (aqueous dispersions of inverse hexagonal 
phase) and cubosomes (aqueous dispersions of a bicontinuous cubic phase) can be 
prepared by dispersion formation in a multiphase region comprising a liquid crystal 
in coexistence with water.13 Within such nanoparticles, the lipid organization and 
dynamic properties of the original non-dispersed phases is retained.14 In 1996 and 
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1997 K. Larsson’s group first published hexosomes’ and cubosomes’ cryo-TEM 
images (see figure 7) .15,16   
 
 
Figure 7. Cryo-TEM images of hexosomes  (a) and cubosomes (b). Reprinted with permission from 
[Langmuir 1997, 13 (6), 6964-6971] © 1997 America Chemical Society.16 
As liposomes, hexosomes and cubosomes are particles with kinetic stability, i.e. 
they need an energetic input to form in excess of water (lyophobic colloids). 
However, lamellar phase is easier to disperse, thanks to the ability of the lamellae to 
bend into a closed structure that avoids the contact between the hydrophobic domain 
and water. Differently, reverse liquid crystalline phases, such as the bicontinuous 
cubic VII and the hexagonal HII, usually show a very limited stability in aqueous 
dispersions due to the boundary conditions imposed on the fragmented crystal.16 
Indeed, to facilitate the dispersion of these phases an additional surface active 
component, which acts as stabilizer, is crucial. This stabilizing agent may be 
inclined to participate in, and sometimes change, the surfactant based liquid crystal 
structure as demonstrate by Landh et al. in 1994.17 Usually such molecules are 
polymeric stabilizers which posses poly-(ethylene oxide) (PEO) moieties, which 
protrude towards the water thus providing steric stabilization. 
4. Monoolein  
Glycerol monooleate, commonly known as monoolein (MO), is a non-toxic clear 
amber or pale yellow waxy paste widely used as emulsifying agent and as food 
additive since the 1950s. From a molecular structure point of view, it consists of a 
hydrocarbon (hydrophobic) chain (oleic acid) attached to the glycerol backbone by 
(a) (b)
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an ester bond. The two remaining hydroxyl groups of the glycerol confer polar 
characteristics to this portion of the molecule. Its oil solubility (MO is totally 
insoluble in water), along with its biocompatibility and biodegradability, make it an 
highly suitable material in food emulsion, in cosmetic and in pharmaceutic 
applications.18 
 
Figure 8. Chemical structure of monoolein (MO). 
4.1. MO/W phase diagram 
MO has self-assembly abilities due to its amphiphilic structure. The hydrophobic 
effect leads, in this case, to a very complex polymorphism in water and thus to a 
very complex MO/W phase diagram. The first construction of such a diagram goes 
back to 1965 by Lutton,19 who built the diagram on the basis of observations from 
polarizing optical microscopy and from the samples consistency. Lamellar, 
hexagonal and cubic phases were in this way named respectively as neat, middle, 
and viscous isotropic phases, while the different types of phase are not 
distinguished. From 1979 until 1983 intensive investigations on this system were 
carried out by Larsson and co-workers20,21 and by Lonlgey and McIntosh,22 
throughout NMR and X-ray diffraction techniques. At this stage the different 
bicontinuous cubic phases were finally identified. 
The first nearly complete MO/W phase diagram was mapped out by Hyde et al. in 
1984.23 The temperature range studied was 20 °C – 110 °C, while the system 
composition range from 0% (w/w) to at least 40% (w/w) in water. In 1996 Briggs et 
al. improved the temperature range going down to 0 °C. They found notable 
agreement with Hyde, except for some significant differences on phases boundaries. 
Furthermore the authors introduced some useful comments on water channel radius 
of Pn3m cubic phase.24  
Finally in 2000 Qiu and co-workers25 extended the temperature range until -15 °C 
and the water content up to 50% (w/w), starting from dry and going to fully hydrated 
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samples. They spent much effort to ensure equilibrium phase behaviour in all the 
temperature range, giving particular attention to sub-zero degrees. By this way it 
was established that phases below 20 °C are metastable, i.e. they are not in 
equilibrium. The phase diagram determined by Qiu et al. is shown in figure 9. 
 
Figure 9. Phase diagram of MO-W system at ambient temperature. Reprinted from Biomaterials, 21, H. Qiu, M. Caffrey, The phase diagram of the monoolein/water system: Metastability and equilibrium aspects, 223-224, ©2000, with permission from Elsevier. 25 
In the lower part of the diagram (low temperatures and low water content) a lamellar 
crystalline region (Lc) can coexist with more than one polymorph. At low water 
content, but higher temperature, the Lc phase melts into a fluid isotropic phase (FI) 
identified in later study as inverse micellar phase (L2). Further increasing the water 
content a lamellar liquid crystalline phase (Lα) takes place, while increasing the 
temperature the Lα phase melts again into the L2 phase. Bicontinuous cubic phases 
are shown at higher water contents in the form of two different type of phases, Ia3d 
(CG, gyroid type) and Pn3m (D, double diamond type), while, increasing the 
temperature from bicontinuous cubic phases, a phase transition occurs into an 
inverse hexagonal phase HII, and into the inverse micellar phase L2 at the end. A 
peculiar characteristic of the MO/W diagram (and of monoglyceride/water systems 
in general) is the liquid crystal + water excess region, were, above a certain 
percentage of solvent, water and a structured phase can coexist separately, thus 
indicating the maximum solubilisation capacity of that phase for water. In particular 
0
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the bicontinuous cubic phase Pn3m can solubilise more water than HII and L2 phases 
(respectively 40%, 25% and 20%).9 
4.2. Applications of MO 
As already hinted in the third paragraph, to date MO find useful application in 
several areas, ranging from pharmaceutics, food, cosmetics and agriculture. The 
reasons of this variety of applications can be find in the physicochemical properties 
of MO, in its high biodegradability and biocompatibility, and in the really significant 
interest over the years towards its phase behaviour. It has been shown to be a 
versatile material since it can be included in many different formulations. 
Pharmaceutical applications of monoolein attracted great attention since it can be 
employed as emulsifier, solubilizer, oral/parenteral/periodontal drug delivery, 
storage system for the protection of macromolecules susceptible to degradation, or 
as colloidal carrier system. Furthermore, thanks to its amphiphilic nature, MO is able 
to deliver both lypophilic and hydrophilic drugs. 
5. Soft matter and drug delivery 
In the lasts decades considerable amount of research effort has been devoted to the 
development of new drugs with the aim to improve therapeutics. Such drugs often 
have an optimum concentration range above which they are toxic and below which 
they are ineffective, and the rapid clearance from the blood circulation, due to their 
low molecular weight (usually under 500 Da), leads to drug concentrations below 
the efficient therapeutic range in a very short time. This unfavourable situation 
brings to a poor pharmacokinetic and an inappropriate biodistribution of the drug 
within the organism. 
Furthermore, the administration of molecularly dispersed drugs (“free drugs”) is the 
reason of an indiscriminate volume distribution of the drug itself with unwelcome 
accumulation in healthy tissues and thus to sometimes severe side effects. Indeed, 
many agents which have been shown to be highly effective in vitro may be relatively 
toxic, or at best ineffective, when administered in vivo.26-28 Moreover a considerable 
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fraction of newly developed drugs has low (or at all) solubility in water and thus it 
would be useless in parenteral administration. 
To date an efficient approach which allows to overcome these problems is the 
encapsulation of drugs in colloidal systems which can act as nanovectors. Such 
strategy implies that the biodistribution of the drug will be determined by that of the 
vector, which will be completely different, mainly because of the size of this 
delivery device, larger than that of the drug itself. To date, a wide variety of 
materials have been used to build nanoparticles for drug delivery, ranging from 
polymers to lipids and also to metals. Some very desirable requirements of such 
materials are biocompatibility and biodegradability, which should underpin their 
“digestion” once administered. The drug release from the matrix may occur either 
via diffusion process (depending upon the geometry, the porosity and the tortuosity 
of the matrix pores) or by its degradation.27 
We will focus particularly on soft materials based nanoparticles, whose components 
can belong mainly to two molecular classes: lipids (like phospholipids and 
glycerides) and polymeric compounds.  
Up to now the less appealing drug delivery technology belonging to soft matter 
consists on micellar systems of small surfactant molecules. This tendency is mostly 
due to their markedly higher CMCs which lead to lower stability of the aggregates at 
high dilution states (those encountered in a hypothetic parenteral administration) and 
thus to shorter retention times of the drug.26,29 
With respect to small surfactant micelles their polymeric counterpart have much 
lower CMCs and lower rate of dissociation, features which make them more suitable 
in drug vectorization.30 Polymeric micelles have dimensions of several tenths of 
nanometres with quite narrow size distribution. Each block of the block-copolymers, 
that constitute these micelles, has a specific role, that can be structural, thus guiding 
the carrier formation, or functional, thus conferring to the aggregate special 
abilities.26 Some examples of block-copolymers used are poly(caprolactone), 
poly(aspartate), and poly(lactate). 
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Close to polymeric micelles are polymersomes, structurally similar to liposomes: 
their bilayered membrane, enclosing an aqueous compartment, allows them to host 
both hydrophilic and hydrophobic drugs.  
Lipids, if compared with small surfactants and polymers, are the most physiological 
option for drug delivery thanks to their biocompatibility and biodegradability. 
Liposomes, hexosomes and cubosomes, already mentioned, are highly appropriate 
for such use. Their corresponding bulk phases (lamellar, reverse bicontinuous cubic 
and reverse hexagonal) have, instead, very limited utilization in the pharmaceutical 
arena because of their high viscosity and difficult handling. As polymersomes, also 
liquid crystalline nanoparticles can deliver both hydrophilic and hydrophobic drugs 
and be extremely stable upon dilution.  
Liposomes are proven candidates for drug delivery and they have already been 
successfully marketed: Doxil, Caelys and Myocet are liposomal systems which are 
used for Kaposi’s sarcoma, ovarian cancer and multiple myeloma.31 A number of 
new liposomal formulations are still involved in pre-clinical and clinical trials. 
With respect to liposomes at least three others abilities may be ascribed to 
hexosomes and cubosomes, making them truly attractive devices in drug delivery 
applications. These are: (i) high mechanical rigidity, (ii) structural stability and  (iii) 
large interfacial surface area per unit of volume. Nevertheless, beyond this 
promising features liposomes, hexosomes and cubosomes suffer of a serious 
drawback, which actually is across-the-board to the most of nanoparticles: they need 
stabilization against the rapid clearance from the bloodstream by plasma proteins, 
and such stabilization is usually achieved with a brush of neutral hydrophilic flexible 
polymers. Most of the times these flexible polymers are poly-(ethylene oxide) (PEO) 
groups protruded outwards of the particles, in the aqueous environment.32 For 
hexosomes and cubosomes the stabilizer is also strictly necessary for their steric 
stabilization against aggregation in aqueous environment. 
Another type of lipid-based drug delivery system is represented by the solid lipid 
nanoparticles (SLN). These particles are made by a core of solid lipids (usually 
glycerides) surrounded by an emulsifier shell that stabilizes the nanocarrier against 
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aggregation phenomena. SLN can mainly deliver hydrophobic drugs into their lipid 
cores.  
 
 
Figure 10. Schematic representation of soft matter nanoparticles for drug delivery. 
At this point, before exploring the basic concepts of theranostic, some attention 
should be paid to nanomedicine definition. From the previous discussion emerged 
that, in the last decades, a great interest was addressed and countless successes were 
achieved in drug delivery applied nanotechnology. Therefore nanomedicine field 
received, and still it is receiving, strong contributions from researchers all over the 
world. It has found large application in the treatment of  critical diseases such 
cancer, neurodegenerative, inflammatory and autoimmune diseases. To date, a very 
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SOFT MATTER
Hard matter and therapeutic applications 
Not only organic and totally biodegradable materials can be employed to produce systems with therapeutic applications. There is a huge research focussed on inorganic nanostructures for therapy, of which magnetic nanoparticles, gold nanoparticles and mesoporous materials constitute the main examples. The presence of a drug is not strictly necessary, for some of these systems, to exert a therapeutic functionality. For instance, the ability of magnetic and gold nanoparticles to produce heat under a specific stimulus (a magnetic field or a laser radiation, respectively) may be useful in cancer treatment by hyperthermia. This is a particular anticancer therapy in which heat is used to induce cell death, when a temperature of at least 42 °C is achieved.102 Differently, mesoporous materials may be drug loaded by means of functionalization of silanol groups present on their surface. This materials are, in fact, made by silica which was previously template by supramolecular assemblies of surfactants.103 
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challenging area of nanomedicine is the
the design of nanocarriers that allow for treatment protocols tailored to each specific
patient. 
6. Theranostic
To face the great incidence of cancer, neurological
the world mortality, new therapeutic and diagnostic strategies are needed, strategies
which could allow for an early detection and treatment.
platform of personalized nanomedicine is developing
It combines in the same entity therapeutic and diagnostic functions
are designed new multi-functional nanoparticles in which the therapeutic and the
diagnostic agents are integrated, instead to be administrated
probes and pharmacologically active molecules (situation in which would be
necessary to take into account their difference
be greatly advantageous if the circulating time and the biodistribution of a
nanomedicine system could be visualized
injection, thanks to the employment of an imagine technique
of imaging agent used.33,34  
Figure 11. Schematic representation of a nanoparticles for theranostic purposes.of Colloid and Interface Science, 393, X. Mulet, B.J. Boyd, C. J. Drummond,c liquid crystalline dispersions, 1
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6.1. Imaging modalities 
In the field of molecular imaging the exploitation of specific molecular probes and 
contrast agents allows for the “visualization, characterization and measurement of 
biological process at molecular and cellular levels in human or other living 
system”.36 Referred to soft matter nanoparticles, the imaging agents, as well as the 
drug, can be included within them or located on their surface.37  
The main imaging techniques include: magnetic resonance imaging (MRI), 
computed tomography (CT), ultrasound (US), radionuclide-bases imaging (positron 
emission tomography, PET, and single-photon emission computed tomography, 
SPECT), and optical imaging (OI). In the following sections each modality will be 
discussed in more detail. 
6.1.1. Magnetic Resonance Imaging (MRI) 
MRI is widely used in hospitals around the word since it received FDA (Food and 
Drug Administration) approval for clinical use. At the basis of this technique there is 
the precession of water hydrogen nuclei if a magnetic field is applied. Following the 
application of radio frequency pulses and magnetic field gradients, the relaxation 
process, through which they return to their original aligned state, can be exploited to 
produce images. The local differences in spin relaxation kinetics along the 
longitudinal (spin-lattice relaxation time, T1) and the transverse (spin-spin relaxation 
time, T2) planes, of the main magnetic field applied, generate the contrast in the 
images obtained. Paramagnetic agents allow for an increasing of this contrast by 
shortening the relaxation parameters T1 and T2. These contrast agents can be tagged 
onto small molecules, macromolecules or nanoparticles. MRI has good spatial 
resolution but suffers from low sensitivities. In the area of soft matter nanoparticles, 
a special role is assigned to the chelates of paramagnetics metals, such as the 
transition element Mn2+ and the lanthanide Gd3+. Examples of biocompatible and 
biodegradable materials employed in the manufacturing of nanoparticles are 
polysaccharides and phospholipids. In polysaccharides, due to the presence of many 
hydroxyl groups it is easy to link Gd3+-chelates through ester bonds.38 Differently, in 
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liposomes constituted by phospholipids, the water-soluble Gd3+-chelates can be 
hosted inside the aqueous interior.39 
6.1.2.  Radionuclide-based imaging (PET and SPECT) 
Both Positron Emission Tomography (PET) and Single Photon Emission Computed 
Tomography (SPECT) imply the use of radiotracer and the detection of γ-rays by a 
camera. Examples of single photons emitter elements are 99mTc, 123I and 111In, while 
examples of positron emitter elements are 18F, 64Cu and 124I. These radioisotopes can 
be used to labelled molecular imaging probes that will be linked to soft matter drug 
delivery systems. The images acquired have a low background signal and need low 
amplification since the γ-rays possess energies in the range of megavolt. SPECT 
radionuclides are simple to prepare, and usually have a longer half-life than those for 
PET. In literature is plenty of examples of soft matter drug delivery system that 
exploit SPECT and PET as imaging modality.40,41 
6.1.3. Computed tomography (CT) 
CT is one of the most used clinical diagnostic tools. It measures the absorption of X-
rays as they pass through the tissues. The different degree of the attenuation from 
tissues, which is at the basis of the images production, depends upon the electron 
density of the tissues themselves.37 
CT contrast agents have, typically, low molecular weight and therefore they suffer 
from a rapid clearance. Thus, nanoparticles containing electron dense elements, such 
as iodine, have been proposed as CT contrast agents. Liposomes containing 
iodinated molecules in high concentration have been formulated.42 
6.1.4. Ultrasound imaging (US) 
US is another very common clinical imaging technique. It is cheap, fast, relatively 
simple and safe. Images are obtained thanks to the back reflection, from internal 
organs, of sound waves produced by a high frequency sound waves emitting 
transducer, placed against the skin.  
Contrast agents, such as gas-filled microbubbles, are used to enhance the ultrasound 
signal. Their major drawback is that they dissolve and collapse within seconds after 
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injection into the blood-stream. Up to now, several strategies have been developed 
to overcome this problem: microbubbles were encapsulated within soft matter 
nanoparticles made by surfactants, lipids or polymers.4344 
6.1.5. Optical imaging (OI) 
OI is a non-ionizing, non-invasive technique that is acquiring great importance in 
early diagnosis and in treatment of specific diseases. It utilizes specific probes that, 
if excited by a radiation, emits light at lower energies than the incident. The 
possibility offered by this imaging modality to avoid ionizing radiations is of crucial 
importance, because allows to expose patients to repeated treatments over time. 
Fluorescence (and phosphorescence) based imaging techniques are very sensitive, 
versatile and easy to use and, remarkably, the instrumentation required is relatively 
cheap (if compared to that of some other imaging techniques). The main problem of 
OI is that, respect to the modalities previous discussed, it suffers from poor 
penetration capacity, caused by attenuation of photon propagation in living tissue. 
Moreover, it has a poor signal to noise ratio due to tissues autofluorescence. These 
not trivial problems can be overcome by using radiations whose wavelength is in the 
NIR region (650-950 nm). In this “biological window” deeper penetration and 
minimization of the background effect can be achieved.45 
Two main kinds of fluorescent imaging may be identified: the first involves imaging 
due to intrinsically fluorescent (bio)chemical species (NADH in tissues or 
chlorophyll in all kinds of plants), the second includes imaging based on samples (or 
cells) made fluorescent for the presence of synthetic fluorescent probes, labels, 
nanoparticles or nanosensors. 
Talking about bioimaging based on synthetic fluorescent probes and nanoparticles, it 
is possible to differentiate between three techniques: i) the most simple concerns the 
use of a strong fluorophore or fluorescent nanoparticles internalized into cells with 
the only aim of make them (or tissues) fluorescents. These fluorophores or 
nanomaterials do not exhibit affinity for any specific site. ii) The second case is the 
“targeted bioimaging”: fluorophores and nanomaterials have been properly 
functionalized with receptors, ligands or antibodies able to recognize their 
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counterparts so that specific domains or sites are detected. iii) The third technique 
requires the use of probes and nanomaterials with sensing capability. By this way 
(bio)chemical species, which are not intrinsically fluorescent, can be imaged.46 
6.2. Targeting strategies  
Among the new personalized strategies for an accurate and early-stage detection of 
diseases there are targeted therapies based on the utilization of passive and active 
methods of accumulation of the bioactive molecules (drugs) in the sites/targets of 
interest. The developing of such approaches should promote an enhanced 
intratumoral drugs concentration, with a consequent limited toxicity to healthy 
tissues.  
6.2.1. Passive targeting 
The volume distribution throughout the body of a molecularly dispersed drug is 
absolutely indiscriminate between healthy and ill tissues. Differently, as already 
mentioned in the fifth paragraph, a drug encapsulated in a nanovector could undergo 
accumulation in the site of interest. Focussing on cancer disease, the first feature of 
nanoparticles that confers them targeting abilities is their size. An ideal window of 
dimensions can be defined by setting the lower size threshold as the minimum size 
required to avoid a rapid clearance from the kidney glomerula, which is 5-6 nm. An 
upper size boundary is harder to specify, but it is mostly determined by the need to 
avoid a rapid elimination by the RES (Reticulo Endothelial System). The RES is 
part of the immune system, and includes phagocytic cells like monocytes and 
macrophages that are localized in the spleen, lymph nodes, and Kupffer cells in the 
liver. Specifically, the smaller the nanomaterials, the harder their elimination by the 
RES. In addition, according to the Enhanced and Permeability Retention (EPR) 
effect, macromolecules and nanoparticles are able to accumulate in tumour tissues 
(at concentrations five to ten times higher than in normal tissue within 1–2 days) 
because of the great permeability of their blood vessels: the altered angiogenesis of a 
tumour mass leads to non-mature, tortuous, and (most important) fenestrated 
vascularisation. These gaps can space from 380 to 780 nm depending on the type of 
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tumour, and, beyond the promoted accumulation in tumour tissues, they lead to an 
increased retention time of macromolecules or nanoparticles once sequestrated 
within the tumour, as consequence of a more difficult extracellular diffusion. To 
date, most drug delivery systems for cancer are being designed based on these 
principles.35,47,48  
6.2.2. Active targeting 
Targeting cancer cells by means the EPR effect is not feasible in all cases because 
the degree of altered angiogenesis can vary with tumour type and status. Active 
targeting is the alternative path to overcoming these limitations. This strategy 
provides for the employment of targeting moieties, attached onto the nanoparticles 
surface, which can induce receptor-mediated uptake of nanoparticles and then drug 
release right inside the target tissue. To achieve a high efficiency of binding and 
internalization of the colloidal dispersions, receptors should be expressed 
exclusively (or at least mostly) on target cells with respect to normal ones. 
When designing the targeting moiety of a nanoparticle several factors need to be 
taken into account. Some of these include the configuration of the targeting 
moieties, where and how they are anchored to the nanovector, their density for unit 
of surface area, and their influence on the stability of the colloidal system.  
Antibodies, peptides, aptamers and small molecules that interact with receptors are 
commonly attached to nanomaterials for active targeting. 
Antibody-based targeting exploits the recognition mechanism between an antigen 
and its antibody to trigger the nanocarrier to the site of interest. In the last decades 
the efficiency of this targeting strategy has been widely demonstrated and chemical 
modifications of monoclonal antibodies (mAbs) have advanced their clinical utility. 
Antibodies are often used as their fragments, however the use of the whole antibody 
with the presence of its two binding sites gives rise to a higher binding activity. A 
further advantage of intact antibodies is their high stability during long-term 
storage.49,50 
Wei and Gao et al. developed multifunctional polymer vesicles formed by carboxy-
terminated poly(-lactic-co-glycolic, PLGA) acid, loaded with magnetic nanoparticles 
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as imaging agent and with docetaxel as chemotherapy agent. They decorated PLGA-
based polymeric nanoparticles with prostate stem cell antigen’s (PSCA, over-
expressed in prostate cancer tissues) antibody as the targeting moiety. Nanoparticles 
designed in such a way facilitated significantly the specific delivery of docetaxel to 
prostate tumor cells.51 
Zhai et al. actively targeted phytantriol-based cubosomes and hexosomes with 
epidermal growth factor receptor (EGFR) antigen binding fragment, via the 
maleimide-thiol reaction.52 They observed the retention of the ligand binding 
affinities to the EGFR target, and the preservation of the size and of the internal lipid 
nanostructure of the particles. 
In spite of the huge effort spent on monoclonal antibodies development they still 
show some limitations: they are large and complex molecules which require a 
noteworthy engineering at molecular level to be effective; they need expensive 
manufacturing and from batch to batch exist significant variations that limit their 
efficiency as targeting molecules.  
Peptides and antibody fragments have been developed to overcome some of these 
shortcomings and are now under clinical development. Due to their small size, low 
immunogenicity, ease of manufacture at small costs, and excellent quality control, 
peptides are very attractive as targeting molecules. Nevertheless they can show some 
drawbacks too, such as low target affinity (with respect to antibodies) and 
susceptibility to proteolytic cleavage.53 
Beyond antibodies and peptides much effort was spent to design targeting agents 
like aptamers. They are small nucleic acid ligands (single stranded DNA, RNA or 
unnatural oligonucleotides) able to fold into unique structures that bind specific 
targets with high affinity and specificity. Furthermore they are non-immunogenic 
and easy to isolate. 
Aptamers can bind a wide variety of targets, such as intracellular proteins, 
transmembrane proteins, soluble proteins and carbohydrates, and some of them have 
also been developed to bind specifically to receptors on cancer cells. 
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Since the smaller the size of the species the more attractive will be its use as 
targeting agent, small molecules such as folic acid and carbohydrates are extremely 
suitable for this task. 
Folic acid has been widely studied as targeting moiety. It is a water-soluble vitamine 
(B6) essential in humans for rapid cell division and growth, especially during 
embryonic development. Folate receptors are homogeneously overexpressed in 
many cancer cells and thus they are able to interact with high affinity with folate 
acid conjugates present onto nanocarriers surface mediating their cellular uptake by 
endocytosis. 
Lectins are carbohydrate-binding proteins, macromolecules that are highly specific 
for sugar moieties (lactose, galactose, mannose). Their presence on cell surface 
membrane represents an interesting opportunity for targeted delivery of 
nanocarriers. However, to compensate for the weak binding affinity of 
carbohydrates, multiple or multivalent molecules should be conjugated to the 
nanocarrier itself.  
7. Cubosomes and hexosomes: a state-of-art 
Some lipids (or lipid mixtures) are able to form lyotropic liquid crystalline structures 
thermodynamically stable in the presence of excess of water. Hexosomes and 
cubosomes are two of the products of the retention of such liquid crystalline 
structures into nanoparticles. Respectively, they consist of 2D inverse hexagonal 
phase or 3D inverse bicontiunuous cubic phase aqueous dispersions. As specified 
earlier, the non-dispersed phases whose they belong to, are very viscous and 
therefore difficult to handle, for example, in intravenous administration.35,54 
Differently, these non-lamellar inverse mesophase possess low viscosity, much more 
suitable for pharmaceutical applications. Compared to liposomes, hexosomes and 
cubosomes show several advantages. Some of them are already reported in 
paragraph 5, but at least another one deserves to be noticed: their internal 
nanostructure permits the loading of different type of molecules, including 
hydrophobic, hydrophilic, and amphiphilic ones (similarly to liposomes) but these 
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agents can be loaded in hexosomes and cubosomes to higher extent because of the 
higher hydrophobic portion per unit of volume with respect to liposomes. This is a 
key advantage for the solubilisation of poorly water-soluble drugs in colloidal 
formulation. Despite these desirable features, drug delivery investigation on 
hexosomes and cubosomes are still in their infancy if compared with liposomes. 
In 1979 Patton and Carey55 observed cubosomes for the first time during fats 
(triglycerides) digestion. In that case the cubic phase was stabilized in presence of 
micellar solutions of bile salts. 
They monitored a fat digestion by means of visible light microscopy, demonstrating 
that the final product of the digestion sequence is a viscous isotropic (non-
birefringent) phase. This phase was hypothesized to be cubic, and composed by a 
MO/W mixture stabilized by a lamellar envelope of bile salt and monoglycerides. 
Larsson in 1989 clarified the structure of those nanoparticles as bicontinuous, and in 
1996 and 1997 his group first published hexosomes and cubosomes cryo-TEM 
images.15,16 Later, in 1999, Baglioni et al. used atomic force microscope to obtain 
the first AFM images of such colloidal dispersions,56 while, investigating the 13C 
NMR relaxation rates of the various MO carbon atoms, Monduzzi et al. found that 
cubosomes retain the lipid organization and the dynamic properties of the original 
bulk (non-dispersed) phases from which they belong to.14 Monoolein, phytantriol, 
monolinolein and monoleiadin is a limited list of the most common lipids with 
propensity to generate lyotropic non-lamellar liquid crystalline phases.57 Anyway, it 
has been taken into account that several variables can determine the arrangement 
adopted by these amphiphiles. Temperature, pressure, purity of lipids used, pH and 
ionic strength may affect the phase behaviour of these systems. The two most 
common used lipids for hexosomes and cubosomes production are MO and 
phytantriol (PHYT), and their phase diagrams were very well explored.25,58 It should 
be noted that the PHYT phase diagram has shown to be sensibly compromised from 
small level of impurities in the lipid.59 
Preparation methods of hexosomes and cubosomes are generally based on a high-
energy emulsification procedure (ultrasonication, high-pressure homogenization or 
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high-speed shearing) and require the presence of a stabilizer. Basically, these 
methods can belong to the bottom-up class or to the top-down one.  
Bottom-up approaches involve the dilution followed by homogenization of the 
mixture of stabilizer and lipid in water. Spicer et al. in 200160 developed a novel 
process for producing cubosomes. The key of this procedure is the inclusion of a 
hydrotrope (molecule with amphiphilic character but incapable of displaying 
surfactant phase behaviour), the ethanol, that exhibits a “salting-in” behaviour by 
increasing the solubility of lipids otherwise insoluble in water. Exploiting both these 
approaches (with or without hydrotrope) the nanoparticles are formed by nucleation 
in the aqueous solution.61–63 It is important to observe that the presence of a 
hydrotrope, besides being useful for the production of attractive nanoparticles 
dispersion, may also represent a problem in more-than-one-component system, since 
the single components may have different solubility in the hydrotrope. Furthermore, 
the presence of a hydrotrope in the final preparation may cause in vivo issues such as 
toxicity. 
First step within the top-down approach is the hydration of the amphiphile. By this 
way its bulk phase is produced, and then significant levels of energy should be 
applied to break it up. The formation of a stable, sub-micron, dispersion of liquid 
crystalline phases is thus achieved with the help of the omnipresent stabilizer agent. 
In principle, the top-down method allows for the entrapment of hydrophilic drugs 
(oligonucleotides, peptides, and proteins) that, otherwise, will be hardly introduced 
throughout the bottom-up approach. An alternative path for introducing water-
soluble additives (such as DNA or RNA), is the addiction of charges in the lyotropic 
liquid crystalline nanoparticles, by the incorporation of ionized lipids. For instance, 
negative or positive charge can be added to nanoparticles through the use of 
phophatidylserine or dioleoyltrime- thylammonium propane (DOTAP) 
respectively.64  
The stabilization of discrete colloidal nanoparticles like hexosomes and cubosomes, 
with the aim of avoiding their aggregation in excess of water, and thus to promote 
their long-term stability, can be achieved by electrostatic or steric effect, or a 
combination of both. Although several stabilizers were investigated over these last 
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decades, which are able to accomplish this role, non-ionic block copolymers are the 
most used to impart steric stabilization even at low concentration. 
In principle, two fundamental features should be considered for the choice of the 
stabilizing agent: the volume and density of the stabilization layer and its adhesion 
strength onto the nanoparticle surface.  The most diffuse molecular moiety chosen 
for this function is poly(ethylene glycol) or poly(ethylene oxide) (PEO), and the 
poloxamer 407 (PEO99–PPO67–PEO99), commercially known as Pluronic F127 is the 
most diffuse block copolymer for this purpose.16,65,66,67 
DSPE-PEG2000,68,69 β-casein,70 hydroxypropyl methyl cellulose acetate succinate 
and poly(ethylene oxide)71 stearate were found to be efficient in stabilizing 
hexosomes or cubosomes.  
A key role of the stabilization layer is to create a stealth barrier able to reduce 
undesirable biological interactions with immune system, responsible for the 
clearance of the nanoparticles. The PEO barrier was discovered to be truly effective 
in reducing the absorption by opsonins (serum protein) by enabling the nanoparticles 
to evade phagocytosis.72 An explanation of such behaviour is that the more 
hydrophilic will be the exposed surface of nanoparticles, the lower will be the 
opsonisation rate.73 
Despite the capability of cubosomes and hexosomes of delivering both therapeutic 
and diagnostic agents,74 the scenario of these lyotropic liquid crystalline 
nanoparticles is still mostly focussed on their characterisation, while investigations 
of their multi-functionality are fully inadequate if compared with those pertaining to 
liposomes. Nevertheless, there are two commercial ventures, Camurus® and 
Phosphagenics®, specialised in the development of lyotropic liquid crystalline 
phases for bioactive delivery.  
The bioactive compound can be loaded in the drug delivery carrier at different stages 
of the preparation, and its localisation will depend on its inherent properties, 
specifically, on its lipophilicity, amphiphilicity, and size. Depending on these 
properties the drug may be located in the water domain, in the lipidic domain or at 
the interface between them.  
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The hydrophilic drugs are hardly loaded in a lyotropic liquid crystalline dispersed 
matrix without considerable modification of the matrix composition itself. Despite 
these complications, Kwon and co-workers in 2010 made attempts in this direction, 
by preparing cubosome formulations for the dermal administration of hinokitiol and 
water soluble extracts of Korean barberry. 75,76  
Because of their difficult administration, poorly water-soluble drugs reached much 
more attention from the drug delivery audience. An interesting example is curcumin, 
a potent therapeutic molecule with antitumor activity, poor bioavailability, pH 
sensitivity, and poor tissue absorption,77 that, similarly to other lipophilic molecules 
of pharmaceutical interest, was successfully encapsulated in hexosomes and 
cubosomes.78 Also oral and ophthalmic administration have been explored for drug 
loaded cubosomes.79–81  
When using a bioactive molecule to be located in the lipid bilayer of liquid 
crystalline nanoparticles, it should be taken into account that these molecules may 
somewhat alter the bilayer curvature and so, to some extent, induce a phase 
change.82 
Loading of proteins and peptides into liquid crystalline phases is a goal of great 
interest in therapeutic and targeting applications. The main problem when using 
these macromolecules is their relatively fragile nature (denaturation events are just 
around the corner), which should be considered during preparation and 
characterization of colloidal dispersions. However, considerable effort has been 
spent in this direction. Angelova and co-workers studied the interaction of 
PEGylated hexosomes with cationic proteins, demonstrating that, depending on 
concentration and amphiphilicity, proteins may lead to either preservation or 
dramatic changes in the inner structure of the hexosomes. From the same group in-
depth investigations were, and still are, focussed on the arena of 
proteocubosomes.83–86 
A crucial part in the design of a lyotropic liquid crystalline nanoparticles, if a 
theranostic use is expected, is their association with a tracking element, useful to 
provide spatial and temporal information about the localisation of the colloidal 
dispersions (both in vitro and in vivo), and to, eventually, allow for an early 
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diagnosis of a disease. As reported in the paragraph 6.1 several techniques, and thus 
several types of imaging agents, are available for this purpose. MRI is a 
non-invasive technique commonly exploited in the clinic, and several times MRI 
contrast agents were loaded into the internal nanostructures of hexosome and 
cubosome nanoparticles. Muir et al. incorporated a nitroxide lipid into the matrix of 
liquid crystal nanoparticles, discovering a great enhancement of relaxivity when a 
Pn3m space group cubic phase is present, if compared with the hexagonal phase that 
appeared at high nitroxide loadings.87 Liu and co-workers incorporate Gd3+-oleate 
into cubosomes to assess their performance.88  
Computed tomography (SPECT/CT) is another attractive imaging technique. 
Nilsson et al. developed PHYT/oleic acid (OA) hexosome radiolabelled via surface 
chelation of technetioum-99m (99mTc).89 
With respect to the imaging techniques discussed above, the field of optical imaging 
by means fluorescent lyotropic liquid crystalline nanoparticles is still in its early life. 
Some examples of such colloidal system, probed with fluorophore, can be found in 
the recent literature. Aleandri et al. developed cubosomes functionalized with biotin 
as target agent and loaded with paclitaxel. Their cubosomes were labelled with a 
hydrophobic fluorescent lipid to follow their cellular uptake in HeLa cells.90 In 2012 
Wu et al. designed odorranalectin targeted cubosomes for brain delivery, and 
labelled them with coumarin-6, a lipophilic fluorophore, to investigate their brain 
distribution in vivo.91 Other fluorescent cubosome dispersions were prepared, but 
none of them were used with theranostic purposes.92–94 A special mention deserves 
an innovative hybrid formulation constituted by hydrophobic Fe3O4 nanoparticles 
entrapped within the lipid matrix of cubosomes, the so-called magnetocubosomes. 
Remarkably authors found that these biocompatible nanoparticles are responsive to a 
low frequency alternating magnetic field, which allows a faster release of model 
drugs confined in the cubic phase.95  
The knowledge of the cytotoxicity of non-lamellar lipid dispersions is a critical point 
when developing these systems for pharmaceutical applications. This aspect may be 
influenced by size, concentration, composition (PHYT-based or MO-based 
nanoparticles), internal phase (hexosomes and emulsified microemulsions seem to 
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induce less cytotoxic activity) and it is strongly dependent on proliferation and 
embryonic origin of the cells chosen for testing. Haemolytic activity and interaction 
with blood component (plasma) were also examined.96–100 
In the light of all these knowledge on lyotropic liquid crystalline nanoparticles, 
collected in decades of dedication from researchers all over the world, we developed 
our colloidal dispersions of MO-based cubosomes and hexosomes. A little amount 
of oleic acid (OA) was employed as additive to induce a phase transition, at room 
temperature, from inverse bicontinuous cubic phase (Pn3m) to inverse hexagonal 
phase (HII) for hexosomes formation. As stabilizer we chose Pluronic F108 instead 
of the widespread Pluronic F127 (see chemical structure in figure 12). It possess a 
number of hydrophilic moieties higher than F127, and a hydrophobic one lower than 
F127, thus, its HLB value is higher than that of F127. Its stabilization power was 
found to be superior to F127 right for this reason.101 
 
 
Figure 12. Chemical structure of Pluronics. 
Thinking about possible applications of hexosomes and cubosomes in the antitumor 
therapy we loaded them with several antineoplastic drugs (structures are reported in 
figure 13) and we labelled them with fluorescent molecules. The latter were, 
sometimes, modified via synthetic approaches with two different goals: i) for a 
better and less invasive encapsulation within the lipid bilayer (which is the case of 
the modification of fluorescein, dansyl and cyanine with long hydrocarbon chains), 
and ii) to avoid, as much as possible, the interactions between the fluoropohore and 
the lipid matrix (which is the case of Pluronic F108-D and F108-R).  
 
F108 F127
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Figure 13. Chemical structure of antitumor drugs used: quercetin (QUE), camptothecin (CPT) and          docetaxel (DTX). 
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Conclusions 
We explored the potential of MO-based non-lamellar liquid crystalline 
nanoparticles, namely cubosomes and hexosomes, as theranostic tools in cancer 
treatments. 
We proved that they allow for the encapsulation of antineoplastic poorly water-
soluble drugs (quercetin, camptothecin, and docetaxel) and that the presence of such 
drugs within the lipid bilayer did not affect the nanostructural and morphological 
characteristics of the nanoparticles. Furthermore, we observed the superior cytotoxic 
ability of docetaxel towards HeLa cells when embedded in the cubosomes matrix 
with respect to its use as a free drug.  
Similarly, we demonstrated that these nanocarriers can be simultaneously coupled 
with fluorescent imaging agents still preserving the original physicochemical 
features of pristine cubosomes and hexosomes nanoparticles. In addition, also the 
photophysical properties of the imaging agents, critical for the fluorescence optical 
imaging, are retained in the colloidal systems. Sometimes, these properties were 
extremely helpful for understanding the fluorophore localization in the nanoparticle 
(solvatochromism).  
In the frame of possible applications in cancer treatments, we made cubosomes and 
hexosomes actively targeted by decorating their surface with folic acid. Thanks to 
this modification the uptake of targeted cubosomes in HeLa cells considerably 
increases with respect to pristine cubosomes. 
A detailed study of changes occurring in HeLa cells, when exposed to treatment 
with MO-based cubosomes, was conducted. Such investigation is of primary 
importance within the context of biomedical applications. It was observed that the 
uptake of cubosome formulations induced modification of the cell lipid profile, lipid 
droplet accumulation, mitochondrial hyperpolarization and mitochondrial ROS 
generation. Remarkably, these modifications did not cause significant toxicity in 
HeLa cells. 
The first proof-of-principle for in vivo fluorescence optical imaging application 
using MO-based cubosomes in a healthy mouse animal model was here successfully 
shown. With the aid of a modified cyanine, we obtained important results about the 
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biodistribution in vivo of cubosomes upon intravenous injection. In particular, we 
noted that the fluorescent cubosomes were rapidly (within six hours) taken up by the 
liver. Furthermore, haemolytic analysis revealed that, at the concentration used for 
the in vivo experiment (about 50 µg/mL of monoolein), the cubosomes formulation 
did not induce lysis of human erythrocytes. 
All these results strongly encourage further investigation of non-lamellar lipid liquid 
crystalline nanoparticles in thereanostic nanomedicine, and for pharmaceutical 
applications in general. 
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ABSTRACT: In this work, monoolein-based cubosomes were
doped with two ﬂuorescent probes, namely, ﬂuorescein and
dansyl, properly modiﬁed with a hydrocarbon chain to increase
their encapsulation eﬃciency within the monoolein palisade. The
same nanocarriers were also loaded with quercetin, a hydro-
phobic molecule with potential anticancer activity. Particularly,
the cubosomes doped with the modiﬁed ﬂuorescein probe were
successfully exploited for single living cell imaging. The
physicochemical and photophysical characterizations reported
here, along with the well-known ability of cubosomes in hosting
molecules with pharmaceutical interest, strongly encourage the
use of these innovative ﬂuorescent nanocarriers for theranostic
purposes.
■ INTRODUCTION
Application of nanotechnology to medicine (nanomedicine)
holds promise to deeply reform the diagnostic and therapeutic
tools available in clinical practice.1,2Indeed, nanotechnology
oﬀers a unique possibility to improve both imaging and drug
delivery techniques. To reach this goal, a myriad of nano-
carriers, belonging to soft and hard matter, have been
engineered and tested for their physicochemical, pharmaceut-
ical, and cytotoxic features. Relevant examples include liposome
formulations,3−6 polymeric,7−11 gold, or iron oxide nano-
particles, as well as dendrimers and quantum dots.12 Nano-
particles were originally developed to transport separately
pharmaceutically active or imaging agents to the pathological
sites with therapeutic or diagnostic scopes. Recently, both of
these aspects were merged into single platforms, thus forming
theranostic nanomedicine, an emerging cross-discipline, where
chemistry, biology, pharmacy, and medicine meet.13 Therefore,
within the same dosage, theranostic nanoparticles may (actively
or passively) deliver both drugs and imaging probes to the site
of disease, overcoming the diﬀerences in biodistribution and
selectivity of these two distinct entities and reducing side
eﬀects.14−20 Although many kinds of nanoparticles have been
proposed for theranostic applications,21−26 cubosomes have
until now been neglected. Cubosomes are lipid-based nano-
particles sterically stabilized by pluronics27−30 that can be
envisaged as aqueous dispersions of bicontinuous cubic liquid-
crystalline phases. Brieﬂy, they are constituted of curved, triply
periodic non-intersecting bilayers folded on an inﬁnite periodic
minimal surface having cubic symmetry and organized to form
two disjointed continuous water channels.31 Cubosomes, which
can be regarded as the nonlamellar analogue of liposomes,
show high mechanical rigidity and structural stability and may
be loaded with both hydrophobic and hydrophilic drugs
(including proteins),32 taking advantage also of their huge
interfacial surface area per unit of volume. Indeed, with respect
to liposomes, cubosomes possess a greater hydrophobic volume
that, in principle, allows encapsulating higher amounts of poor
water-soluble drugs. Moreover, they are mostly prepared using
monoolein, a monolgyceride that can be easily biodegraded by
lipases.33,34 Due to these features, cubosomes are often
suggested as drug delivery systems useful in parenteral
administration (i.e., all routes of drug administration diﬀerent
from mouth).32 However, they possess further appealing
features that could be exploited in theranostic nanomedicine.
Indeed, they are suﬃciently large to avoid a rapid clearance
from the bloodstream while their nanostructure is enclosed
within a PEG corona that, similarly to stealth liposomes, should
protect cubosomes against opsonisation (opsonins are proteins
that bind to foreign particles, allowing phagocytic cell
recognition) and consequent clearance from the bloodstream.12
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With the aim of exploring the potentiality of aqueous
cubosome dispersions for theranostic applications, in this work,
we decorated cubosomes with two modiﬁed ﬂuorophores and
loaded this kind of nanoparticle with a therapeutic dose of
quercetin (3,3′,4′,5,7-pentahydroxyﬂavone). Two commercially
available ﬂuorophores, namely, ﬂuorescein and dansyl, were
functionalized with a C18 hydrocarbon chain to give,
respectively, F1 and F2 (Figure 1). Particularly, quercetin is a
polyphenolic compound widely distributed in plants that,
similarly to many other hydrophobic drugs, has a limited
clinical use due to its poor water solubility with a consequent
very low bioavailability. Quercetin exerts multiple pharmaco-
logical eﬀects. Among these, a potent in vivo antioxidant
activity, induction of apoptosis, modulation of cell cycle,
antimutagenesis, inhibition of angiogenesis, and anti-inﬂamma-
tory eﬀects are well-recognized. Moreover, quercetin is
considered to be an anticancer drug since some studies have
shown its inhibitory eﬀects on tumor growth.35−37
■ MATERIALS AND METHODS
Chemicals. Monoolein (MO, 1-monooleoylglycerol, RYLO MG
19 PHARMA, glycerol monooleate; 98.1 wt %) was kindly provided by
Danisco A/S, DK-7200, Grinsted, Denmark. Pluronic F108 (PEO132−
PPO50−PEO132), quercetin, ﬂuorescein isothiocyanate isomer I (90%),
dansyl chloride (≥95%), octadecylamine (≥99%), sodium sulfate
(≥99.0%), potassium carbonate (99%), acetonitrile (≥99.9%), diethyl
ether (≥99.5%), dichloromethane (≥99%), and tetrahydrofuran
(≥99%) were purchased from Sigma-Aldrich. Distilled water passed
through a Milli-Q water puriﬁcation system (Millipore) was used to
prepare the samples.
Sample Preparation. Cubic phases were prepared by weighing
the appropriate amounts of components (MO, water, quercetin, and
ﬂuorophore) into glass tubes (L ≈ 0.5 cm) that were immediately
sealed, centrifuged at 2300 rpm at 25 °C, and allowed to equilibrate at
25 °C for 1 week. Cubosomes, empty or doped with the ﬂuorophore
molecule, were prepared by dispersing the appropriate amount of MO
in a solution of Pluronic F108 using an ultrasonic processor UP100H
by Dr. Hielscher, cycle 0.9, amplitude 90%, for 10 min. To obtain
ﬂuorescent cubosomes, the ﬂuorophore was dispersed in the melted
monoolein with the help of an ultrasonic bath before dispersion in
Pluronic F108. The sample volume was usually 4 mL with
approximately 96.4 wt % of water, 3.3 wt % of MO, and 0.3 wt %
of Pluronic F108. The percentage of the ﬂuorophore was 2.5 × 10−3
and 2.8 × 10−3 wt % for F1 and F2, respectively. The same procedure
was followed when the ﬂuorescent cubosomes were also loaded with
quercetin. The percentage of added quercetin was 6.4 × 10−6 wt %.
Light Microscopy. The homogeneous liquid-crystalline phases
were observed by optical microscopy (Zeiss Axioplan II) in polarized
light at 25 °C.
Cryogenic Transmission Electron Microscopy (Cryo-TEM).
Vitriﬁed specimens were prepared in a controlled environment
vitriﬁcation system (CEVS) at 25 °C and 100% relative humidity. A
drop of the sample was placed on a perforated carbon ﬁlm-coated
copper grid, blotted with ﬁlter paper, and plunged into liquid ethane at
its freezing point. The vitriﬁed specimens were transferred to a 626
Gatan cryo-holder and observed at 120 kV acceleration voltage in an
FEI Tecnai T12 G2 transmission electron microscope at about −175
°C in the low-dose imaging mode to minimize electron-beam radiation
damage. Images were digitally recorded with a Gatan US1000 high-
resolution CCD camera.
Ultraﬁltration and Dialysis. Ultraﬁltrated cubosomes were
carried out by means of Amicon Ultra 0.5 mL centrifugal ﬁlters (RC
100 kDa, 7000 rpm/10 min). After quercetin was loaded, cubosome
dispersion was puriﬁed from the non-encapsulated drug by dialysis as
follows: 2 mL was loaded into a Spectra/Por membrane (12−14 kDa
MW cutoﬀ; Spectrum Laboratories Inc., USA) and dialyzed against
water (1000 mL) for 2 h (by replacing the water after 1 h) at 5 °C.
Drug loading eﬃciency (E%), expressed as percentage of the drug
amount initially used, was determined by UV−vis spectroscopy after
disruption of cubosomes with methanol. Quercetin content was
quantiﬁed at 373 nm using a Thermo Nicolet Evolution 300 UV−vis
spectrophotometer.
Dynamic Light Scattering (DLS). Particle size and ζ-potential
determinations of the nanoparticles were performed with a ZetaSizer
Nano ZS (Malvern Instruments, Malvern, UK) at a temperature of 25
± 0.1 °C. Samples were backscattered by a 4 mW He−Ne laser
(operating at a wavelength of 633 nm) at an angle of 173°. Diluted
samples (1:50) were housed in disposable polystyrene cuvettes of 1 cm
optical path length with water as solvent. At least two independent
samples were taken, each of which was measured from three to ﬁve
times. The width of DLS hydrodynamic diameter distribution is
indicated by PDI (polydispersion index).
Photophysical Measurements. Cubosome solutions were
diluted with Milli-Q water and ultraﬁltered before performing the
photophysical measurements. The emission and excitation spectra
were recorded with an Edinburgh FLS920 equipped photomultiplier
Hamamatsu R928P. The same instrument connected to a PCS900 PC
card was used for the TCSPC (time-correlated single photon
counting) experiments (excitation laser λ = 405 nm). Fluorescence
intensities were corrected for inner ﬁlter eﬀects according to standard
methods.38 All ﬂuorescence anisotropy measurements were performed
on an Edinburgh FLS920 equipped with Glan-Thompson polarizers.
Anisotropy measurements were collected using an L-format
conﬁguration, and all data were corrected for polarization bias using
the G-factor. Low-volume quartz cuvettes with an optical path length
of 1.0 × 0.2 cm were used to reduce the scattering eﬀects from the
cubosome solutions.
Small-Angle X-ray Scattering (SAXS) Experiments. Small-
angle X-ray scattering was recorded with a S3-MICRO SWAXS camera
system (HECUS X-ray Systems, Graz, Austria). Cu Kα radiation of
wavelength 1.542 Å was provided by a GeniX X-ray generator,
operating at 50 kV and 1 mA. A 1D-PSD-50 M system (HECUS X-ray
Systems, Graz, Austria) containing 1024 channels of width 54.0 μm
was used for detection of scattered X-rays in the small-angle region.
The working q range (Å−1) was 0.003 ≤ q ≤ 0.6, where q =
4πsin(θ)λ−1 is the scattering wave vector. A stainless steel sample
holder with thin polymeric sheet (Bratfolie, Kalle) windows enclosing
a few milligrams of the sample was used for cubic phases, while thin-
walled 2 mm glass capillaries were used for cubosome dispersions. The
diﬀraction patterns for cubic phases and cubosomes were recorded,
respectively, for 30 min and 7 h. The lattice parameter a of the cubic
phases was determined using the relation a = d(h2 + k2 + l2)
1/2 from
linear ﬁts of the plots of 1/d versus (h2 + k2 + l2)
1/2, where d = 2π/q (q
is the measured peak position) and h, k, and l are the Miller indices.
Water channel radii were calculated using the relation Rw = [(A0/−
2πχ)1/2a] − L, where L is the lipid length value (17 Å), a is the lattice
parameter obtained from the SAXS analysis, and A0 and χ are the
surface area and the Euler characteristic of the IPMS geometries (Ia3d,
A0 = 3.091, χ = −8; Pn3m, A0 = 1.919, χ = −2). To minimize scattering
from air, the camera volume was kept under vacuum during the
measurements. Silver behenate (CH3−(CH2)20−COOAg) with a d
Figure 1. Fluorophores F1 (a) and F2 (b).
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spacing value of 58.38 Å was used as a standard to calibrate the angular
scale of the measured intensity.
Cell Cultures and Treatment. Mouse 3T3 ﬁbroblasts (ATCC
collection) were grown at 37 °C in phenol red-free Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Invitrogen, USA) with high
glucose, supplemented with 10% (v/v) fetal bovine serum, penicillin
(100 U mL−1), and streptomycin (100 μg mL−1) (Invitrogen) in a 5%
CO2 incubator at 37 °C. Cells were grown in 35 mm dishes, and
experiments were carried out 2 days after seeding when cells had
reached 80−90% conﬂuence. Nanoparticle formulations were added to
the cells at a concentration of 1:1000 (2 μL of sample in 2 mL of
medium) and incubated at 37 °C for 3 h. For live cell imaging, the
sample suspension was replaced with fresh serum-free medium before
the imaging session.
Fluorescence Microscopy. Fluorescent microscopy observations
of the cells were made using a Zeiss (Axioskop) upright microscope
(Zeiss, Oberkochen, Germany) equipped with a ﬁlter system of 470 ±
20 nm for excitation and 535 ± 40 nm for emission, a 40×/0.75 NA
water immersion objective, and a HBO 50 W L-2 mercury lamp
(Osram, Berlin, Germany). Twelve-bit-deep images were acquired
with a monochrome cooled CCD camera (QICAM, Qimaging,
Canada) and analyzed with Image Pro Plus software (Media
Cybernetics, Silver Springs, MD). The ﬂuorescence images of
cubosomes in a diluted aqueous solution mixed with ethylene glycol
(see Figure 4) were obtained with an inverted microscope (Olympus
IX71) equipped with a Basler CCD color camera (SC A640-70gs) and
using as excitation light the 488 nm laser emission of an Ar+ ion laser
(Melles Griot, IMA1-Multiwavelength, 43 series ion laser).
■ RESULTS AND DISCUSSION
Here, we explored monoolein (MO)-based cubosomes doped
with two hydrophobically modiﬁed ﬂuorophores and loaded
with quercetin as nanoparticles for theranostic applications.
First, the two ﬂuorophores F1 and F2 (see Figure 1) were
synthesized by reﬂuxing octadecylamine with ﬂuorescein
isothiocyanate isomer I in THF (in the case of F1) or with
dansyl chloride in MeCN in the presence of K2CO3 (in the case
of F2), to give the desired thiourea (F1) or sulfonamide (F2) in
35.5 and 74.5% yields, respectively.
Indeed, hydrophobic derivatization is a common approach to
improve encapsulation of diﬀerent probes within lipid
nanostructures.38 Here, it should be noticed that ﬂuorescein
cannot be easily dispersed within cubosomes. Actually, through
an optical microscope, we observed crystals of this ﬂuorophore
in bulk cubic phases even at very low concentration. Therefore,
to facilitate the accommodation of the ﬂuorophores within the
MO palisade while preserving the original cubosome nano-
nstructure, ﬂuorescein and dansyl were functionalized with a
C18 hydrophobic chain to obtain the ﬂuorophores F1 and F2
(Figure 1). Moreover, as ﬂuorescein and dansyl are slightly
water-soluble, while F1 and F2 are highly hydrophobic, the
adopted approach should allow increased encapsulation
eﬃciency in the nanoparticles.
To evaluate the capacity of the MO bicontinuous cubic phase
to host the ﬂuorophores, F1 and F2 were initially encapsulated
in a MO/W (water) = 70/30 (wt %) Ia3d (gyroid) cubic bulk
phase rather than in the cubosome dispersion. The ﬂuorophore
concentration was kept below a threshold of 0.1 wt % to avoid
structural alterations of the original cubic nanostructure. The
MO/W = 70/30 cubic samples loaded with F1 and F2 were
observed with an optical microscope under polarized light to
check the absence of undissolved crystals, while their
ﬂuorescence was conﬁrmed by exposing the cubic bulk phase
to ultraviolet light. Noticeably, F1 and F2 show rather strong
ﬂuorescence in the bicontinuous bulk cubic phases, with an
emission maximum at 544 and 500 nm and a high anisotropy
value of 0.2 and 0.1, respectively (see Table 1). Since
ﬂuorescein undergoes deactivation by self-quenching pro-
cesses,39,40 this is additional proof that the F1 ﬂuorophore is
dispersed within the MO matrix rather than self-aggregated.
Results from this preliminary study demonstrated that the
optimal ﬂuorophore concentration in the MO/W = 70/30 Ia3d
cubic bulk phase was approximately 0.05 and 0.06 wt % for F1
and F2, respectively. At this concentration, no crystals were
observed and strong ﬂuorescence was detected. The preserva-
tion of the cubic nanostructure was assessed by SAXS. The
diﬀraction pattern showed at least ﬁve Bragg peaks with relative
positions in a ratio of √6:√8:√14:4:√20, which are
characteristic of the Ia3d space group (Figure S1 in Supporting
Information). The lattice parameter and the water channel radii
extracted from the SAXS diﬀraction patterns were found to be
131.1 ± 0.3 and 15.5 Å for F1 and 130.4 ± 0.4 and 15.3 Å for
F2. These structural parameters are almost identical to those
found in the absence of the ﬂuorophores. It is worth recalling
here that, upon increasing the water content, the Ia3d phase
evolves toward a diﬀerent bicontinuous cubic phase charac-
terized by a Pn3m (double diamond) space group. The aqueous
dispersions of MO bicontinuous cubic phases (cubosomes)
should possess this type of inner nanostructure since the Pn3m
phase can coexist with an excess of water.
According to a bottom-up approach, ﬂuorescent cubosomes
were prepared by dispersing a melted mixture of MO and F1 or
F2 in a pluronic F108 (PF108) solution via sonication. In this
study, PF108 was chosen since it demonstrated superior ability
in cubosome formulation.27 Cubosome dispersions were
prepared at the composition MO/W/PF108 = 3.3/96.4/0.3
(wt %), while the amount of F1 or F2 was, respectively, 2.5 ×
10−3 and 2.8 × 10−3 wt %. Cubosomes were then characterized
for particle size and morphology, as well as for their inner
structure and photophysical properties. The cryo-TEM image
of F1-doped cubosomes is reported in Figure 2. Several
nanoparticles with inner cubic structure are clearly discernible.
On the basis of repeated observations, the sample under
Table 1. Photophysical Properties of F1 and F2 in the Bulk, Loaded Inside the Cubosomes (Aqueous Solution, pH 7 after
Ultraﬁltration), in Basic Aqueous Solution (F1), and in Ethanol Solution (F2)
epsilon (M−1 cm−1) exca (λmax/nm) em
b (λmax/nm) r
c τd (ns)
F1 bulk cubic phase 485 544 0.2 3.9
cubosomes (aqueous dispersion) 484 517 0.3 3.8
H2O buﬀered pH 9 89000 (λ = 500 nm) 494 517 0.0 3.0
F2 bulk cubic phase 333 500 0.1 12.7
cubosomes (aqueous dispersion) 336 520 0.1 12.8
EtOH 4200 (λ = 340 nm) 333 507 0.0 13.3
aExcitation spectra (F1, λem = 520 nm; F2, λem = 510 nm).
bEmission spectra (F1, λexc = 470 nm; F2, λexc = 340 nm).
cEmission anisotropy (F1, λexc
= 470 nm; F2, λexc = 340 nm).
dAverage lifetime (F1 and F2, laser source λexc = 405 nm).
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investigation was found to be a dispersion of cubosomes having
a diameter in the range of 100−200 nm.
The optical diﬀractogram obtained by the fast Fourier
transform (inset in Figure 2) of the cryo-TEM image suggests
the presence of an inner cubic arrangement, as it shows the
typical motifs of the {111} reﬂection of a Pn3m phase.41
Diﬀerently, when F2 was added to the formulation along with
the expected cubosomes, a new kind of nanoparticles was
observed (Figure 3). In other words, the insertion of the F2
ﬂuorophore within the MO palisade causes a profound
alteration of the surfactant packing, thus originating the new
nanostructure having a rose-like morphology (Figure 3b). Such
“roses” coexist with the ordered cubic phase dispersion,
representing about 15% of the dispersed phase (as a rough
estimate). In some cases, transition between the cubic and the
rose-like morphology can be observed (see Figure S2).
The inner cubic structure of the cubosomes was conﬁrmed
by SAXS. The diﬀraction pattern shows at least three Bragg
peaks with relative positions in a ratio of √2:√3:2, which are
characteristics of the Pn3m phase (Figure S3). For empty or
variously loaded cubosomes, Table 2 reports the structural
parameters from the SAXS analysis along with mean diameters,
polydispersion indexes, and ζ-potentials obtained from dynamic
light scattering (DLS). Also note that, in striking agreement
with cryo-TEM images, DLS analysis certiﬁes very similar
nanoparticles’ dimensions, besides a quite low PDI. Concerning
the F2-doped sample, given the high dilution, the characteristic
pattern (if any) of the rose-like nanostructure was not
discernible in the SAXS pattern.
The presence of free dye in the aqueous dispersion of
cubosomes doped either with F1 or F2 was avoided by
purifying samples via ultraﬁltration. Their absence was checked
through ﬂuorescence optical microscopy observations, as
exempliﬁed in Figure 4. Particularly, to decrease the
cubosomes’ diﬀusion on the glass microscopy slide, the
ultraﬁltrated aqueous solutions of F1- and F2-doped
cubosomes were diluted with ethylene glycol before the
pictures were taken. If some free dye was molecularly dispersed
in the aqueous phase, the image shown in Figure 4 should have
appeared as a more or less homogeneous bright ﬁeld. On the
contrary, the ﬂuorescent spots on a dark background observed
in Figure 4 represent an additional proof that F1 is completely
encapsulated within the nanoparticles. The same holds for F2.
The photophysical properties of an aqueous dispersion (pH
7) of cubosomes are very similar to those of F1 dissolved in a
basic aqueous solution at pH 9 (where F1 is soluble), with a
maximum of the emission band at 517 nm, an excitation band
that overlaps that of F1, as shown in Figure 5, and a slightly
longer averaged excited state lifetime (3.8 ns for F1 within the
cubosomes and 3.0 ns for F1 in aqueous solution at pH 9; see
Table 1).
These results are expected since the energetics of the π−π*
excited state of the ﬂuorescein unit is known to be independent
of the polarity of the environment. A very interesting result
Figure 2. Cryo-TEM image of MO-based cubosomes loaded with F1.
Fast Fourier transformation of the domain indicated by the arrow is
shown in the inset.
Figure 3. Cryo-TEM image of MO-based sample loaded with F2: (a)
cubosomes and (b) rose-like nanoparticles.
Table 2. Lattice Parameter (a), Water Channel Radius (rW),
Mean Diameter (Dav), Polydispersion Index (PDI), and ζ-
Potential of the Cubosome Nanoparticles Empty or Loaded
with Various Cargos
cubosome
cargos a (Å) rW (Å) Dav (nm) PDI
ζ-potential
(mV)
98 ± 1 21.3 ± 0.8 161 ± 2 0.17 −29.4 ± 0.6
F1 101 ± 1 22.4 ± 0.8 148 ± 2 0.12 −26.6 ± 0.6
F2 98 ± 1 21.2 ± 0.8 148 ± 2 0.14 −24.5 ± 0.1
quercetin 98 ± 1 21.3 ± 0.8 161 ± 3 0.15 −25.6 ± 0.9
F1 +
quercetin
99 ± 1 21.6 ± 0.8 160 ± 2 0.19 −27.6 ± 0.2
F2 +
quercetin
96 ± 1 20.3 ± 0.8 159 ± 2 0.12 −22.8 ± 0.3
Figure 4. Fluorescence microscopy image of F1-doped cubosomes
(see the text).
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emerged from ﬂuorescence anisotropy measurements. The
observed value of 0.3 clearly indicates that F1 is inserted into a
large structure with a reduced mobility since the anisotropy of
freely mobile ﬂuorescein is negligible. This conclusion is
supported by the photophysical characterization of MO-based
cubosomes doped with the dansyl derivative F2. Indeed, dansyl
is known to have photophysical properties that strongly depend
on the solvent polarity. We found that F2-doped cubosomes
show an emission maximum at 520 nm and an excited state
lifetime of 12.8 ns (see Figure S4 and Table 1).
These results are very similar to those observed for F2 in
ethanol (507 nm and 13.3 ns) and very diﬀerent from those
reported for dansyl derivatives in water solution (560 nm and
2.9 ns in water; 500 nm and 13.4 ns in ethanol).42 These results
also conﬁrm that F2 is embedded within the nanoparticles and
give some information on its localization. Indeed, these data
suggest that the ﬂuorescent moiety of F2 is located in the same
region of the MO polar heads, experiencing interactions with
the MO OH groups.
On the basis of the cryo-TEM analysis, which in the case of
the F2-doped cubosome dispersion evidenced the presence of
nanoparticles having an inner structure diﬀerent from cubic,
only the cellular uptake of MO-based cubosomes doped with
F1 was investigated. 3T3 ﬁbroblast cells were incubated in the
presence of nanoparticles for 3 h and imaged with ﬂuorescent
microscopy. These observations were made immediately after
replacing the nanoparticle suspension in the medium with fresh
particle-free medium. Diﬀuse ﬂuorescence was detected in the
cytosol and, particularly, in the perinuclear region of living cells
(Figure 6). Therefore, as conﬁrmed by the intracellular
ﬂuorescence detection, we can conclude that F1 penetrates
into the cells via the cubosome carrier.
Finally, the F1-doped cubosome dispersion was loaded with
quercetin, a polyphenolic molecule endowed of anticancer
activity. The calculated loading eﬃciency (see the Materials and
Methods section) was 80%. SAXS and DLS results reported in
Table 2 demonstrate that the presence of quercetin does not
signiﬁcantly alter the inner nanostructure of the cubosome, as
well as their size and charge. Interestingly, although pluronic-
stabilized cubosomes are basically uncharged, they display a
negative ζ-potential, as reported by other authors.43,44 The
origin of this negative charge is still unclear, but preferential
adsorption of hydroxyl ions at the oil−water interface, as in case
of oil droplets in water, has been proposed to explain the
observed values of ζ-potential.44
■ CONCLUSIONS
Cubosomes are often proposed as suitable drug nano-
carriers,29,32,45−47 and the ability of bicontinuous cubic phases
to host molecules with pharmaceutical interest has been proved
numerous times.48,49 In this paper, we demonstrated that MO-
based cubosomes, still retaining the characteristics given by
their peculiar inner nanostructure, can eﬃciently and easily be
coupled with properly designed ﬂuorophores and loaded with
an anticancer drug. Therefore, the physicochemical and
photophysical measurements, along with the single living cell
imaging analysis here reported, make these innovative
ﬂuorescent nanocarriers a candidate for theranostic applica-
tions.
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ABSTRACT: This work was devoted to the development of a
new type of lipid-based (cubosome) theranostic nanoparticle
able to simultaneously host camptothecin, a potent anticancer
drug, and a squarain-based NIR-emitting ﬂuorescent probe.
Furthermore, to confer targeting abilities on these nano-
particles, they were dispersed using mixtures of Pluronic F108
and folate-conjugated Pluronic F108 in appropriate ratios. The
physicochemical characterization, performed via SAXS, DLS,
and cryo-TEM techniques, proved that aqueous dispersions of
such cubosomes can be eﬀectively prepared, while the
photophysical characterization demonstrated that these nanoparticles may be used for in vivo imaging purposes. The superior
ability of these innovative nanoparticles in targeting cancer cells was emphasized by investigating the lipid droplet alterations
induced in HeLa cells upon exposure to targeted and nontargeted cubosomes.
■ INTRODUCTION
The main goal of nanomedicine is probably the improvement
of diagnostic and therapeutic tools available in clinics.
Therefore, considerable eﬀorts has been made to develop the
physicochemical and biological characteristics of the nano-
carriers engineered to encapsulate drugs or imaging agents with
pharmaceutical purposes. Since nanocarriers may be formulated
using an extensive range of organic and inorganic materials,
these eﬀorts resulted in the assembly of a huge number of “soft”
and “hard” nanocarriers, such as polymeric,1−5 silica,6,7 or iron
oxide nanoparticles,8−10 liposomes,11−13 dendrimers,10,14,15 and
quantum dots.16−18 Recently, the development of single
platforms able to simultaneously transport and release
pharmaceutically active and imaging agents has led to so-called
theranostic nanoparticles. Besides, the latter usually contain a
targeting ligand as a third component to speciﬁcally direct both
the therapeutic and diagnostic agents to the pathological site. In
principle, these multifunctional nanocarriers should fulﬁll a
number of requisites that include the controlled (co)delivery of
poorly water-soluble (multiple) drugs, the selective targeting of
malignant cells for minimizing side eﬀects, and the in-progress
evaluation of the treatment eﬃcacy via molecular detec-
tion.19−29
The accumulation of nanoparticles in tumor tissues passively
occurs as a result of aberrant tumor angiogenesis that forms
nonmature, leaky capillaries. Indeed, the primary consequences
of the defects in tumor vessels are great permeability to
colloidal macromolecules or nanoparticles in comparison to
physiological vessels and reduced lymphatic drainage of these
colloids from the interstitial space of tumors, a phenomenon
called the enhanced permeation and retention (EPR) eﬀect.30
Conversely, nanoparticles may be actively targeted to tumor
tissues employing cancer-cell-speciﬁc ligands such as folic acid.
The popularity of this ligand has mainly grown because cancer
cells frequently overexpress folate receptors (which is the case
for ovary, breast, brain, kidney, head, neck and other tumors)
and because of its high binding aﬃnity, ease of modiﬁcation,
stability during storage, and low cost.31,32
Fluorescent imaging is one of the most powerful techniques
in clinical diagnosis33 for monitoring biological processes in
living systems due to its characteristics of high spatial and
temporal resolution. Contrast agents such as Gd3+ complexes34
and ﬂuorodeoxyglucose35 are widely used in MRI (magnetic
resonance imaging) and PET (positron emission tomography).
In the last few decades, a profusion of ﬂuorescent probes has
been developed by synthesis chemists. However, most of them
can hardly be used for in vivo applications because the majority
of the conventional ﬂuorophores emit in the UV−vis region.
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Indeed, in this portion of the electromagnetic spectrum the
absorption of biomolecules (water, hemoglobin, etc.), the
autoﬂuorescence of the cells, and the light scattering are high,
causing limited tissue penetration as well as low signal-to-noise
ratios, resulting in unsuitability for in vivo imaging. Conversely,
dyes active in the NIR (near infrared) region of the spectrum
(650−900 nm) have attracted much attention because of
minimum photodamage to biological samples, deep tissue
penetration, and minimum interference from background
autoﬂuorescence by biomolecules in living systems.36−38
Diﬀerent classes of NIR-emitting ﬂuorophores have been
developed such as phtalocyanines, cyanines, and squaraines. In
particular, the latter39 are the dicondensation products of
electron-rich molecules with squaric acid and are characterized
by a sharp and intense low-energy absorption associated with
strong ﬂuorescence in solution.
Among the various nanocarriers engineered for theranostic
nanomedicine, cubosomes have been only recently proposed.40
Basically, these are aqueous dispersions of lipid-based
bicontinuous liquid-crystalline phases typically stabilized by
Pluronics.41,42 Therefore, the inner nanostructure of the
nanoparticles is constituted of curved, triply periodic non-
intersecting bilayers folded on an inﬁnite periodic minimal
surface of cubic symmetry and organized to form two disjointed
continuous water channels.43,44
Throughout this article it will be shown that cubosome
nanoparticles coloaded with both an NIR ﬂuorescent probe and
an anticancer drug can be prepared and eﬀectively stabilized by
mixtures of F108 and folate-conjugated F108 Pluronics that
give these nanoparticles superior targeting ability toward HeLa
cancer cells with respect to traditional cubosomes.
■ EXPERIMENTAL SECTION
Chemicals. Monoolein (MO, 1-monooleoylglycerol, RYLO MG
19 PHARMA, glycerol monooleate, 98.1 wt %) was kindly provided by
Danisco A/S, DK-7200, Grinsted, Denmark. Pluronic F108 (PEO132−
PPO50−PEO132), folic acid (≥97%), camptothecin (≥90%), 2,4-di-3-
guaiazulenyl-1,3-dihydroxycyclobutenediylium dihydroxide bis(inner
salt), acetonitrile (≥99.9%), diethyl ether (≥99.5%), N,N′-carbon-
yldiimidazole (CDI, ≥ 97%), ethylenediamine, (≥99.5%), N-
hydroxysuccinimmide (NHS, 98%), N,N′-dicyclohexylcarbodiimide
(DCC, ≥ 99.5%), and triethylamine (≥99.5%) were purchased from
Sigma-Aldrich. Distilled water passed through a Milli-Q water-
puriﬁcation system (Millipore) was used to prepare the samples.
Nuclear Magnetic Resonance Experiments. 1H NMR measure-
ments were performed on a Bruker Avance 300 MHz (7.05 T)
spectrometer at an operating frequency of 300.131 MHz at 25 °C. A
standard variable-temperature control unit with an accuracy of ±0.5
°C was used. Chemical shifts for 1H NMR are reported in parts per
million (ppm), with coupling constants reported in Hertz (Hz). The
following abbreviations are used for spin multiplicity: s, singlet; d,
doublet; t, tripletl and m, multiplet. A selection of the characteristic 1H
signals are reported in the synthesis of F108-CDI, F108-NH2, and
F108-FA Pluronics.
Synthesis of Folate-Conjugated Pluronic F108. Synthesis of
CDI-Activated Pluronic F108 (F108-CDI). To a solution of Pluronic
F108 (2.01 g, 0.14 mmol) in dry acetonitrile (10 mL), a solution of a
great excess of N,N′-carbonyldiimidazole (CDI, 0.26 g, 1.6 mmol) in
dry acetonitrile (5 mL) was added dropwise during a period of 45 min.
The mixture was kept stirring at room temperature under a nitrogen
atmosphere for 6 h. Then, the solution was concentrated in a rotary
evaporator and washed with diethyl ether (3 × 10 mL) to remove
unreacted CDI. The product was dried under vacuum and collected as
a white powder. Yield: 93% (1.890 g, 0.13 mmol); mp: 54 °C. 1H
NMR (300 MHz, DMSO-d6, 298 K): δH 1.03 (d, J = 6 Hz; 3H × 50,
−CH3 of PPO), 3.47−3.54 (m, 3H × 50, 4H × 264, −CH2−
CH(CH3)−O− of PPO and −CH2−CH2−O− of PEO), 7.50−7.65
(m, 2H × 2, protons of the imidazole moiety), 8.25 (s, 1H × 2, proton
of the imidazole moiety). IR (solid state, cm−1) ν = 2885 (s), 1743
(w).
Synthesis of NH2-Terminated Pluronic F108 (F108-NH2). To a
solution of F108-CDI (1.010 g, 0.068 mmol) in dry acetonitrile (10
mL), 0.78 mL of ethylenediamine was added. The reaction mixture
was kept stirring for 24 h at room temperature under a nitrogen
atmosphere. The solvent and unreacted ethylenediamine were
removed under vacuum. The crude product was precipitated with
diethyl ether and collected as a beige powder. Yield: 81% (0.813 g;
0.055 mmol); mp: 56 °C. 1H NMR (300 MHz, DMSO-d6, 298 K): δH
1.03 (d, J = 6 Hz, 3H × 50, −CH3 of PPO), 2.65−2.75 (m, 2H × 2
protons adjacent to the terminal amine), 2.96 (q, J = 6 Hz, 2H × 2
protons adjacent to the amide bond), 3.47−3.54 (m, 3H × 50, 4H ×
264, −CH2−CH(CH3)−O− of PPO and −CH2−CH2−O− of PEO),
7.17 (t, J = 6 Hz, 1H × 2, amidic NH). IR (solid state, cm−1) ν = 2885
(s), 1716 (w).
Synthesis of Folate-Conjugated Pluronic F108 (F108-FA). F108-
NH2 (0.498 g, 0.034 mmol), N-hydroxysuccinimmide (NHS, 0.033 g,
0.29 mmol), N,N′-dicyclohexylcarbodiimide (DCC, 0.055 g, 0.27
mmol), and folic acid (FA, 0.053 g, 0.12 mmol) were dissolved in 10
mL of DMSO in the presence of triethylamine (50 μL). The reaction
mixture was stirred for 24 h at room temperature under a nitrogen
atmosphere. Twenty milliliters of deionized water was added to the
reaction mixture to precipitate DCU (dicyclohexylurea), and then the
mixture was centrifuged and the supernatant was dialyzed (molecular
weight cutoﬀ of the dialysis tube was 14 kDa) for 3 days against
deionized water, which was changed every 3−6 h. The resulting
product was lyophilized for 3 days in order to remove all of the
residual water. Yield: 45% (0.230 g, 0.015 mmol); mp: 145 °C. 1H
NMR (300 MHz, DMSO-d6, 298 K): δH 1.03 (d, J = 6 Hz; 3H × 50,
−CH3 of PPO), 3.47−3.54 (m, 3H × 50, 4H × 264, −CH2−
CH(CH3)−O− of PPO and −CH2−CH2−O− of PEO), 6.63 (d, J = 9
Hz, 2H × 2 of the phenilic ring), 6.88 (t, J = 7.5 Hz, 1H × 2, aryl NH),
7.10−7.30 (m, 1H × 2, amidic NH from the precursor), 7.50−7.80
(m, 2H × 2, of the phenilic ring), 7.80−8.10 (m, 1H × 2, amidic NH),
8.66 (s, 1H × 2, pteridinic CH). IR (solid state, cm−1) ν = 2885 (s),
1608, 1642, 1689, 1723 (w).
Sample Preparation. Monoolein-based cubosomes were prepared
and stabilized by dispersing the appropriate amount of MO in water
solutions of diﬀerent F108/F108-FA mixtures (100:0, 90:10, 80:20,
60:40, 50:50, 30:70, and 0:100 wt %/wt %) using an UP100H
ultrasonic processor developed by Hielscher, cycle 0.9, amplitude 90%,
for 10 min. Doped cubosomes were obtained by dispersing the
ﬂuorophore and the drug in the melted monoolein with the help of an
ultrasonic bath before dispersion in the stabilizer solution. The sample
volume was usually 4 mL with approximately 96.4 wt % water, 3.3 wt
% MO, and 0.3 wt % Pluronics mixture. Fluorophore and
camptothecin quantities were, respectively, 2.8 × 10−4 and 4.0 ×
10−4 wt %.
Dialysis and Drug-Loading Eﬃciency (E%). After drug loading,
cubosome dispersions were puriﬁed from the nonencapsulated drug by
dialysis as follows: 2 mL was loaded into a dialysis tubing cellulose
membrane (14 kDa MW cutoﬀ, purchased from Sigma-Aldrich) and
dialyzed against water (1000 mL) for 2 h (by replacing the water after
1 h) at 5 °C. The drug-loading eﬃciency, expressed as a percentage of
the initially used amount of drug, was determined by UV−vis
spectroscopy after the disruption of cubosomes with acetonitrile.
Camptothecin and ﬂuorophore contents were quantiﬁed respectively
at 363 and 755 nm using a Thermo Nicolet Evolution 300 UV−vis
spectrophotometer.
Cryogenic Transmission Electron Microscopy (Cryo-TEM).
Vitriﬁed specimens were prepared in a controlled-environment
vitriﬁcation system (CEVS) at 25 °C and 100% relative humidity. A
drop of the sample was placed on a perforated carbon ﬁlm-coated
copper grid, blotted with ﬁlter paper, and plunged into liquid ethane at
its freezing point. The vitriﬁed specimens were transferred to a 626
Gatan cryo-holder and observed at a 120 kV acceleration voltage in an
FEI Tecnai T12 G2 transmission electron microscope at about −175
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°C in low-dose imaging mode to minimize electron-beam radiation
damage. Images were digitally recorded with a Gatan US1000 high-
resolution CCD camera.
Dynamic Light Scattering (DLS). Particle size and ζ-potential
determinations of the nanoparticles were performed with a ZetaSizer
Nano ZS (Malvern Instruments, Malvern, U.K.) at a temperature of 25
± 0.1 °C. Samples were backscattered by a 4 mW He−Ne laser
(operating at a wavelength of 633 nm) at an angle of 173°. Diluted
samples (1:50) were housed in disposable polystyrene cuvettes of 1 cm
optical path length with water as the solvent. At least two independent
samples were taken, each of which was measured three to ﬁve times.
The autocorrelation function (ACF) of scattered light intensity was
converted to the ACF of the scattered electric ﬁeld. From this last
quantity, the software supplied by the producer evaluates the z-
averaged hydrodynamic diameter (Dav) and the variance of the
intensity-weighted size distribution function through cumulant analysis
(second order) and subsequent application of the Stokes−Einstein
equation. The intensity-weighted size distribution function, i.e., the
fraction of the light intensity scattered by particles of diﬀerent size, was
also recovered by taking the inverse Laplace transform of the ACF
using the software implemented by the manufacturer. In all cases, the
intensity-weighted size distribution functions were monomodal with
mean and variance indistinguishable from those recovered through
cumulant analysis. The hydrodynamic diameter distribution is
indicated by the PDI (polydispersion index).
Small-Angle X-ray Scattering (SAXS) Experiments. Small-
angle X-ray scattering was recorded with a S3-MICRO SWAXS camera
system (HECUS X-ray Systems, Graz, Austria). Cu Kα radiation of
wavelength 1.542 Å was provided by a GeniX X-ray generator,
operating at 50 kV and 1 mA. A 1D-PSD-50 M system (HECUS X-ray
Systems, Graz, Austria) containing 1024 channels of width 54.0 μm
was used for the detection of scattered X-rays in the small-angle
region. The working q range (Å−1) was 0.003 ≤ q ≤ 0.6, where q = 4π
sin(θ)λ−1 is the scattering wave vector. For the analysis, thin-walled 2
mm glass capillaries were ﬁlled with the cubosome dispersions. The
diﬀraction patterns of cubosomes were recorded for 2 h. The lattice
parameter a of the cubic phases was determined using the relation a =
d(h2 + k2 + l2)1/2 from linear ﬁts of the plots of 1/d versus (h2 + k2 +
l2)1/2, where d = 2π/q (q is the measured peak position) and h, k, and l
are the Miller indices. Water channel radii were calculated using the
relation Rw = [(A0/−2πχ)1/2a] − L, where L is the lipid length value
(17 Å), a is the lattice parameter obtained from the SAXS analysis, and
A0 and χ are the surface area and the Euler characteristic of the IPMS
geometries (Pn3m, A0 = 1.919, χ = −2). To minimize scattering from
air, the camera volume was kept under vacuum during the
measurements. Silver behenate (CH3−(CH2)20−COOAg) with a d
spacing value of 58.38 Å was used as a standard to calibrate the angular
scale of the measured intensity.
Photophysical Measurements. Cubosome solutions were
diluted with Milli-Q water. UV−vis absorption spectra were recorded
at 25 °C with a PerkinElmer Lambda 45 spectrophotometer. Quartz
cuvettes with an optical path length of 1 cm were used. Corrected
ﬂuorescence emission and excitation spectra (450 W Xe lamp) were
obtained with an Edinburgh Instruments FLS920 modular UV−vis−
NIR spectroﬂuorimeter equipped with a Hamamatsu R928P P
photomultiplier tube (for the 500−850 nm spectral range) and an
Edinburgh Instruments Ge detector (for the 800−1600 nm spectral
range). The same instrument connected to a PCS900 PC card was
used for the TCSPC (time-correlated single-photon counting)
experiments (excitation laser λ = 405 nm). Corrections for
instrumental response, inner ﬁlter eﬀects, and phototube sensitivity
were performed.45 All ﬂuorescence anisotropy measurements were
performed on an Edinburgh FLS920 equipped with Glan-Thompson
polarizers. Anisotropy measurements were carried out by an L-format
conﬁguration, and all data were corrected for polarization bias using
the G factor.
Cell Culture and Treatments. Human carcinoma cell line HeLa
(ATCC collection) was grown in phenol red-free Dulbecco’s modiﬁed
Eagle’s medium (DMEM, Invitrogen, USA) with high glucose,
supplemented with 10% (v/v) fetal bovine serum, penicillin (100 U
mL−1), and streptomycin (100 μg mL−1) (Invitrogen) in a 5% CO2
incubator at 37 °C. Cells were seeded in 35 mm dishes, and
experiments were carried out 2 days after seeding, when cells had
reached 90% conﬂuency. Cubosomes (1:500, 4 μL in 2 mL of free-
serum medium) were added to the cells and incubated at 37 °C for 2,
4, and 24 h. For live cell imaging, after replacing the particle
suspension with fresh serum-free medium, cells were loaded with
ﬂuorescent probes, and after the incubation time, the probes were
washed out before the imaging session. Cells were supravitally stained
with the following probes: 300 nM Nile red (NR) (9-diethylamino-
5H-benzo[a]phenoxazine-5-one) for 15 min and 650 nM Hoechst
33258 (HOE) for 30 min. Vehicles were DMSO for NR and water for
HOE. Stock solutions were 1000-fold concentrated not to exceed the
0.1% concentration of vesicles in the medium. Nile red was from Fluka
(Buchs, SG, Switzerland); Hoechst was from Sigma-Aldrich (St. Louis,
MO, USA).
Fluorescence Microscopy. Light microscopy observations were
made with a Zeiss (Axioskop) upright ﬂuorescence microscope (Zeiss,
Oberkochen, Germany) equipped with 10×, 20×, and 40×/0.75 NA
water-immersion objectives and an HBO 50 W L-2 mercury lamp
(Osram, Berlin, Germany). Twelve-bit-deep images were acquired
with a monochrome-cooled CCD camera (QICAM, Qimaging,
Canada) with variable exposure. For the observation of the HOE
Scheme 1. Reaction Scheme Adopted for the Synthesis of F108-FA
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probe, the ﬁlters were ex 360 ± 20 nm and em 460 ± 25 nm. For NR,
the ﬁlters were ex 470 ± 20 nm and em 535 ± 40 nm for nonpolar
lipids and ex 546 ± 6 nm and em 620 ± 60 nm for total lipids. The
adopted ﬁlters allowed a virtually complete separation of the emissions
and the simultaneous observation of NR and HOE probes. Image
alignments were obtained with Image Pro Plus software.
Lipid Droplet Staining and Quantiﬁcation. Cells were seeded
in 35 mm dishes and cultured in serum-containing media. After
nanoparticle treatments, cells were stained with NR and HOE. NR is
an ideal probe for the detection of lipids, as it exhibits high aﬃnity,
speciﬁcity, and sensitivity to the degree of hydrophobicity of lipids.
The latter feature results in a shift of the emission spectrum from red
to green in the presence of polar and nonpolar lipids, respectively.46
For this reason, in staining living cells with NR, cytoplasmic
membranes are stained red, whereas neutral lipids of lipid droplets
are stained green. Fluorescent images of NR-stained cells were
acquired at 10× and 40× magniﬁcations of a ﬂuorescence microscope.
Measurements, made on a single-cell basis, gave the amount of lipid
droplet content, evaluated by the ﬂuorescence intensity of NR-green
emission. The IOD (integrated optical density) per cell was calculated
using Image ProPlus software (Media Cybernetics, Silver Springs,
MD).
Confocal Microscopy. Measurements were performed on
mounted slides by a Leica TCS SP5 SM (Leica Microsystems,
Mannheim, Germany) inverted confocal microscope. For Hoechst
(nuclear stain), excitation was provided by a 405 nm 40 MHz pulsed
laser diode (Picoquant, Berlin, Germany), whereas the 458 nm laser
line of a cw Ar laser was used to excite the dye. In both cases, the
typical excitation average power was in the 100−800 μW range, when
measured after the objective. Hoechst emission was collected at 420−
480 nm by the internal monochromator of the microscope interfaced
with a photomultiplier detector. Dye emission was ﬁltered at
wavelengths >680 nm by an interferential ﬁlter (Semrock, Rochester,
NY, USA) and collected by one avalanche photodiode detector
(Picoquant, Berlin, Germany). The confocal pinhole was set to a 1
Airy size; a 100× 1.4 NA objective was used for all measurements. The
line-scanning speed was 400−700 Hz in standard acquisition mode.
■ RESULTS AND DICUSSION
Cubosomes Characterization. Here, the use of mono-
olein (MO)-based cubosomes as nanoparticles for the active
targeting of cancer cells was investigated. For this purpose, the
surfactant used to stabilize cubosomes (Pluronic F108, F108)
was conjugated to folate47 (Scheme 1), a targeting ligand which
displays a high aﬃnity for the folate receptor overexpressed on
the tumor cell membrane. Brieﬂy, F108, initially activated with
CDI, was reacted with ethylenediamine to obtain amine-
terminated F108, and the resulting F108-NH2 was ﬁnally
reacted with NHS, DCC, Et3N, and folic acid (see Supporting
Information for characterization details). The purity of F108-
FA and then the absence of unreacted F108-NH2 were
conﬁrmed by a thin-layer ninhydrin assay. Furthermore, after
the pH value was decreasing to 2, there was no precipitation of
unreacted folic acid.48
Subsequently, mixtures of F108 and its folate-conjugated
counterpart were used to stabilize the aqueous cubosome
dispersions. At ﬁrst, the physicochemical characterization of
cubosome nanoparticles stabilized with diﬀerent F108/F108-
FA ratios was performed by SAXS and DLS. The results are
summarized in Table 1. As can be seen from the SAXS data,
nanoparticles retained the Pn3m structure found in traditional
cubosomes (i.e., those prepared with 100% F108), with no
signiﬁcant variations in the lattice parameter, even after the
complete substitution of F108 with F108-FA. Conversely, the
DLS analysis indicated that the amount of F108-FA used to
stabilize nanoparticles strongly aﬀected the mean particles size,
which increased from 133 nm (100% F108) to 168 nm (100%
F108-FA). Although a slight increase in the PDI was detected
upon decreasing the F108/F108-FA ratio, independently by the
presence of the folate-conjugated Pluronic, the various
solutions consisted mainly of homogeneous cubosome
dispersions. The nanoparticles growth was also conﬁrmed by
SAXS experiments because while increasing the amount of
F108-FA the proﬁle of the quasi-Bragg peaks became sharper
(Figure 1). Indeed, the absence of well-deﬁned Bragg peaks in
SAXS patterns of cubosome dispersions is typically related to
the very small nanoparticle size (in which the peak width is
inversely proportional to the crystalline domain size). There-
fore, the quasi-Bragg peaks’ appearance in the sample
containing 100% F108-FA represents an additional proof of
the increased size of the nanoparticles.
Table 1. Space Group, Lattice Parameter (a), Water Channel Radius (rW), Mean Diameter (Dav), Polydispersion Index (PDI), ζ
Potential, and Stability of the Cubosome Nanoparticles Stabilized with Diﬀerent F108/F108-FA Ratios (Wt %)a
F108/F108-FA space group a (Å) rW (Å) Dav (nm) PDI ζ potential (mV) stability (weeks)
100/0 Pn3m 99 ± 2 22 ± 1 133 ± 1 0.11 −28 ± 2 >24
90/10 Pn3m 95 ± 1 20 ± 1 135 ± 3 0.13 −20 ± 1 >24
80/20 Pn3m 97 ± 2 21 ± 1 139 ± 3 0.11 −29 ± 1 >24
60/40 Pn3m 100 ± 1 22 ± 1 142 ± 1 0.13 −29 ± 1 18
50/50 Pn3m 93 ± 1 19 ± 1 151 ± 1 0.13 −23 ± 1 18
30/70 Pn3m 99 ± 1 22 ± 1 159 ± 2 0.12 −25 ± 1 2
0/100 Pn3m 96 ± 1 20 ± 1 168 ± 1 0.13 −25 ± 1 2
80/20 + drug Pn3m 102 ± 1 23 ± 1 145 ± 2 0.14 −23 ± 1 >24
80/20 + drug + dye Pn3m 102 ± 1 23 ± 1 141 ± 1 0.12 −25 ± 1 >24
aErrors are reported as mean ± SD.
Figure 1. SAXS patterns of cubosome dispersions stabilized by F108
and F108-FA Pluronics. Relevant peaks are indicated.
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Concerning the measured ζ-potential values (reported in
Table 1), they were found to be in the range of −20 to −30
mV, almost equivalent to those of nontargeted cubosomes
(−28 mV), with some ﬂuctuations that appeared independently
of the F108/F108-FA ratio. Nevertheless, the stability over time
was found to depend greatly on the F108-FA content because
samples prepared with a higher percentage of F108-FA
exhibited a reduced shelf life, as demonstrated by the observed
phase separation (Table 1).
The role of Pluronics in this kind of formulation consists of
stabilizing the obtained nanoparticles against coalescence or
coagulation basically via mixing and entropic eﬀects.2 There-
fore, the reported experimental ﬁndings suggest that the
conjugation of the folate to the terminal end of the PEO
moieties greatly modiﬁes the original stabilizing properties of
F108, thus producing the observed alteration in cubosome
formulations when F108 is gradually replaced by F108-FA.
Indeed, it is likely that such a conjugation destabilizes the
delicate balance between the PEO−solvent and PEO−PEO
interactions, on the basis of the mixing eﬀect, thus leading to
the observed changes in size and stability of the cubosomes. In
other words, the regular increase in the nanoparticles’
hydrodynamic radii as well as the reduced stability and the
increased PDI of the cubosome dispersions while the F108-FA
content is increased is strong evidence of the less eﬀective
dispersant and stabilizing properties of F108-FA with respect to
those of F108.
Given the potential biomedical application of these
formulations and on the basis of the stability tests, the
cubosome dispersion stabilized with mixture F108/F108-FA =
80/20 (wt %) was selected for loading with the anticancer drug
camptothecin (Scheme 2), which, along with its analogues, has
been demonstrated to be eﬀective against a broad spectrum of
tumors.49−51
SAXS and DLS revealed that inclusion of camptothecin (a
highly hydrophobic drug) within the lipid bilayer basically did
not alter the cubosome nanostructure. The morphology of
these nanoparticles was observed by cryo-TEM (Figure 2).
Several nanoparticles with inner cubic structure are clearly
discernible, along with the vesicular structures often seen in
cubosome formulations. By means of repeated observations, the
sample that was investigated was found to be a dispersion of
cubosomes having a diameter of 100−200 nm, in good
agreement with the dimensions obtained by DLS. It is worth
noticing that all of the size distributions obtained from DLS
appeared to be monomodal with mean sizes ranging from 133
to 168 nm. At variance, an inspection of TEM images reveals
the coexistence of large cubosomes with small unilamellar
vesicles. This is because the ACF (Experimental Section)
measured in DLS reﬂects the intensity-weighted size distribu-
tion function, i.e., the fraction of the light intensity scattered by
particles of diﬀerent sizes. Since the eﬃciency of light scattering
increases dramatically with particle size, such a size distribution
is heavily biased toward large particles, and the presence of
large cubosomes fully dominates the correlogram. Cryo-TEM
experiments performed on targeted cubosomes not containing
the drug (data not shown) revealed that they possess an
identical nanostructure with respect to those loaded with
camptothecin and the dye. The loading eﬃciencies (E%) for
the drug and the ﬂuorophore were found to be 71 and 95%,
respectively.
NIR Fluorescent Probe Characterization. The absorp-
tion spectrum of an aqueous suspension of cubosomes loaded
with both camptothecin and NIR dye 2,4-di-3-guaiazulenyl-1,3-
dihydroxycyclobutenediylium dihydroxide bis(inner salt)
(Scheme 2) did not show any characteristic band because the
turbidity of the suspension originated strong light scattering.
However, a shoulder at around 760 nm ascribable to the dye
could be observed (data no shown). When excited at 340 nm,
an unstructured emission band at 428 nm (Figure 3a) with an
excited-state lifetime of 0.6 ns, which can be assigned to
camptothecin,52−54 was observed. Moreover, an emission band
with a maximum at 938 nm was observed when exciting the
sample at 418 nm (Figure 3b). The ﬂuorescence anisotropy
measurement at 938 nm (r = 0.1) suggested that the dye has
reduced mobility, indicating that it is enclosed in the
nanoparticle. This conclusion is also supported by the
insolubility of the dye in pure water. (The absorption and
emission spectra of an aqueous solution of the dye did not
show any of the characteristic bands of the ﬂuorophore.)
Lipid Droplet Evaluation. The selective cellular uptake of
targeted cubosomes was investigated via IOD analysis by
observing the lipid droplet (LD) formation in HeLa cells after
treatment with the monoolein-based nanoparticles following a
previously developed protocol.12 LDs are cytoplasmic organ-
elles consisting of a hydrophobic core of neutral lipids (such as
triglycerides and cholesterol esters) encased by a phospholipid
monolayer harboring a set of enzymes and regulatory proteins,
which catalyze the metabolically controlled synthesis and
mobilization of fat stores.55 LD formation is a regulated
cellular process that culminates in the compartmentalization of
Scheme 2. Chemical Sturucture of Camptothecin (Left) and
NIR Dye 2,4-Di-3-guaiazulenyl-1,3-
dihydroxycyclobutenediylium Dihydroxide Bis(inner salt)
(Right)
Figure 2. Cryo-TEM image of MO-based cubosomes containing both
the drug and the dye and stabilized by the mixture F108/F108-FA =
80/20.
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lipids, when long-chain unsaturated fatty acids, such as oleic
acid, are available from exogenous sources inside the cells.56
Indeed, after entering the cells, unsaturated fatty acids are
rapidly activated, esteriﬁed, and stored as triglycerides inside
the lipid droplets. Therefore, detecting changes in LD
formation and size may be useful in diﬀerentiating between
targeted and traditional cubosome uptake.
Within this scope, HeLa cells, used as model cancer cells
since they express high levels of folate receptors,57 were
exposed at diﬀerent times to both types of cubosomes coloaded
with NR and HOE probes to identify LDs and nuclear
morphology, respectively. The IOD per cell value of nontreated
control cells was set to 100%, and values of cubosome-treated
cells were expressed as a percentage of control. Results are
reported in Figure 4a,b.
At a short incubation time (2 h) with targeted cubosomes,
the size and number of LDs, detectable as punctuated green
ﬂuorescent cytoplasmic structures dispersed throughout the
cytoplasm, did not show signiﬁcant diﬀerences in comparison
to treated nontargeted cubosomes and untreated control cells.
On the contrary, statistically signiﬁcant diﬀerences were
observed after 4 h of incubation. In those cells, a noteworthy
increase in the IOD per cell of 1.6-fold (p < 0.05) was
estimated with targeted cubosomes, in comparison to the 2 h
treatment and 1.8-fold (p < 0.001) increase in comparison to
that of nontargeted cubosomes. In contrast, the latter did not
show signiﬁcant diﬀerences in comparison to the 2 h treatment.
At a longer exposure time (24 h), both nanoparticles were
eﬀectively internalized. However, treatment with targeted
cubosomes caused a 1.2-fold increase (p < 0.05) in the IOD/
cell in comparison to that of nontargeted nanoparticles (2.9-
and 3.5-fold increases (p < 0.0001) in traditional and FA-
containing cubosomes, respectively, versus the control). At this
time, LDs appeared as ﬂuorescent bright spots with a globular
shape that were more numerous and larger in a remarkable way
(1 to 2 μm diameter). Importantly, neither a sign of
morphological damage nor chromatin condensation (Hoechst
positive nuclei) was observed after both types of nanoparticle
treatment (data not shown).
Confocal Microscopy. HeLa cells treated with dye-
unloaded (control) or dye-loaded cubosomes were imaged by
confocal microscopy after ﬁxation with 4% paraformaldehyde
for 10 min at room temperature (Figure 5). Note that
chromatin was also stained with the Hoechst marker to identify
the positions of cell nuclei (Figure 5b,e). Since the dye is
infrared-emitting, ﬂuorescence collection at >680 nm was
obtained by using a single-photon avalanche photodiode with
30 and 5% photon sensitivities at 700 and 900 nm, respectively.
An inspection of control cells reveals that some autoﬂuor-
escence is produced in the IR region of ﬂuorescence collection
upon excitation at 458 nm (Figure 5c). However, dye-loaded
cells display signiﬁcant diﬀerences in the morphology and
distribution of emitters (Figure 5f). In fact, the dye-treated cells
display a bright, cell-wide emission background together with
large emitting perinuclear spots, while both features are nearly
absent in control cells. (Note that panels c and f share the same
ﬂuorescence pseudocolor scale, i.e., the intensity diﬀerences are
real.) Overall, these ﬁndings are consistent with an internal-
ization of the dye mediated by cubosome nanocarriers.
Figure 3. Normalized emission of an aqueous dispersion of targeted
cubosomes (stabilized with the mixture F108/F108-FA = 80/20)
loaded with camptothecin and the NIR-emitting dye. (a) Emission
band of camptothecin at 428 nm (λexc = 340 nm); (b) emission band
of the dye at 938 nm (λexc = 418 nm).
Figure 4. Lipid droplet accumulation induced in HeLa cells by
cubosome treatment. (a) Representative color images of nontreated
HeLa cells (control) and cells exposed to the monoolein-based
cubosomes dispersed through a 80/20 mixture of F108/F108-FA at 4
and 24 h of incubation time. Scale bar = 20 μm. (b) Results of lipid
droplet formation at diﬀerent incubation times. Data are expressed as
the mean ± SD from at least two independent experiments.
Statistically signiﬁcant diﬀerences are indicated by * (p < 0.05) and
*** (p < 0.0001) via the t test.
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■ CONCLUSIONS
Recent works suggested the possibility of using cubosomes in
theranostic nanomedicine.40,58,59 Here, the potential use of
cubosomes as theranostic nanoparticles also having targeting
properties was explored. The physicochemical investigations
proved that these nanoparticles, still retaining their inner
nanostructure, can be eﬀectively stabilized by mixtures of
Pluronic F108 and folate-conjugated F108. Furthermore, it was
demonstrated that camptothecin, a potent anticancer drug, and
an NIR-emitting ﬂuorescent probe (a squaraine) can be
successfully loaded within the cubosomes. Finally, the cellular
uptake of these innovative nanocarriers was monitored on
HeLa cells. Following the indication given by the cell lipid
droplets in terms of their increase in number and growth in
size, the superior performance of the cubosomes stabilized
through the F108 and folate-conjugated F108 Pluronics
mixtures was conﬁrmed. Indeed, even if at longer treatment
times (24 h) both targeted and nontargeted cubosomes were
eﬀectively internalized and diﬀerences were partially leveled
out, results collected at short incubation time (4 h) clearly
evidenced that the conjugation of Pluronic with folate speeds
the cubosomes uptake as a result of receptor−ligand
interactions.
On the whole, the results presented here validate cubosomes
as a useful platform for theranostic nanomedicine.
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Figure 5. Fluorescence microscopy images of HeLa cells treated with dye-free (a−c) or dye-loaded cubosomes (d−f). (a, d) Transmission
micrographs of cells; scale bar = 10 μm. (b, e) Fluorescence micrographs collected in the 420−480 nm interval where nuclear marker Hoechst emits.
(c, f) Fluorescence micrographs collected at >680 nm where the dye emits; both images display ﬂuorescence according to the same pseudocolor
intensity scale (inset).
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We  present  here  an  innovative,  ﬂuorescent,  monoolein-based  cubosome  dispersion.  Rather  than  embed-
ded within  the  monoolein  palisade,  the  ﬂuorescent  imaging  agent,  namely  dansyl,  was  conjugated  to the
terminal  ethylene  oxide  moieties  of  the  block  copolymer  Pluronic  F108. We  discuss  the  physicochemical
and  photophysical  properties  of this  ﬂuorescent  Pluronic  and  of a cubosome  formulation  stabilized  by  a
mixture of  dansyl-conjugated  and  non-conjugated  Pluronic,  also  including  an  anticancer  drug  (quercetin).
Furthermore,  we  performed  biocompatibility  tests  against  HeLa  cells  to  assess  internalization  and  cyto-eywords:
onoolein
ubosomes
heranostic nanomedicine
luronic F108
luorophores
toxicity  features  of  this  nanoparticles  aqueous  dispersion.  Cryo-TEM,  SAXS,  and  DLS analysis,  proved  the
bicontinuous  cubic  inner  nanostructure  and  the morphology  of this  ﬂuorescent  cubosome  dispersion,
while  photophysical  measurements  and  biocompatibility  results  basically  validate  their potential  use  for
theranostic  nanomedicine  applications.
©  2015  Elsevier  B.V.  All  rights  reserved.
uercetin
. Introduction
Recent advances in nanomedicine resulted in the engineering of
 number of nanoparticle systems based on hard and soft matter,
ble to simultaneously transport therapeutics and act as diagnostic
gents. The new cross-discipline originating from these advances
s known as theranostic nanomedicine [1–4]. With the purpose
f enhancing the efﬁcacy of the formulation, while reducing side
ffects, theranostic nanoparticles are designed for delivery to the
ite of disease, and within the same dosage, both pharmaceutically
ctive molecules and imaging probes. This goal is often achieved
y coating the surface of theranostic nanoparticles with a target-
ng ligand to speciﬁcally address the nanocarrier and its cargo to
he pathological site. Additionally, this strategy of administration
∗ Corresponding authors. Tel.: +39 0706754453; fax: +39 0706754388.
E-mail addresses: murgias@unica.it (S. Murgia), amfalchi@unica.it
A.M. Falchi), meliv@unica.it (V. Meli), karin.schillen@fkem1.lu.se (K. Schillén),
ippolis@unica.it (V. Lippolis), monduzzi@unica.it (M.  Monduzzi), anrosa@unica.it
A. Rosa), sjudy@tx.technion.ac.il (J. Schmidt), ishi@tx.technion.ac.il (Y. Talmon),
anieri.bizzarri@nano.cnr.it (R. Bizzarri), ccaltagirone@unica.it (C. Caltagirone).
ttp://dx.doi.org/10.1016/j.colsurfb.2015.03.025
927-7765/© 2015 Elsevier B.V. All rights reserved.should allow to overcome the differences in biodistribution and
selectivity of the two distinct entities represented by the drug and
the diagnostic agent [5,6].
Monoolein (MO, glycerol monooleate) is a polar lipid that in
water, besides a reverse micellar and a lamellar phase, origi-
nates two  cubic bicontinuous liquid–crystalline phases, namely,
the gyroid (CG, space group Ia3d) and the double diamond (CD,
space group Pn3m), constituted by a curved, triply periodic, and
non-intersecting MO  bilayer, folded to form two disjointed con-
tinuous water channels [5–9]. The CG and the CD phases were
virtually found ubiquitous in nature [10], and several papers were
devoted to investigate the biological role of these nanostructures
[10–13]. Remarkably, dispersion agents like Pluronics, nonionic
poly(ethylene oxide)–poly(propylene oxide)–poly(ethylene oxide)
(PEO–PPO–PEO) triblock copolymers, can be used to formulate
these liquid–crystalline phases with cubic symmetry into stable
colloidal dispersions in water, known as cubosomes [14,15]. It
deserve noticing that colloidal dispersions characterized by a cubic
inner structure are also formulated using other kinds of polar
lipids (e.g., phytantriol or mixtures of soy phosphatidylcholine
and glycerol dioleate), and dispersants (e.g., D-alpha-tocopheryl
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oly(ethylene glycol) 1000 succinate, or Polyoxyethylene (20) sor-
itan monooleate) [16,17].
Cubosomeswereonly recently indicated as candidates for appli-
ations in theranostic nanomedicine [15,18,19]. Particularly, we
emonstrated that cubosomes can be at the same time loaded
ith ﬂuorophore probes (UV-visible or NIR emitting) and anti-
ancer drugs (such as quercetin or camptothecin), and that they
an be formulated with a mixture of Pluronic F108 (PF108) and
olic acid-conjugated PF108 to make them cancer cell-speciﬁc tar-
eted [20,21]. Among the numerous appealing features that can be
xploited in theranostic nanomedicine, we can list the high struc-
ural stability and mechanical rigidity of cubosomes (due to their
emi-rigid periodicity) they possesswith respect to liposomes [22],
heir biodegradability (they are mainly prepared using monoolein,
biocompatible and biodegradable monoglyceride generally rec-
gnized as safe, GRAS, by the FDA) [23], and the possibility of
arrying both hydrophobic and hydrophilic drugs. Importantly,
heir size ﬁts perfectly that required in cancer therapy for the
xploitation of the enhanced permeation retention (EPR) mecha-
ism, while their PEG corona should prevent opsonization of these
anoparticles, thus slowing clearance from the bloodstream by
he reticuloendothelial system[15,24]. Furthermore, in comparison
ith other lipid-basednanoparticles such as liposomes, cubosomes
ossess a huge interfacial surface area per unit of volume. Worth
entioning, in vitro investigations reported that components of
he human plasma interact with the monoolein-based cubosomes
rovoking a cubic-to-hexagonal phase transition of the nanostruc-
ure [25,26]. According to SAXS experiments, such transition can
e recorded few minutes after contact of the cubosomes with
lasma, and it is completed after 1h. Yet, an in vivo investigation
f monoolein-based cubosomes loaded with a MRI contrast agent
erformed in rats, evidenced that the formulation, characterized
y a half-life of about 90min, was well tolerated, and success-
ully provided MRI contrast in vivo [18]. Therefore, independent
f structure of the nanoparticles that ﬁnally reach the target tissue,
he originally administered cubosome formulation was effective in
elivering the imaging agent.
The formulation of functionalized cubosome dispersions is not
rivial. Indeed, similarly to other self-assembled nanoparticles,
ubosomes suffer of an intrinsic fragility. Therefore, even small
mounts of additives used, for example, to impart them the desired
eatures for nanomedicine application, may disturb the local sur-
actant dynamics, thus altering the original surfactant effective
acking parameter with a consequent collapse of the cubic matrix
15,27]. In other words, additive loading may induce the transi-
ion toward other kinds of nanostructured dispersions, or to phase
eparation.
An innovative approach to confer cubosomes ﬂuorescent prop-
rties while avoiding the impact of the imaging probe on the lipid
ilayer was developed here. Particularly, the ﬂuorophore, namely
ansyl, was conjugated to the hydrophilic moieties of the PF108
sed to stabilize the formulation. Given its solvatochromic proper-
ies, suchaﬂuorophorewaschosen toobtain further informationon
he nanostructure. In this paper, we discuss the physicochemical,
hotophysical, and HeLa cells internalization, and cytotoxic char-
cteristics of this new cubosome formulation, also loaded with the
nticancer drug quercetin.
. Materials and methods
.1. ChemicalsMonoolein (MO, 1-monooleoylglycerol, RYLO MG 19
HARMA, glycerol monooleate; 98.1wt %) was kindly pro-
ided by Danisco A/S, DK-7200, Grinsted, Denmark. The nonionic: Biointerfaces 129 (2015) 87–94
poly(ethylene oxide)–poly(propylene oxide)–poly(ethylene oxide)
(PEO–PPO–PEO) triblock copolymer Pluronic PF108 with a block
length composition of EO132–PO50–EO132 and an average molar
mass of 14,600g/mol, DMSO, Nile Red, MTT, quercetin, dansyl
chloride (≥95%), potassium carbonate (99%), acetonitrile (≥99.9%),
diethyl ether (≥99.5%), and dichloromethane (≥99%) were pur-
chased from Sigma-Aldrich. Distilled water passed through a
Milli-Q water puriﬁcation system (Millipore) was used to prepare
the samples.
2.2. Synthesis of dansyl-conjugated F108 (PF108-D)
K2CO3 (4mg, 2.9×10−2 mmol) and dansyl chloride (6.3mg,
2.32×10−2 mmol) were added to a solution of PF108–NH2 (86mg,
5.82×10−3 mmol) in anhydrous MeCN (5ml), and the result-
ing mixture was reﬂuxed under N2 atmosphere overnight. The
resulting turbid pale yellow solution was dried and the residue
was dissolved in dichloromethane, ﬁltered, and evaporated, under
reduced pressure. The yellowoil obtainedwaswashedwith diethyl
ether to eliminate excess dansyl chloride. The resulting yellow
stickyoilwaspuriﬁedbydialysis (14kDaMWcutoff) against deion-
ized water, changed every 3–6h for 3 days. The resulting product
was lyophilized for 3 days to remove all of the residualwater. Yield:
68% (60mg, 3.94mmol); mp: 49 ◦C. 1H-NMR (400MHz, DMSO-
d6, 298K): H 1.03 (d, J=4Hz; 3H×50, CH3 of PPO), 2.83 (s,
3H×4, -N(CH3)2 of the dansyl moieties) 3.48–3.55 (m, 3H×50,
4H×264, CH2 CH(CH3) O of PPO and CH2 CH2 O of PEO),
4.50–4.65 (m, 1H×2, sulphonamidic NH), 7.10–7.30 (m, 1H×2,
amidic NH), 7.7–8.2 (m, 6H×2, aromatic protons).
2.3. Sample preparation
Monoolein-based cubosomes were prepared and stabilized by
dispersing the appropriate amount of MO in water solutions of
a 65/35 mixture of PF108/PF108-D using an ultrasonic processor
UP100H by Dr. Hielscher (100W, 30kHz), at 90% of the maxi-
mum power with pulses of 1 s interrupted by 1 s breaks for 10min.
Doped cubosomes were obtained by dispersing the drug in the
melted monoolein with the help of an ultrasonic bath before mix-
ingwith the Pluronic solution. The sample volumewas usually 4ml
with approximately 96.4wt% of water, 3.3wt% of MO, and 0.3wt%
Pluronics mixture. Quercetin percentage was 3.3×10−4 wt%. SAXS
experiments were performed on samples prepared with 92.8wt%
of water, 6.6wt% of MO, and 0.6wt% of Pluronic mixture.
2.4. Dialysis and drug loading efﬁciency
After loadingwithquercetin, the cubosomedispersionwaspuri-
ﬁed from the non-encapsulated drug by dialysis: 2ml were loaded
into a dialysis tubing cellulose membrane (14kDa MW cutoff) and
dialyzed against water (1000ml), for 2h (by replacing the water
after 1h) at 5 ◦C. Drug loading efﬁciency (E%), expressed as per-
centage of the drug amount initially used, was determined by
UV–vis spectroscopy after disruption of cubosomeswithmethanol.
Quercetin content was quantiﬁed by a Thermo Nicolet Evolution
300 UV–vis spectrophotometer at 373nm.
2.5. Cryogenic transmission electron microscopy
Cryogenic transmission electron microscopy (cryo-TEM) exper-
iments were performed to visualize the cubosome nanoparticles.
Vitriﬁed specimens were prepared in a controlled environment
vitriﬁcation system (CEVS) at 25 ◦C and 100% relative humidity.
A drop (3l) of the sample was placed on a perforated carbon
ﬁlm-coated copper grid, blotted with ﬁlter paper, and plunged into
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iquid ethane at its freezing point. More details about the method-
logy can be found elsewhere [28]. The vitriﬁed specimens were
ransferred to a 626 Gatan cryo-holder and observed at 120 kV
cceleration voltage in an FEI Tecnai T12 G2 transmission elec-
ron microscope at about −175 ◦C in the low-dose imaging mode to
inimize electron-beam radiation-damage. Typical electron expo-
ures were 10 to 15 e-/Å2. Images were digitally recorded with a
atan US1000 high-resolution (2k × 2k pixels) CCD camera, using
he DigitalMicrograph software.
.6. Dynamic light scattering
For the determination of the size of the nanoparticles, the block
opolymer micelles and unimers, as well as the -potential of the
anoparticles, dynamic light scattering (DLS), and electrophoretic
obility measurements, respectively, were performed at either
5 ◦C or 50 ◦C (±0.1 ◦C) using ZetaSizer Nano ZSP (Malvern Instru-
ents Ltd., Worcestershire, U.K.), which is equipped with a 10 mW
elium–neon laser (operating at a wavelength of 633 nm). With
his instrument, the DLS measurements are carried out at a ﬁxed
cattering angle  = 173◦ using a backscattering technique. The
lectrophoretic mobility measurements are performed at  = 17◦
sing the M3-PALS (phase analysis light scattering) technique
o detect the particle movement, which is used to calculate its
lectrophoretic mobility and from which the -potential of the
anoparticles can be estimated [29,30]. The samples were put in
isposable polystyrene cuvettes of 1 cm optical path length with
illi-Q water as solvent and the two types of measurements were
hereafter conducted one after another, (DLS ﬁrst). The cubosome
anoparticle samples were diluted 1:50 times prior to the mea-
urements. The DLS measurements on the pure PF108 and PF108-D
lock copolymer solutions were performed without dilution at
 concentration of 2.9 × 10−4, and 3.8 × 10−4 M,  respectively. The
easured time correlation functions of the scattered intensity
ere analyzed using the software available in the Malvern instru-
ent (CONTIN for PF108 and PF108-D block copolymer solutions)
o obtain the intensity-weighted size distributions based on the
pparent hydrodynamic diameter, dH, which is calculated from
he Stokes–Einstein relation dH = kT/60D, where D is the trans-
ational collective diffusion coefﬁcient, obtained from the decay
ime of the correlation function, and 0 is the viscosity of water.
he reported dH values correspond to an average of between three
o ﬁve measurements. The DLS data were also analyzed using the
umulant method where the Z-average (intensity-weighted) dH is
alculated from the ﬁrst cumulant from the second order analy-
is [31,32]. The polydispersity index (PDI) deﬁned as the second
umulant, i.e.,  the width of the size distribution, divided by the ﬁrst
umulant squared was obtained in the cumulant analysis. For all
ystems and both techniques, at least two independently prepared
amples were investigated.
.7. Small-angle X-ray scattering (SAXS)
Small-angle X-ray scattering was recorded with a S3-MICRO
WAXS camera system (HECUS X-ray Systems, Graz, Austria). Cu K
adiation of wavelength 1.542 A˚ was provided by a GeniX x-ray gen-
rator, operating at 50 kV and 1 mA.  A 1D-PSD-50 M system (HECUS
-ray Systems, Graz, Austria) containing 1024 channels, 54.0 m
ide was used for detection of scattered X-rays in the small-
ngle region. The working q range (Å−1) was 0.003 ≤ q ≤ 0.6, where
 = 4sin()−1 is the scattering wave vector. For the analysis,
hin-walled 2 mm glass capillaries were ﬁlled with the cubosome
ispersions. The diffraction patterns of cubosomes were recorded
or 3 h. The lattice parameter a of the cubic phases was deter-
ined using the relation a = d(h2 + k2 + l2)1/2 from linear ﬁts of the
lots of 1/d  versus (h2 + k2 + l2)1/2, where d = 2/q (q is the measured: Biointerfaces 129 (2015) 87–94 89
peak position) and h, k, and l, are the Miller indices. Water channel
radii were calculated using the relation Rw = [(A0/–2)1/2a]–L [33],
where L is the lipid length value (17 A˚), a is the lattice parameter
obtained from the SAXS analysis, and A0 and  are the surface area
and the Euler characteristic of the inﬁnite periodic minimal surface
geometries (Pn3m, A0 = 1.919,  = −2; Im3m,  A0 = 2.345,  = −4).
2.8. Photophysical characterization
Cubosome dispersions were diluted with Milli-Q water (1:6)
and ultraﬁltered with 450 m ﬁlter before performing the photo-
physical measurements. The emission and excitation spectra were
recorded with a PerkinElmer LS 55 spectroﬂuorimeter. The ﬂuo-
rescence quantum yield on PF108-D was determined by using the
quinine sulphate dissolved in H2SO4 0.1 N as the reference standard
(˚ref = 0.5654). The absorption spectra were recorded on a Thermo
Nicolet Evolution 300 spectrophotometer.
2.9. Cell culture
Human carcinoma HeLa cell line (ATCC collection) was grown
in Phenol Red-free Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Invitrogen, USA) with high glucose, supplemented with 10% (v/v)
fetal bovine serum, penicillin (100 U ml−1), and streptomycin
(100 g ml−1) (Invitrogen) in a 5% CO2 incubator at 37 ◦C. Cells were
seeded in 35 mm dishes, and experiments were carried out 2 days
after seeding, when cells had reached 90% conﬂuency. Cubosomes
(1:500, 2 l of formulation in 1 ml  of medium) were added to the
cells and incubated at 37 ◦C for 4 h. Live cell imaging experiments
were performed as follows. The cubosome suspension was initially
replaced with fresh serum-free medium, and then cells were loaded
with the ﬂuorescent probe Nile Red (NR). The ﬂuorescent probe was
washed out before the imaging session.
2.10. Fluorescence microscopy
Cells were stained with 300 nM NR (9-diethylamino-5H-
benzo[a]phenoxazine-5-one) for 30 min. Microscopy observations
were made with a Zeiss (Axioskop) upright ﬂuorescence micro-
scope (Zeiss, Oberkochen, Germany) equipped with 10×,  20×,  and
40×/0.75 NA water-immersion objectives and an HBO 50 W L-2
mercury lamp (Osram, Berlin, Germany). Twelve-bit-deep images
were acquired with a monochrome-cooled CCD camera (QICAM,
Qimaging, Canada) with variable exposure. For the observation of
the NR probe, the ﬁlters were ex 470 ± 20 nm and em 535 ± 40 nm
for nonpolar lipids, and ex 546 ± 6 nm and em 620 ± 60 nm, for
total lipids. Image alignments were obtained with Image Pro Plus
software (Media Cybernetics, Silver Springs, MD).
2.11. Lipid droplet quantiﬁcation
Cells, after nanoparticle treatments, were stained with NR. The
latter is an ideal probe for the detection of lipids, as it exhibits high
afﬁnity, speciﬁcity, and sensitivity, to the degree of hydrophobic-
ity of lipids. The latter feature results in a shift of the emission
spectrum from red to green in the presence of polar, and nonpolar
lipids, respectively. For this reason, in staining live cells with NR,
cytoplasmic membranes are stained red, whereas neutral lipids of
lipid droplets are stained green. Measurements, made on a single-
cell basis, concerned the amount of lipid droplet content, evaluated
by the ﬂuorescence intensity of NR-green emission. The IOD (inte-
grated optical density) per cell was  calculated using the Image
ProPlus software.
90 S. Murgia et al. / Colloids and Surfaces B: Biointerfaces 129 (2015) 87–94
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.12. Cytotoxic activity: MTT assay
The cytotoxic effect of nanoparticle formulations was evalu-
ted in HeLa cells by the MTT assay. HeLa cells were seeded in
4-well plates at density of 3×104 cells/well in 500l of serum-
ontaining media. Experiments were carried out 2 days after
eeding when cells had reached 90% conﬂuence. Cubosomes were
dded to the cells at a concentration of 1:500 (2l of sample
n 1ml of serum-free medium) and incubated at 37 ◦C for 4h. A
0l portion of MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-
iphenyltetrazolium bromide) (5mg/ml in H2O), was then added
nd left for 2h at 37 ◦C. The mediumwas aspirated, 500l of DMSO
as added to the wells, and color development was measured at
70nm with an Inﬁnite 200 auto microplate reader (Inﬁnite 200,
ecan, Austria). The absorbance is proportional to the number of
iable cells. All measurements were performed in quadruplicate
nd repeated at least three times. Results are shown as percent of
ell viability in comparison with non-treated control cells.
.13. Statistics
Statistical analysis was carried out with Excel (Microsoft Co.,
edmond, WA) or Graph Pad INSTAT software (GraphPad software,
an Diego, CA). Results were expressed as a mean± standard devi-
tion (SD) of two independent experiments involving duplicate
nalyses for each sample. Statistically signiﬁcant difference was
valuated by two sample t-tests with p<0.05 as a minimal level
f signiﬁcance, or using one-way analysis of variation (One-way
NOVA) and the Bonferroni Post Test.
. Results
.1. Fluorescent cubosome formulation and physicochemical
haracterization
The block copolymer Pluronic F108 (PF108) was synthetically
odiﬁedas recently reported in the literature [20], by reactionwith
thylenediamine after activation with CDI (carbonyldiimidazole)
o obtain PF108-NH2. The aminated derivative was then reacted
ith commercially available dansyl chloride in anhydrous MeCNn the presence of K2CO3 as a base (Scheme 1). The sulfonamide
erivative PF108-D was obtained in 68% yield. To avoid signiﬁcant
lterations of the pristine cubosome characteristics, the ﬂuorescent
lock copolymer PF108-D was used to stabilize the formulation inthe synthesis of F108-D.
mixture with the non-conjugated PF108. Preliminary tests
indicated this mixture to be adequate in the ratio PF108/PF108-
D=65/35. The cryo-TEM images of the monoolein colloidal
dispersion stabilized with such a mixture (cubosomes-D), encap-
sulating an anticancer drug, namely quercetin, are shown in Fig. 1.
Quercetin loading efﬁciency (E%) was found to be 80%.
The cryo-TEM direct images of the nanoparticle dispersions
reveal a colloidal dispersion consisting of nanoparticles of a diame-
ter varying in the range fromabout 50 to 300nm, characterized by a
highly ordered inner nanostructure consistent with that expected
for cubosomes. From a morphological point of view, along with
many cubic-shaped nanoparticles, numerous round-shaped cubo-
somes were also observed. Moreover, as previously reported in the
literature, cryo-TEM images also show several small unilamellar
vesicles as well as nanoparticles where the so-called inter-lamellar
attachments can be clearly seen. [34]
SAXS was used to conﬁrm the cubic symmetry of the nanoparti-
cles. To improve the signal-to-noise ratio, these experiments were
performed on samples formulated with 7.2wt% of the dispersed
phase (MO+PF108/PF108-D mixture, see also paragraph 2.3). The
diffraction patterns reported in Fig. 2 revealed the coexistence of
two phases identiﬁed through at least two Bragg peaks with rela-
tive positions in a ratio of
√
2:
√
3, which we indexed as the (110)
and (111) reﬂections of a double diamond inverse bicontinuous
cubic phase (Pn3m crystallographic space group), and three Bragg
peaks with relative positions in a ratio of
√
2:
√
4:
√
6, which we
indexed as the (110), (2 00), and (211) reﬂections of a primitive
inverse bicontinuous cubic phase (Im3m crystallographic space
group) [34]. Structural parameters from SAXS measurements, such
as the lattice parameter (a) and the water channel radius (rW), are
reported in Table 1.
DLS results reported in Table 1 showed that the average hydro-
dynamicdiameters of thenanoparticles are ingoodagreementwith
that estimated from cryo-TEM images, and the size polydispersity
(i.e., the PDIs) and the -potential do not signiﬁcantly diverge from
those reported for similar formulations [20,21].
Formulations here investigated display a negative charge
although they are constituted by nonionic molecules. This fact
deserves some comments. To exclude the possibility that the neg-
ative charge might be ascribed to the presence of MO impurities,
a cubosome formulation was prepared using pure (>99%) MO from
Sigma Aldrich. This formulation was characterized by an average
diameter of the nanoparticles of 133±1nm and a negative zeta-
potential of −16±1mV. Moreover, also cubosomes formulations
S. Murgia et al. / Colloids and Surfaces B: Biointerfaces 129 (2015) 87–94 91
Fig. 1. Cryo-TEM image of monoolein-based cubosome nanoparticles empty (A) or containing the anticancer drug quercetin (B) and prepared using a mixture of PF108 and
PF108-D in the ratio 65/35. Small dark globules in B are frost particles. Bars correspond to 100 nm.
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oig. 2. SAXS diffractograms of monoolein-based cubosome nanoparticles either em
n  the ratio 65/35. Experiments were performed on samples formulated with 7.2 wt
repared using phytantriol (3,7,11,15-tetramethylhexadecane-
,2,3-triol) show a negative zeta-potential (about −9 mV)  [35]. It
hould be noticed that, differently from monoolein, this polar lipid
oes not contain ester bonds that can be hydrolyzed to form a
arboxylic acid. Consequently, also the presence of small amounts
f acids due to monoolein hydrolysis products (though possible)
annot fully justify the measured zeta-potentials in all these dif-
erent systems. On the other hand, hydroxide ions adsorption (a
henomenon often observed at the oil/water interface), originat-
ng a polarized water layer surrounding the outer surface of the
anoparticles, could explain the observed negative charge [36,37].
As expected, cryo-TEM, SAXS, and DLS analysis conﬁrmed
hat the presence of the ﬂuorophore molecules in the external
able 1
pace groups (in parenthesis), lattice parameters (a), and water channel radii (rW) obta
ndexes  from cumulant analysis (PDI), and -potentials obtained from DLS experiments o
5/35  ratio (wt%). An estimation of the sample stability is also reported. DLS and SAXS exp
f  the dispersed phase (see also the text). Errors are reported as ± estimated standard dev
Formulation a (Å) rW (Å) 
Cubosomes-D 104 ± 1 (Pn3 m)146 ± 1 (Im3 m)  24 ± 128 ± 1 
Cubosomes-D + QUE 102 ± 1 (Pn3 m)143 ± 1 (Im3 m)  23 ± 127 ± 1 ) or loaded with quercetin (B) and prepared using a mixture of PF108 and PF108-D
he dispersed phase (see also the text).
polyethylene oxide corona of the cubosomes did not modify the
supramolecular morphological features of the colloidal disper-
sion. Furthermore, after encapsulation of quercetin within the lipid
bilayer, the inner nanostructure of the cubosomes was preserved.
3.2. PF108-D, PF108 and ﬂuorescent cubosomes. Physicochemical
and photophysical characterization
Before analyzing the UV–visible light emission/absorption char-
acteristics of the new cubosome formulation, the physicochemical
and photophysical properties of the pure block copolymers (PF108
and PF108-D) in water were investigated. When dispersed in
aqueous solution the PEO–PPO–PEO block copolymers essentially
ined from SAXS experiments, mean hydrodynamic diameters (dH), polydispersity
n the cubosome formulations prepared with a mixture of F108 and F108-D in the
eriments were respectively performed on samples formulated with 3.6 and 7.2 wt%
iation (SD).
dH (nm) PDI -Potential (mV) Stability (weeks)
168 ± 1 0.15 −21 ± 1 >24
171 ± 1 0.14 −23 ± 1 >24
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cynamic diameter) obtained from DLS measurements on PF108 and PF108-D
olutions with the concentrations of 3.8×10−4 and 2.9×10−4 M respectively at 25
nd 50 ◦C.
ehave like classical surfactants containing PEO. Therefore, above
he critical micelle concentration (CMC), these block copolymers
elf-assemble forming variously shaped (spherical or rod-like
epending on the PPO and PEO block length) micelles [38]. These
opolymers also present a critical micelle temperature (CMT) due
he fact that PPO becomes hydrophobic at higher temperatures.
he CMT can be determinedusing differential scanning calorimetry
DSC) as the DSC signal is related to the change in the hydra-
ion of PPO, a process with an endothermic transition enthalpy,
hich occurs when the micelles are formed [39]. Furthermore,
n the same study, it was found that the CMT increases with a
ecreasing copolymer concentration. However, the description of
phericalmicelleswith a coreof dehydratedPPOblocks surrounded
y hydrated PEOblocks constituting an outer corona, although use-
ul for explaining most of the experimental data, is quite far from
epresenting the real micellar organization, since water can pene-
rate the micellar core to some extent, and miscibility of the PEO
nd PPO blocks is also allowed [40].
Water solutions of PF108 and PF108-D with the concentra-
ions of 3.8×10−4 M, and 2.9×10−4 M, respectively, were studied
t 25 and 50 ◦C using dynamic light scattering. The intensity-
eighted hydrodynamic diameter distributions obtained from the
ata analysis described above are reported in Fig. 3. The absence
f micelles in both solutions at 25 ◦C was expected because of
he low concentrations used, which were well below the CMC
t this temperature [41]. In our measurements, the PF108 solu-
ion at 25 ◦C presents a monomodal size distribution with a mean
ydrodynamic diameter of 8.1nm, which can be attributed to the
opolymer monomers. When the temperature is raised to 50 ◦C
above the critical micelle temperature for a PF108 concentra-
ion of 3.8×10−4 M), the monomodal size distribution shifts to a
arger mean diameter of 24.3nm. This mode can be assigned to
icelles of PF108 and the size is in accordance with literature [41],
ifferently from the unmodiﬁed copolymer solution, at 25 ◦C, the
F108-D solution shows a bimodal size distribution characterized
y two peaks centered at 8.7 and 137.3nm, respectively (Fig. 3).
imodal size distributions are often found in DLS measurements
n PEO–PPO–PEO block copolymer solutions with concentrations
elow CMC or at temperatures below CMT. The two modes are typ-
cally related to the simultaneous presence of unimers and clusters.
he latter is an effect of the presence of low molecular weight (and
ore hydrophobic) copolymer fragments, the amount of which
an differ between different commercial batches [42,43]. These: Biointerfaces 129 (2015) 87–94
contaminants become incorporated into the micelles once they are
formed, except themost hydrophilic components, that stay in solu-
tion [44,45]. Here, this scenario can be ruled out because of the
absence of clusters in the PF108 solution (both block copolymers
belong from the same batch). It is rather the hydrophobic inter-
actions between the dansyl moieties that may play an important
role in the formation of aggregates of PF108-D. This can justify the
existence of a second slowmode in the distribution. TheDLS results
for the PF108-D solution at 50 ◦C also reveal two modes, one corre-
sponding to a hydrodynamic mean diameter of 26.2nm and one to
150.5nm. The fastmode is attributed to PF108-Dmicelles, whereas
the slower one could possibly be related to aggregates of some sort
(however, not to unimer clusters as discussed above). It is worth
noticing that they are very few in numbers, but could well be the
effect of an ill-set base line in the calculations. Indeed, this peak
was found strongly affected by a base line contribution (several
measurements were performed). An evidence of their low number
is given in Fig. S1 (Supplementary data), where the same size distri-
bution presented in Fig. 3 is reported as number-averaged instead
of intensity-averaged.
As a concluding remark, DLS results evidenced that conjugation
of the dansylmoiety to the end of the PF108 arms signiﬁcantly alter
the self-assembling properties of this block copolymer.
Dansyl is a hydrophobic naphthalene derivative showing a
ﬂuorescence emission that shifts bathocromically as the polar-
ity of the surrounding medium increases. Therefore, ﬂuorescence
spectroscopy studies can give important information about
the environment experienced by this molecule. The absorp-
tion spectrum of PF108-D showed an absorption band at
247nm (ε=30,168M−1cm−1) and a less intense band at 344nm
(ε=7980M−1cm−1) as shown in Fig. 4A. Upon excitation at
344nm, an emission band centered at 532nm (˚=4.25×10−3)
was observed, as shown in Fig. 4B. Previous studies on the dansyl
molecule reported a ﬂuorescence emission maximum, which shifts
from 494nm when dispersed in a 10% Pluronic L62 (EO6PO36EO6)
water solution (where the dye preferentially resides in the micelle
hydrophobic core) to about 529nm when the dispersion medium
was a tetraethylene glycol/watermixture (used tomimic themicel-
lar PEOcorona) [46].Moreover, Bright and co-workers [47], showed
that in a dendrimeric family functionalized with a dansyl moi-
ety increase in dendrimers generation (from the ﬁrst to the third)
caused a hypsochromic shift in the ﬂuorophore emission (547nm,
542nm, and 535nm, for the ﬁrst, second, and third generation,
respectively) as a result of a less polarmicroenvironment surround-
ing the dansyl group. These results are also in accordance with
those reported in the literature for a dansyl group attached to den-
drimers [47,48], silica nanoparticles [49], or cyclodextrines [50].
Consequently, the emission observed in the aqueous solution of
the PF108-D can be considered a robust evidence that, rather than
completely exposed to the water molecules, the ﬂuorogenic frag-
ments experience a less polar environment mainly constituted by
the EO groups.
The absorption spectrum of the cubosomes formulation pre-
pared using the mixture of PF108 and PF108-D as a stabilizer could
not be recorded due to the intense scattering of the sample. How-
ever, when excited at 344nm, an emission band at 531nm was
found. The similarityof this emissionbandwith thatobserved in the
PF108-D aqueous solution strongly suggests that the ﬂuorogenic
fragments are at least partially buried within the PEO corona.
3.3. Fluorescent cubosome internalization and cytotoxic features
against HeLa cellsThe ﬂuorescent cubosome formulation was then investigated
in vitro to test cellular internalization and cytotoxicity features in
HeLa cell culture. Fig. 5A shows the optical images which highlight
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Fig. 4. Absorption (A) and emission (B) spectra (exc = 344 nm, em = 532 nm)  of a 6.9 × 10−5 M water solution of PF108-D.
Fig. 5. Lipid droplet accumulations induced in HeLa cells by cubosome treatment.
(A) Representative composite color images of HeLa cells exposed to monoolein-
based cubosomes (without quercetin loading) at 4 h incubation. Membranes (red)
and  lipid droplets (green) were stained with Nile Red. (B) IOD (integrated optical
density) per cell related to lipid droplet accumulation in HeLa cells exposed to lipid-
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he lipid droplet accumulation in HeLa cells as a result of cubosome
reatment.
The lipid droplets (LDs), cytoplasmic organelles involved in the
ontrolled synthesis and mobilization of fat stores, consist of a
hospholipid monolayer surrounding a hydrophobic core of neutral
ipids [51]. Although marked differences in terms of size, num-
er, and lipid content, are observed from one cell type to another
52], their increase basically occurs because of exogenous lipids
ptake. Indeed, cell internalization exposes cubosomes to endo-
omal/lysosomal degradation into the single components (MO  and
he block copolymer), with a consequent redistribution of the lipids
etween the cytoplasmic membranes and the lipid droplets. There-
ore, the amount of LDs straightforwardly reﬂect the internalization
f the cubosomes via endocytosis pathway, and LDs accumulation
an be used, at least in principle, to validate the cellular uptake of all
inds of lipid-based nanoparticles. Accordingly, LDs accumulation
ollowing monoolein-based nanoparticles (vesicles or cubosomes)
dministration was previously reported [20,53]. Here, the lipid
roplet growth caused by the internalization of two cubosome for-
ulations (not carrying the quercetin) prepared with PF108 or withFig. 6. Viability, expressed as % of the control, induced by incubation for 4 h with
lipid-based cubosomes (1:500, 2 l/ml) in HeLa cells culture. Three independent
experiments were performed and data are presented as mean ± SD (n = 12).
the PF108/PF108-D mixture was  conﬁrmed and quantiﬁed via esti-
mation of the IOD (integrated optical density) per cell. An increased
production of lipid droplets was observed for both nanoparticles at
4 h of incubation time in comparison with untreated-control cells,
as shown in Figs 5A and B. Results evidenced a statistically differ-
ent IOD/cell between nanoparticle formulations, very likely caused
by the dansyl moieties exposed on the surface of the cubosomes.
Indeed, dansyl may  to some extent, alter the molecular recognition
characteristics of the cubosomes’ surface, changing their interac-
tions with the cells.
The two aforementioned nanoparticle formulations were also
tested for cytotoxicity (MTT assay) in HeLa cells. Fig. 6 shows the
viability, expressed as % of the control, induced in HeLa cells after 4 h
incubation, and evidences that treatments with both nanoparticle
formulations did not induce a relevant reduction in cell viability in
comparison with control cells.
4. Conclusions
When dealing with soft matter based nanoparticles (such as
cubosomes or hexosomes), one of the issues researchers working in
the ﬁeld of nanomedicine have to face is the preservation of their
morphology and internal structure after cargos loading. To over-
come this problem, we proposed here a strategy that considers the
conjugation of a ﬂuorescence probe, namely dansyl, to the end of
the hydrophilic arms of the PEO–PPO–PEO block copolymer PF108,
which is used to stabilize an aqueous dispersion of monoolein-
based cubosomes. In this way, both the morphology and topology
were not signiﬁcantly altered by the presence of the ﬂuorescent
molecules.
The physicochemical investigation presented here demonstrate
that a mixture of this new ﬂuorescently labeled block copolymer
PF108-D and the original PF108 copolymer is effective in stabilizing
in water the cubosome formulation also encapsulating the anti-
cancer drug quercetin. The performed steady-state ﬂuorescence
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nd UV–vis experiments evidenced good photophysical properties
f such a formulation, while the microscopic observations on HeLa
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Taken on the whole, the results presented in our study validate
he potential use of this new cubosome formulation in theranostic
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ABSTRACT: Here, we describe a novel monoolein-based
cubosome formulation engineered for possible theranostic
applications in oncology. The Docetaxel-loaded nanoparticles
were stabilized in water by a mixture of commercial Pluronic
(poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene
oxide) triblock copolymer) F108 (PF108) and rhodamine-
and folate-conjugated PF108 so that the nanoparticles possess
targeting, therapeutic, and imaging properties. Nanoparticles
were investigated by DLS, cryo-TEM, and SAXS to conﬁrm
their structural features. The ﬂuorescent emission character-
ization of the proposed formulation indicated that the
rhodamine conjugated to the PF108 experiences an environ-
ment less polar than water (similar to chloroform), suggesting
that the ﬂuorescent fragment is buried within the poly(ethylene oxide) corona surrounding the nanoparticle. Furthermore, these
nanoparticles were successfully used to image living HeLa cells and demonstrated a signiﬁcant short-term (4 h incubation)
cytotoxicity eﬀect against these cancer cells. Furthermore, given their analogy as nanocarriers for molecules of pharmaceutical
interest and to better stress the singularities of these bicontinuous cubic nanoparticles, we also quantitatively evaluated the
diﬀerences between cubosomes and multilamellar liposomes in terms of surface area and hydrophobic volume.
1. INTRODUCTION
The amphiphilic characteristics of polar lipids drive their self-
assembly in water, giving a number of liquid-crystalline
phases.1,2 Among them, the most interesting are probably the
reverse bicontinuous cubic phases.3 These are a family of three-
dimensional cubic structures constituted by a curved, non-
intersecting lipid bilayer folded to form two disconnected,
continuous water channels with a crystal lattice that can be
described by three diﬀerent types of inﬁnite periodic minimal
surfaces: the double diamond (space group Pn3m), the gyroid
(space group Ia3d), and the primitive (space group Im3m).
These phases have been extensively investigated in recent
decades because they represent versatile nanostructures able to
incorporate molecules of biological relevance.4−8 Interestingly,
cubic phases can be formulated as aqueous nanoparticle
dispersions, known as cubosomes.9 Although various emulsi-
ﬁers have been suggested,10,11 in general, the stabilization in
water of such liquid-crystalline nanoparticles is achieved using
amphiphilic polymers having long poly(ethylene oxide) (PEO)
chains, e.g., Pluronics (poly(ethylene oxide)-poly(propylene
oxide)-poly(ethylene oxide) triblock copolymers) or poly-
sorbate 80.9,12
Similar to the reverse liquid-crystalline cubic bulk phases,
pharmaceutical applications are predicted for cubosomes,13−17
and their potential use as nanocarriers for MRI probes has been
investigated.18,19 These nanoparticles have also been proposed
for theranostic applications.20−25 Indeed, several peculiar
characteristics make cubosomes appealing as theranostic tools
in oncology. Among these, one of the most distinguishing is the
higher hydrophobic volume with respect to liposomes, often
considered to be the golden standard for lipid-based nano-
carriers in medicine. However, a quantitative comparison of the
hydrophobic portion of these two kinds of nanoparticles has
never been reported in the literature. Other cubosome-speciﬁc
features are the simultaneous possibility of host therapeutics
and imaging agents as well as a size (typically in the range 100−
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200 nm) that, at least in principle, allows the exploitation of the
enhanced permeation retention mechanism for the passive
targeting of cancer tissues.9,26 In view of their application as
nanomedicine, it is also worth mentioning that the clearance
from the bloodstream via the mononuclear phagocytic system
should be retarded since, by analogy to stealth liposomes, these
nanoparticles are enclosed within a sort of a PEO corona that
should prevent eﬃcient recognition by opsonin, thus hindering
phagocytosis.27 Moreover, it was demonstrated that cubosomes
(and hexosomes) can be suitably formulated by covering their
surface with folate residues20,28 or anti-EGFR Fab29 to actively
target these nanocarriers toward cancer cells, while the eﬀects
on the subcellular level of pristine monoolein-based cubosomes
were recently investigated for HeLa cells.30 Remarkably,
nanoparticles with reverse bicontinuous cubic internal structure
endowed with long-time stability and thermoresponsive
capabilities can be formulated using polymer−surfactant
mixtures.31
To explore further the potential of lipid-based liquid-
crystalline nanoparticles as theranostic nanomedicine in cancer
treatments, we report here the loading of monoolein-based
cubosomes with a potent anticancer drug (Docetaxel). Such a
formulation was stabilized with a mixture of commercial
Pluronic F108 (PF108), folate-conjugated PF108 (PF108-FA),
and rhodamine-conjugated PF108 (PF108-R) to simultane-
ously confer targeting, therapeutic, and imaging abilities on
these nanoparticles. It deserves notice that engineering stable,
multifunctional cubosome formulations can be a hard task.
While the hydrophobic eﬀect represents the main force that
drives the self-assembly of the lipids constituting the nano-
particles, their inner phase is basically determined by the
geometrical features of the lipid hydrophobic tail and polar
head. This is rationalized by the molecular eﬀective packing
parameter (Peff) given by the ratio v/al, where v and l are,
respectively, the hydrophobic chain volume and length (taken
as 80% of the fully extended chain) and a is the headgroup
area.1 Peff is strongly dependent on the surrounding environ-
ment; therefore, the type of phase that characterizes the
nanoparticles (and their very existence) is barely predictable in
the presence of additives, since encapsulation within the lipid
bilayer of molecules useful for giving these nanoparticles
theranostic skills may signiﬁcantly alter Peff, thus provoking the
transition of the inner phase or the collapse of the formulation.9
In addition, the decoration of the cubosome surface with
targeting and/or ﬂuorescent moieties may disturb both the
colloidal stability of the formulation and the cellular uptake of
the nanoparticles. Throughout this paper we will demonstrate
that the proposed cubosome formulation, although prepared
with a high portion (40%) of conjugated PF108, is stable and
successfully delivers its cargo to HeLa cells, taken as the
standard for cancer cells.
Moreover, considering the analogies between liposomes and
cubosomes, we also presented here a theoretical evaluation of
the hydrophobic volume of these liquid-crystalline nano-
particles.
2. MATERIALS AND METHODS
2.1. Materials. Monoolein (MO, 1-monooleoylglycerol, RYLO
MG 19 PHARMA, glycerol monooleate, 98.1 wt %) was kindly
provided by Danisco A/S, DK-7200, Grinsted, Denmark. Pluronic
F108 (PEO132-PPO50-PEO132), Docetaxel (≥97%), N-hydroxysucci-
nimmide (NHS, 98%), N,N′-dicyclohexylcarbodiimide (DCC, ≥
99.5%), triethylamine (≥99.5%), and dimethyl sulfoxide (≥99.7%)
were purchased from Sigma-Aldrich. Distilled water passed through a
Milli-Q water puriﬁcation system (Millipore) was used to prepare the
samples.
2.2. Sample Preparation. Monoolein-based cubosomes were
prepared and stabilized by dispersing the appropriate amount of MO
in aqueous solutions of a 60/20/20 mixture of Pluronic F108 (PF108)
and folate-conjugated and rhodamine-conjugated PF108 (PF108/
PF108-FA/PF108-R) using an ultrasonic processor (UP100H by Dr.
Hielscher, cycle 0.9, amplitude 90%) for 10 min. Docetaxel-doped
cubosomes were obtained by dispersing the drug in the melted lipids
(at 37 °C) with the help of an ultrasonic bath before mixing with the
Pluronic solution. The sample volume was usually 4 mL with
approximately 96.4 wt % water, 3.3 wt % MO, and 0.3 wt % Pluronics
mixture.
2.3. Synthesis of Rhodamine-Conjugated PF108 (PF108-R).
PF108-NH2 (0.1976 g, 0.013 mmol), N-hydroxysuccinimmide (NHS,
0.0125 g, 0.108 mmol), N,N′-dicyclohexylcarbodiimide (DCC, 0.0188
g, 0.091 mmol), and N-(9-(2-(4-(3-carboxypropanoyl)piperazine-1-
carbonyl)benzyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-ethyle-
thanaminium (4; 0.024 g, 0.039 mmol) were dissolved in 8 mL of
anhydrous DMSO in the presence of triethylamine (20 μL). To
precipitate DCU (dicyclohexylurea), 20 mL of deionized water was
added, and the mixture was then centrifuged and ﬁltered to obtain a
red limpid solution. This was dialyzed (14 kDa MW cutoﬀ membrane)
for 3 days against ultrapure water, which was changed every 2−6 h.
The resulting product was lyophilized for 1 day to remove all of the
residual water. Yield 63% (130.3 mg, 0.008 mmol); mp 48−50 °C. 1H
NMR (400 MHz, DMSO-d6, 298 K): δH 1.045 (3H × 50, −CH3 of
PPO), 1.17−1.33 (m, 3H × 2, −N(CH2−CH3)2), 2.66−2.69 (m, 4H
× 2, aliphatic protons from rhodamine moiety), 3.29−3.55 (m, 3H ×
50, 4H × 264, −CH2−CH(CH3)−O− of PPO and −CH2−CH2−O−
of PEO), 3.60−3.73 (m, 2H × 2, −N(CH2−CH3)2), 4.53−4.56 (m,
1H × 2, amidic −NH), 6.95−8.07 (m, 10H × 2, aromatic protons). IR
(solid state, cm−1) ν = 2876 (s), 1584, 1635, 1714 (w).
2.4. Photophysical Characterization. Cubosome dispersions
were diluted with Milli-Q water (1:100) before performing the
photophysical measurements. The emission and excitation spectra
were recorded with a PerkinElmer LS 55 spectroﬂuorimeter. The
ﬂuorescence quantum yield on PF108-R was determined by using
Rhodamine 6G dissolved in EtOH as the reference standard (Φref =
0.94). The absorption spectra were recorded on a Thermo Nicolet
Evolution 300 spectrophotometer.
2.5. Cryogenic Transmission Electron Microscopy (cryo-
TEM). Vitriﬁed specimens were prepared in a controlled environment
vitriﬁcation system (CEVS) at 25 °C and 100% relative humidity. A
drop (∼3 μL) of the sample was placed on a perforated carbon ﬁlm-
coated copper grid, blotted with ﬁlter paper, and plunged into liquid
ethane at its freezing point. The vitriﬁed specimens were transferred to
a 626 Gatan cryo-holder and observed at 120 kV acceleration voltage
in an FEI Tecnai T12 G2 transmission electron microscope at about
−175 °C in the low-dose imaging mode to minimize electron-beam
radiation damage. Images were digitally recorded with a Gatan US1000
high-resolution CCD camera.
2.6. Small-Angle X-ray Scattering (SAXS). The characterization
of the nanoparticle structure as a function of temperature was carried
out by SAXS using a Ganesha 300XL (SAXSLAB ApS, Skovlunde,
Denmark). This instrument is equipped with a 2D 300 K Pilatus
detector (Dectris Ltd., Baden, Switzerland) and a Genix 3D X-ray
source (Xenocs SA, Sassenage, France), generating X-rays at a
wavelength, λ, of 1.54 Å. The scattering data was collected over a q
range of 0.014 < q (Å−1) < 0.753, where the magnitude of the
scattering vector, q, is deﬁned as q = (4π/λ) sin(θ/2), where θ is the
scattering angle. The two-dimensional scattering pattern was radially
averaged using SAXSGui software to obtain I(q). Measurements were
performed in 1.5 mm quartz capillaries (Hilgenberg GmbH, Malsfeld,
Germany). The temperature was controlled by an external
recirculating water bath within ±0.3 °C. Samples were equilibrated
for 1 h at the measurement temperature prior to performing the
experiment.
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Water channel radii of the reverse bicontinuous cubic phases were
calculated using the relation rw = [(A0/−2πχ)1/2a] − L, where L is the
length of the lipid hydrophobic chain (17 Å, in the case of MO), a is
the lattice parameter obtained from the SAXS analysis, and A0 and χ
are the surface area and the Euler characteristic (integral Gaussian
curvature scaled by 2π) of the inﬁnite periodic minimal surface
geometries within the unit cell, explained further in the Appendix
(Pn3m, A0 = 1.919, χ = −2; Im3m, A0 = 2.345, χ = −4). At least two
Bragg peaks were used to estimate the errors associated with a and rw,
unless otherwise indicated.
2.7. Light Scattering. Dynamic light scattering (DLS) experi-
ments were performed to obtain the size evolution of the nanoparticles
as a function of temperature. For that we used a light-scattering
goniometer instrument (3D LS spectrometer, LS Instruments,
Fribourg, Switzerland), equipped with a 35 mW He−Ne laser light
source (wavelength of 632.8 nm). The instrument implements the so-
called cross-correlation scheme to suppress contributions from
multiple scattering32−34 together with a modulation unit.35 The
samples were placed in 10 mm diameter cylindrical borosilicate
disposable culture tubes (Fisherbrand, Thermo Fisher Scientiﬁc Inc.,
Waltham, MA, USA) and kept at the measurement temperature in a
temperature-controlled index-matching bath. Samples were equili-
brated at the measurement temperature for 10 min before the
experiment. Measurements were performed at a range of scattering
angles between 40 and 100° (in triplicate at each scattering angle).
The initial decay rate, Γ, was derived from the second-order cumulant
analysis of the normalized ﬁeld autocorrelation function, which was
used to calculate the apparent collective diﬀusion coeﬃcient, D0, of the
nanoparticles
Γ = D q0 2 (1)
where q is the module of the scattering vector, q = (4πn/λ)sin(θ/2),
with n being the refractive index of the solvent, λ being the wavelength
of the incoming laser light, and θ being the scattering angle. The
hydrodynamic radius, Rh, was obtained by the Stokes−Einstein
relation (D0 = kBT/6πηRh), where kB is the Boltzmann constant, T
is the absolute temperature, and η is the viscosity of the solvent at
temperature T.
2.8. Cell Culture. HeLa cells (ATCC collection) were grown in
phenol-red-free Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Molecular Probes, USA) with a high glucose concentration,
supplemented with 10% (v/v) fetal bovine serum, penicillin (100 U
mL−1), and streptomycin (100 μg mL−1) (Invitrogen) in a 5% CO2
incubator at 37 °C. Cells were seeded in 35 mm dishes; experiments
were carried out 2 days after seeding, when cells reached 90%
conﬂuency. Liquid-crystalline nanoparticles were added to the cells at a
concentration of 1:500 (2 μL in 1 mL of fresh medium) and incubated
at 37 °C for 4 h. For live cell imaging, fresh serum-free medium was
used to remove the extracellular particle suspension before the imaging
session.
2.9. Fluorescence Microscopy. Light microscopy observations
were made using a Zeiss (Axioskop) upright ﬂuorescence microscope
(Zeiss, Oberkochen, Germany) equipped with 10×, 20×, and 40×/
0.75 NA water immersion objectives and an HBO 50 W L-2 mercury
lamp (Osram, Berlin, Germany). Twelve-bit-deep images were
acquired with a monochrome-cooled CCD camera (QICAM,
Qimaging, Canada). For the observation of dye ﬂuorescence, ﬁlters
were ex 546 ± 6 nm and em 620 ± 60 nm. Digital images were
obtained with Image Pro Plus software (Media Cybernetics, Silver
Springs, MD, USA).
2.10. Cytotoxic Activity (MTT Assay). The cytotoxic eﬀect of
cubosome formulations was evaluated in HeLa cells by the MTT assay.
HeLa cells were seeded in 24-well plates at a density of 3 × 104 cells/
well in 500 μL of serum-containing media. Experiments were carried
out 2 days after seeding when cells had reached 90% conﬂuence. The
diﬀerent formulations were added to the cells at a concentration of
1:500 (2 μL in 1 mL of serum-free medium) and incubated at 37 °C
for 4 h. The eﬀect of Docetaxel 10 μM (speciﬁcally, 1 μL of a 10 mM
solution of Docetaxel in DMSO was added to 1 mL of serum-free
medium) on HeLa cell viability was also tested for comparison at the
same incubation time. A 50 μL portion of MTT solution (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (5 mg/mL in
H2O) was then added and left for 2 h at 37 °C. The medium was
aspirated, 500 μL of DMSO was added to the wells, and color
development was measured at 570 nm with an Inﬁnite 200
automicroplate reader (Inﬁnite 200, Tecan, Austria). The absorbance
is proportional to the number of viable cells. All measurements were
performed in quadruplicate and repeated at least three times. Results
are shown as the percentage of cell viability in comparison with
nontreated control cells. Data were expressed as a mean ± standard
deviation (SD) of three independent experiments involving quad-
ruplicate analyses for each sample.
2.11. Determination of MO and Docetaxel Content in
Cubosomes. After loading with Docetaxel, the cubosome dispersion
was puriﬁed from the nonencapsulated drug by dialysis: 2 mL was
loaded into a dialysis tubing cellulose membrane (14 kDa MW cutoﬀ)
and dialyzed against water (1000 mL) for 2 h (by replacing the water
after 1 h) at 25 °C. It should be noticed that this puriﬁcation step did
not inﬂuence the concentration of the dye in the formulation since the
ﬂuorophore-conjugated PF108 has a MW higher than the membrane
cutoﬀ (about 16 kDa). Therefore, in comparison to traditional
methods that require enclosing the dye within the lipid bilayer, this
new procedure allows a huge saving of the (typically very expensive)
dye. Aliquots (10 μL) of the nanoparticle preparations were dissolved
in 300 μL of CH3CN with 0.14% CH3COOH (v/v). The samples
were vortex mixed to obtain a clear solution, and aliquots (20 μL)
were injected into the Agilent Technologies 1100 liquid chromato-
graph (Agilent Technologies, Palo Alto, CA) equipped with a diode
array detector (DAD). Analyses of MO (detected at 200 nm) and
Docetaxel (at 230 nm) in nanoparticle dispersions were carried out
with a XDB−C18 Eclipse (150 ×́ 4.6 mm2, 3.5 mm particle size)
(Agilent Technologies) equipped with a Zorbax XDB−C18 Eclipse
(12.5 × 4.6 mm2, 5 mm particle size) guard column (Agilent
Technologies), with a mobile phase of CH3CN/H2O/CH3COOH
(75/25/0.12 v/v/v) at a ﬂow rate of 2.3 mL/min. The temperature of
the column was maintained at 37 °C. Recording and integration of the
chromatogram data was carried out through an Agilent OpenLAB
chromatography data system. The identiﬁcation of lipid components
and drug was made using standard compounds and conventional UV
spectra. Calibration curves of all of the compounds were constructed
using standards and were found to be linear, with correlation
coeﬃcients >0.995.
The drug encapsulation eﬃcacy (EE%) was calculated by the
following equation:36 EE% = (weight of the drug in nanoparticles)/
(weight of the feeding drug) × 100%. Data were expressed as a mean
± standard deviation (SD) of three independent experiments involving
duplicate analyses for each sample.
2.12. Statistical Analysis. An evaluation of the statistical
signiﬁcance of diﬀerences was performed using Graph Pad INSTAT
software (GraphPad software, San Diego, CA, USA). Comparison
between groups was assessed by one-way analysis of variance (one-way
ANOVA) followed by the Bonferroni multiple comparisons test.
3. RESULTS
3.1. Synthesis of Rhodamine-Conjugated PF108 and
Liquid-Crystalline Nanoparticle Characterization. When
designing a nanoparticle for diagnostic or theranostic
applications, two diﬀerent approaches could be adopted: one
is doping the nanoparticle with the imaging agent (a ﬂuorescent
probe, for instance); the other is functionalizing the nano-
particle with the imaging agent. This approach is quite
straightforward in the case of silica-based nanoparticles, which
can be easily functionalized by well-established siloxane
chemistry.37 The functionalization of nanoparticles as the
cubosomes reported here can eﬃciently be achieved by
conjugating the amphiphilic polymers used to stabilize the
formulation (Pluronic F108, PF108, in our case) with a suitably
Langmuir Article
DOI: 10.1021/acs.langmuir.5b02101
Langmuir 2015, 31, 9566−9575
9568
chemically modiﬁed imaging agent.38 Here, ﬂuorogenic
molecule rhodamine B was conjugated to PF108 via a
multisteps approach (Scheme 1). First, the ﬂuorophore was
synthetically modiﬁed as reported in the literature39 to obtain
its piperazine amide derivative (4) that was subsequently
conjugated to the aminated derivative of PF108.40 The reaction
was carried out in DMSO in the presence of DCC, NHS, and
Et3N. Then, the product was dialyzed against deionized water
and lyophilized.
Since the folate receptor is overexpressed on the cancer cell
membrane, PF108 was also conjugated with folic acid as
previously reported20 to actively target the nanoparticles toward
cancer tissues.
A mixture of commercial PF108, folate-conjugated PF108
(PF108-FA), and rhodamine-conjugated PF108 (PF108-R) was
used to formulate cubosome dispersions in water also loaded
with anticancer drug Docetaxel (DTX). According to
preliminary tests, it was found that a mixture having the ratio
PF108/PF108-FA/PF108-R = 60/20/20 (wt %) suitably
stabilizes the dispersion for more than two months. This
formulation was then investigated for its morphological and
structural aspects by cryo-TEM, SAXS, and DLS measure-
ments.
Figure 1 shows a typical cryo-TEM image of the cubosome
formulation we proposed. A close inspection of the image in
Figure 1 reveals a number of spherical cubosomes of diﬀerent
sizes and an inner structure characterized by a dark matrix and
alternate bright spots, respectively, representing the lipid bilayer
and the water channels. As often occurs, some vesicular
materials can be seen to be attached to the liquid-crystalline
nanoparticles while, diﬀerently from other cubosome for-
mulations, only a few vesicles are noticed. Indeed, unilamellar
or oligolamellar vesicles typically form during the process of
cubosome production, very likely because of the presence of
the Pluronic used as a dispersant (MO in water does not
produce small unilamellar or oligolamellar vesicles).41 Actually,
depending on the method of preparation, vesicles may exceed
Scheme 1. Synthesis Procedure Adopted for the Preparation of PF108-R
Figure 1. Cryo-TEM image of the cubosome formulation stabilized by
a 60/20/20 mixture of commercial PF108, folate-conjugated PF108,
and rhodamine-conjugated PF108.
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cubosomes in terms of number density.42 Therefore, the
absence of vesicular material observed here could be ascribed to
the use of the conjugated Pluronics as a stabilizer for cubosome
formulation.
Taking into account the possible use of the system under
study as a theranostic nanocarrier, the variation of the size and
inner structure upon temperature changes was monitored
through DLS and SAXS measurements in the range of 10−50
°C. In particular, the temperatures were chosen to include two
extreme storage temperatures (10 and 50 °C) as well as room
and physiological temperatures. Moreover, to ﬁnd out if the
system nanostructure after temperature cycling is reestablished,
SAXS measurements were performed in the following order:
25, 37, 50, 10, 25, and 37 °C. Results are reported in Figure 2
and Table 1.
SAXS results conﬁrmed the bicontinuous cubic inner
structure of the formulation. Actually, the diﬀraction pattern
of the cubosome formulation at 25 °C (Figure 2) is dominated
by four Bragg peaks placed in a q ratio of 21/2:31/2:2:61/2 that
clearly identify the double diamond (Pn3m) bicontinuous cubic
phase. However, a weak reﬂection at low q reveals the
simultaneous presence of the primitive (Im3m) bicontinuous
cubic phase. The coexistence of the Pn3m and the Im3m phases
in cubosome formulations is widely reported in the literature; it
is attributed to a Pn3m to Im3m intercubic phase transition
caused by the interaction of the hydrophobic moiety of the
Pluronic with the surface of the cubosome nanoparticles.43
The lattice parameter, a, obtained from the SAXS experi-
ments performed at diﬀerent temperatures along with the
calculated radius of the water channels rw (section 2.3) are
reported in Table 1. As usually detected in liquid-crystalline
systems, although the nanostructure is retained, the lattice
parameter (and consequently the radius of the water channels)
of the cubosomes decreases while the temperature increases in
the sequence 25, 37, 50 °C. This phenomenon is related to the
enhanced disorder of the lipid chain at higher temperatures
that, in turn, induces higher negative curvature at the lipid/
water interface.43 The disappearance of the weaker Bragg peaks
detected in the diﬀraction patterns obtained at 10 °C (Figure
2) indicates that the inner structure is in some way altered,
although not completely lost. When the temperature is raised
again to 25 or 37 °C, the nanostructure is recovered. However,
some signiﬁcant diﬀerences can be noticed in the intensity of
the Bragg peaks and the general appearance of the diﬀracto-
grams after the temperature cycle. Therefore, it can be
concluded that while the nanostructure is reestablished, the
system evolution upon temperature changes is characterized by
a certain degree of hysteresis.
The overall trend described by the DLS measurements of the
nanoparticles’ hydrodynamic radius can be extrapolated from
the results reported in Table 2. Essentially, the nanoparticle
average size does not vary signiﬁcantly with temperature
changes.
3.2. Rhodamine-Conjugated Liquid-Crystalline Nano-
particle Photophysical Characterization and HeLa Cell
Imaging. The photophysical properties of PF108-R and those
of cubosomes were investigated. Rhodamine dyes belong to the
Figure 2. I(q) vs q data obtained by SAXS recorded at diﬀerent temperatures of the cubosome formulation stabilized by the same Pluronic mixture
as in Figure 1. The Miller indices are reported on top of the corresponding Bragg peaks with the indication of the space group in the case of the
bicontinuous cubic phases.
Table 1. Cubosome Lattice Parameters (a) and Radius of the
Water Channels (rw)
a
Pn3m Im3mb
T (°C) a (Å) rw (Å) a (Å) rw (Å)
25 97.0 ± 0.5 20.9 ± 0.2 129.6 22.6
37 89.2 ± 0.2 17.9 ± 0.1 118.7 19.3
50 80.7 ± 0.2 14.5 ± 0.1 109.6 16.5
25 97.1 ± 0.6 21.2 ± 0.3 123.1 20.6
37 90.5 ± 0.7 18.4 ± 0.3 118.7 19.3
aExperiments were performed at diﬀerent temperatures in the order
reported in the table. bStandard deviations on a and rw pertaining to
Im3m phase were not reported since these parameters were obtained
from the single Bragg peak discernible in the diﬀraction pattern.
Table 2. Average Hydrodynamic Radius (Rh) and
Polydispersity Index (PdI) of the Cubosome Formulation at
Diﬀerent Temperatures
T (°C) Rh (nm) PdI
10 85 0.13
25 90 0.16
37 88 0.14
50 87 0.21
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class of xanthene dyes, characterized by an intense red
ﬂuorescence, high brightness, excellent photostability, and the
ability to modulate the properties of the dye through
substitution.44 A key property of these dyes is the equilibrium
between an open, colored, ﬂuorescent quinoid form or a closed,
colorless, nonﬂuorescent lactone, which can be controlled by
appropriate substitution.45 In particular, rhodamine B (bearing
two diethyl amino substituents) is one of the most common
derivatives.
The emission/absorption properties of PF108-R were
investigated in water and chloroform to test its photophysical
features in media of diﬀerent polarities. In both solvents PF108-
R has a strong absorption band at 560 nm (ε = 30 660 M−1
cm−1, 31 770 M−1 cm−1 in water and chloroform, respectively)
and a shoulder at 522 nm (ε = 13 100 M−1 cm−1, 9950 M−1
cm−1 in water and chloroform, respectively). Upon excitation at
522 nm in water, an emission band at 594 nm is generated.
Conversely, the excitation at the same wavelength in chloro-
form generates a strong emission band at 584 nm. The
quantum yields measured were 0.16 and 0.58, respectively, in
water and chloroform. As expected, water has a quenching
eﬀect on the rhodamine ﬂuorescence. The shift of the emission
to higher energy could be explained by considering the
solvatochromic properties of the ﬂuorophore.
The emission spectrum of the cubosome formulation
stabilized with the PF108/PF108-FA/PF108-R = 60/20/20
(wt %) mixture was also recorded after 1:100 dilution in water.
Excitation at 522 nm resulted in emission bands centered at
581 nm (Figure 3). The position of the maximum emission
wavelength is similar to that observed for PF108-R in
chloroform. These results suggest that the rhodamine fragment
conjugated to the Pluronic F108, rather than protruding toward
the bulk water, is hidden within the poly(ethylene oxide)
corona surrounding the nanoparticle, thus experiencing a less
polar environment. The excitation spectrum of cubosomes is in
accordance with PF108-R absorption in both water and
chloroform. Due to the turbidity of the solution the
determination of the quantum yield of the dye in the
nanoparticles was not possible.
The uptake of cubosome nanoparticles was investigated by
ﬂuorescence microscopy. After 4 h of incubation, faint diﬀuse
ﬂuorescence was distributed within the cytoplasm of HeLa
cells, whereas in untreated control cells no ﬂuorescence was
detected (Figure 4). However, it was not possible to determine
whether the dye molecules were localized in speciﬁc cell
compartments.
3.3. Monoolein and Docetaxel Levels in Cubosome
Formulations and Cytotoxic Activity (MTT Assay). The
amount of MO (expressed as mg/mL of dispersion) and
Docetaxel (DTX, μg/mL) in diﬀerent cubosome formulations
was monitored by HPLC. The formulations analyzed were the
traditional cubosome formulation stabilized with PF108
(CUB), the cubosome formulation stabilized with the
PF108/PF108-FA/PF108-R = 60/20/20 (wt %) mixture
(CUB-R), and the latter formulation also loaded with DTX
(CUB-R/DTX).
Monoolein contents in CUB, CUB-R, and CUB-R/DTX
formulations were 33 ± 3, 35 ± 2, and 29 ± 2 mg/mL,
respectively. The CUB-R/DTX formulation was loaded with
328 ± 25 μg/mL of drug, with a DTX/MO molecular ratio of
1/200. The encapsulation eﬃcacy (EE%) was 103 ± 13%.
These formulations were tested for cytotoxicity (MTT assay)
in HeLa cells. Figure 5 shows the viability, expressed as the % of
the control, induced in HeLa cancer cells in the presence of the
nanoparticle formulations at a concentration of 1:500 (2 μL/
mL of medium) after 4 h of incubation. The cytotoxic eﬀect of
10 μM DTX (section 2.10) was also determined after 4 h of
incubation for comparison. Treatment with CUB and CUB-R
formulations did not induce a signiﬁcant reduction in cell
viability, in comparison with control cells (Ctrl). Diﬀerently,
the incubation with CUB-R/DTX particles induced a statisti-
cally signiﬁcant decrease in HeLa cell viability (36% reduction)
Figure 3. Normalized emission (λexc = 522 nm) and excitation (λem =
581 nm) spectra of the aqueous cubosome formulation stabilized using
the same Pluronic mixture as in Figure 1.
Figure 4. Fluorescence microscopy of living HeLa cells treated with
cubosomes not carrying the drug (incubation for 4 h) showing a
diﬀuse cytoplasmic ﬂuorescence in treated cells indicating nanoparticle
uptake. Scale bar = 20 μm.
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with respect to the control as a result of the presence of the
anticancer drug. A signiﬁcant cytotoxic eﬀect (27% reduction in
cell viability) was also observed in cells treated with the
anticancer drug (DTX) directly added to the cell culture.
Remarkably, the HeLa cell treatment with DTX-loaded
cubosomes (DTX dose of approximately 0.8 μM) induced a
superior cytotoxic eﬀect compared to the molecularly dispersed
anticancer drug tested at much higher (12.5-fold) concen-
tration.
DTX is one of the most eﬀective anticancer agents and has
activity against a wide range of cancers. The growth inhibitory
eﬀect of DTX was examined in several cancer cell lines, and the
IC50 (50% inhibitory concentration) values of this taxoid were
in the nanomolar range at long-time incubation (72 h)46,47 The
24 and 48 h IC50 values of the free DTX in HeLa cells were
previously found to be 5.01 and 2.62 μg/mL, respectively.48
Here, the higher cytotoxicity after 4 h of incubation of DTX
administered via the nanoparticles (0.66 μg/mL) with respect
to free drug molecules (8.08 μg/mL) can be explained by
calling into play diﬀerent uptake mechanisms. Indeed,
cubosomes can deliver DTX into cells via endocytosis while
free DTX can enter cells via passive diﬀusion with inherent
lipophilicity, and various ABC eﬄux transporters, expressed at
the cellular membrane, can minimize its eﬀective penetration by
eﬃciently eliminating the drug from the cell.49
3.4. Cubosomes versus Multilamellar Liposome
Hydrophobic Volume. One important feature that distin-
guishes cubosomes (reverse bicontinuous cubic liquid-crystal-
line nanoparticles) from liposomes (their lamellar counterpart)
is the higher hydrophobic volume of the former. Since
cubosomes are mainly proposed as nanocarriers for hydro-
phobic molecules of pharmaceutical interest as an alternative to
liposomes, this fact may be extremely relevant in view of their
theranostic applications. Given the very convoluted volumes
occupied by lipid chains in bicontinuous morphologies
compared to the shells of liposomes, it is tempting to assume
that the former contains a far larger hydrophobic volume
(suitably) normalized than the latter. Surprisingly, the
quantiﬁcation of the hydrophobic volumes of bicontinuous
cubosomes with respect to multilamellar liposomes has never
been reported.
Assume for simplicity that we have two nanoparticles
composed of monoolein in water whose outer diameter is
100 nm. Assume that the liposome is composed of N
concentric spherical monoolein bilayers, composed of pairs of
monolayers, each with a hydrophobic thickness of 17 Å,
corresponding to the likely chain length in molten monoolein
assemblies. Furthermore, assume that adjacent bilayers are
separated by polar ﬁlms that are 16 Å thick, so that each
monolayer has an associated polar layer of thickness of 8 Å
(corresponding to dimensions in the fully hydrated lamellar
mesophase).50 Each repeat unit of chains, monoolein head-
groups, and water is therefore 50 Å thick. The hydrophobic
volume is then calculated as the chain contribution to the total
volume within N concentric nested shells whose outermost
radius is scaled such that the outermost monolayer and
associated polar layer has a diameter of 100 nm. These
dimensions imply that the hydrophobic volume fractions within
the liposome (whose total volume is 5.24 × 105 nm3) are
approximately 0.18, 0.33, 0.445, 0.53, and 0.59 nm3 for N = 1−
5 bilayers, respectively. The exposed outermost monolayer has
an area of 2.83 × 104 nm2.
The structural dimensions of a typical cubosome can be
estimated as follows. We assume the cubosome to be a single-
crystalline domain of the Im3m phase, also contained within a
spherical shell of diameter 100 nm (cubosome nanoparticles,
although characterized by a cubic inner nanostructure, can be
spherical in shape, such as those shown in Figure 1). We
choose a typical lattice dimension of the Im3m unit cell,
namely, 130 Å, and ﬁx the chain length to be the same as that in
the liposome, 17 Å (the polar dimensions are then ﬁxed by
those parameters). The resulting total exposed area is then 1.68
× 105 nm2 (equal to the summed area of each monolayer
displaced 17 Å from the bilayer midsurface, whose geometry is
assumed to lie on the P surface, the cubic periodic Im3m
minimal surface). Surprisingly, the membrane area exposed to
water in the liposome is substantially larger than the total area
in the cubosome. The corresponding hydrophobic volume
fraction within the 100 nm cubosomal sphere is 0.59 nm3,
which is greater than that of the liposome with up to ﬁve
bilayers (Table 3).
4. CONCLUSIONS
In this paper we demonstrated that cubosomes loaded with an
anticancer drug, namely, Docetaxel, can be formulated by
decorating their nanoparticle surface with both a cancer-cell-
targeting ligand and an imaging probe. It is worth noticing that
this is the ﬁrst time that Docetaxel is successfully loaded within
cubosomes and that the cubosome surface is simultaneously
decorated with targeting and imaging moieties. To this aim, the
commercial block copolymer Pluronic F108 (PF108) and its
folate- and rhodamine-conjugated counterparts were used in a
60/20/20 (wt %) mixture to stabilize the lipid liquid-crystalline
Figure 5. Viability, expressed as % of the control, induced in HeLa
cells by incubation for 4 h in the presence of diﬀerent types of
cubosome formulations (CUB, CUB-R, and CUB-R/DTX, see the
text) and Docetaxel (DTX). The drug concentration in the CUB-R/
DTX formulation (0.8 μM) is 12.5-fold lower than in the DTX
molecular dispersion (10 μM). Results are expressed as a mean ±
standard deviation (SD) of four independent experiments involving
quadruplicate analyses for each sample (n = 4). *** = P < 0.001; ** =
P < 0.01 versus Ctrl, and data were analyzed using one-way ANOVA.
Table 3. Cubosome-to-Liposome Hydrophobic Volume
Ratios (Vh) as a Function of the Number of Concentric
Bilayers in the Liposomea
number of bilayers 1 2 3 4 5
Vh ratios 3.22 1.79 1.33 1.12 1.00
aSee also the text.
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dispersion. SAXS, DLS, and cryo-TEM investigation, over the
temperatures range explored, conﬁrmed the cubic bicontinuous
inner structure of the nanoparticles and showed the
physicochemical aspects (morphology and size) akin to those
of traditionally prepared cubosome dispersions. Photophysical
measurements suggested that the ﬂuorogenic fragment,
although conjugated to the terminal ethylenoxide moiety of
PF108, was very likely exposed to the less polar environment
constituted by the poly(ethylene oxide) corona surrounding the
nanoparticles, rather than protruding toward the bulk water.
This formulation, not loaded with the drug, was successfully
used to image living HeLa cells. Besides, viability tests revealed
a signiﬁcant cytotoxic eﬀect (more than 1 order of magnitude
larger than the molecularly dispersed drug) of the Docetaxel-
loaded nanoparticles against HeLa cells. These results
evidenced that the loading of cubosomes with a Docetaxel
dose able to induce cytotoxic eﬀects on HeLa cells and the
decoration of their surface with 40% conjugated PF108 did not
compromise the intrinsic nature of these peculiar nanoparticles
and their cellular uptake. We have also evaluated the diﬀerences
between cubosomes and multilamellar liposomes in terms of
surface area and hydrophobic volume. Under the imposed
constraints (same molecular building block and nanoparticle
volume, cubosome nanostructure characterized by the Im3m
space group with a lattice parameter of 130 Å, and multilamellar
liposome constituted of adjacent bilayers), these calculations
demonstrated that the hydrophobic volume of cubosomes is
more than 3 times larger than that of single-bilayer liposomes,
but the cubosome-to-liposome hydrophobic volume ratio
rapidly converges to unity as the number of the bilayers in
the liposome increases. It is worth noting that this ratio will be
even larger if the liposome contains nonadjacent bilayers.
Remarkably, the cubosome surface exposed to water is about
60% with respect to that of the liposome.
Taken together, these ﬁndings demonstrate the good
performance of cubosomes as peculiar nanocarriers for
hydrophobic molecules with therapeutic/diagnostic relevance
and encourage the investigation of a cubic bicontinuous liquid-
crystalline dispersion for possible applications as theranostic
tools.
■ APPENDIX
Geometrical Calculations
Denote the chain length by d, the thickness of the polar layer
(containing water plus headgroups) by t, and the lattice
parameter in the cubic mesophase by a. Assume that the outer
shape of the liposome and the cubosome is a sphere of outer
diameter L.
We assume that all interfaces, lining the monolayers at the
chain−water interface and the free chain ends, are parallel. We
then use the formalism described elsewhere1 to deduce
dimensions. All dimensions are calculated from the geometry
of the imaginary surface S that runs between the chain ends in
opposed monolayers at the midsection of the hydrophobic shell
for each bilayer. The “outer” surfaces, exposed to water, are
parallel to S and displaced by d from S. We have two formulae
derived from the geometry of parallel surfaces, both related to
the mean and Gaussian curvatures of S, denoted HS and KS,
respectively. One is for the area of the surface Sx, parallel to S,
displaced by a distance x
= + +Sx S Hx Kxarea( ) area( )(1 2 )2
(where the sign of x depends on whether it is on the outside or
the inside of the surface). The second describes the volume of
the ﬁlm lying in between S and Sx:
= + +
⎛
⎝⎜
⎞
⎠⎟Sx S x Hx
Kx
volume( ) area( ) 1
3
2
In the liposome, those surfaces are parallel spheres, and if it is
made of N bilayers, there are N such spheres, each one with
radius
= − − +r i L i d t( )
2
(2 1)( )
These dimensions impose mean and Gaussian curvatures on
bilayer i equal to
= −H i r i( ) ( ) 1
= −K i r i( ) ( ) 2
The exposed area of the liposome is that of the outermost
spherical monolayer (displaced a distance t inwards from the
100 nm external shell), namely, 4πr(1)2. The total volume is
Vtotal = (4/3)π(L/2)
3. The hydrophobic (chain) volume in the
liposome is determined by summing over all 2N monolayers, N
displaced x and N displaced −x:
∑π= + +
+ − +
=
⎧⎨⎩
⎛
⎝⎜
⎞
⎠⎟
⎛
⎝⎜
⎞
⎠⎟
⎫⎬⎭
N d r i H i d
d
K i
H i d
d
K i
volume( ) 4 ( ) 1 ( )
3 ( )
1 ( )
3 ( )
i
N
1
2
2
2
(1)
The corresponding calculation for the cubosome follows
directly from the normalized surface to volume ratio or
“homogeneity index” characteristic of a particular folded surface
geometry
πχ
=
−
:
area
( 2 ) volume
Q
3/2
1/2/
where χ is the Euler characteristic of the hyperbolic bilayer
within the particle. If the cubosome is contained within a
spherical shell of diameter L and the membrane within folds
onto a periodic minimal surface to form a cubic lattice of edge a
whose topology per unit cell is χ0, then χ = χ0(Vtotal/α
3). The
radius of curvature of the minimal surface is given by the
expression
πχ
=
−
⎧⎨⎩
⎫⎬⎭r 2Q
1/3/
which corresponds to minimal surface curvatures HQ = 0 and
KQ = −rQ−2.
50 It follows that the minimal surface area in the
cubosome is
πχ= −Varea { ( 2 ) }Q total 1/2 2/3/
so that the exposed area (at the hydrophobic/hydrophilic
interface) is
= − Kdarea 2area (1 )exposed Q 2
and the hydrophobic volume is
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= +
⎛
⎝
⎜⎜
⎞
⎠
⎟⎟dKvolume 2area 1 3Q exposed
3
Q (2)
If the internal bilayer geometry within the cubosome
corresponds to the Im3m bicontinuous mesophase, then the
relevant data are = 0.7163/ and χ0 = −4.51 The ratios of
hydrophobic volumes are calculated from the results of eqs 1
and 2 above.
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Valeria Meli,a Maura Monduzzi,a Tommy Nylander,c Antonella Rosa,b Judith Schmidt,d
Yeshayahu Talmond and Sergio Murgia*a
We here discuss the potential theranostic nanomedicine application of an innovative formulation consisting
of monoolein-based nanoparticles with a two-dimensional hexagonal inner structure stabilized in water
using a mixture of PEO132–PPO50–PEO132 block copolymers with and without conjugated folate for
targeting. The proposed tumor-cell targeted formulation was shown to be able to simultaneously host
the model anticancer drug camptothecin and a pyrene-modiﬁed BODIPY ﬂuorophore, based on
dynamic light scattering, small-angle X-ray scattering, and cryogenic transmission electron microscopy.
The photophysical properties of the ﬂuorophore were studied in solution in various solvents. A marked
ﬂuorescent solvatochromism, whose origin was explained by time-dependent density functional theory
theoretical calculations, was observed. Fluorescence microscopy showed that HeLa cells readily
internalize these nanoparticles, and that the ﬂuorophore localizes within the lipid droplets. In addition,
cytotoxicity test revealed that these nanoparticles are not toxic at the concentration used for the
imaging analysis.1. Introduction
Polar lipids such as phospholipids or monoglycerides are
amphiphilic in nature, therefore they self-assemble in aqueous
solution to form a number of diﬀerent liquid crystalline phases.
Among others, monoolein (MO, glycerol monooleate) received
much attention in the last three decades because of its rich
structural polymorphism.1–3 Besides a reverse micellar phase
found at very low water content, the MO binary phase diagram
at 25 C is characterized by a lamellar (La) and two cubic
bicontinuous liquid crystalline phases, namely, the gyroid (CG,
space group Ia3d) and the double diamond (CD, space group
Pn3m). The last two are constituted by a curved, triply periodic,
and non-intersecting MO bilayer folded to form two disjoint
continuous water channels. Although the role of the CG and the
CD phases in the cell machinery is not fully claried, they werehe, Universita` degli Studi di Cagliari, S.S.
CA, Italy. E-mail: ccaltagirone@unica.it;
ta` di Cagliari, S.S. 554 Bivio Sestu, I-09042,
t of Chemistry, Center for Chemistry and
. Box 124, SE-221 00 Lund, Sweden
ion – Israel Institute of Technology, Haifa
(ESI) available: Material and methods;
lculations. See DOI: 10.1039/c5ra01025j
hemistry 2015virtually found ubiquitous in nature,4 and several papers were
devoted to shed some light on the biological function of this
amazing nanostructures.5–7 Remarkably, the entrapment of
lipophilic molecules into these cubic bicontinuous phases may
alter the MO eﬀective packing parameter, causing the evolution
towards a reverse hexagonal phase8 (i.e., a bulk phase organized
in water cylinders surrounded by a MO monolayer, and packed
in a two-dimensional hexagonal array), while the local order and
dynamics of the MO alkyl chain remains unaltered.9,10 The
polymorphism of MO in water can be extended by adding small
amounts of lauroylcholine chloride, which causes the formation
of a very stable solution of small unilamellar vesicles.11,12 When
increasing the dispersed phase content, they organize into a
vesicle gel.13
As for lamellar phases that can be dispersed into vesicles, the
cubic and hexagonal phases can be formulated into stable
colloidal dispersion in water, known as cubosomes and hex-
osomes, respectively. In order to obtain mono-disperse formu-
lations, a dispersion agent like the nonionic poly(ethylene oxide)–
poly(propylene oxide)–poly(ethylene oxide) (PEO–PPO–PEO) tri-
block copolymers, known as Pluronics, can be used.14,15 These
copolymers anchor their hydrophobicmoiety in the nanoparticle,
while protruding their hydrophilic segments into the solvent.
This provides the particles with a PEO corona, which ensures a
strong steric stabilization of the nanoparticles. Recently, such
dispersions were proposed as platforms in theranostic nano-
medicine.16–20 With the purpose of discovering and treatingRSC Adv., 2015, 5, 23443–23449 | 23443
Scheme 1 Adopted synthetic procedure for the preparation of Py-
BODIPY.
Table 1 Quantum yield (F), excitation and emission wavelength (lexc
and lemis, respectively) of Py-BODIPY with diﬀerent solvents
Solvent lexc (nm) lemis (nm) F
Hexane 504 523 0.25
Toluene 507 582 0.14
DCM 505 670 2.0  102
THF 504 630 4.0  102
EtOAc 502 627 4.3  103
Acetone 502 662 8.9  103
DMF 505 670 6.1  103
MeCN 499 708 4.9  103
DMSO 507 709 9.5  103
EtOH 502 651 6.8  103
MeOH 501 662 5.6  103
Fig. 1 Fluorescence spectra of Py-BODIPY in diﬀerent solvents. [Py-
BODIPY] ¼ 2.5  105 M; lexc between 499 and 507 nm (see Table 1).
RSC Advances Paperdiseases at the earliest stage and with limited side eﬀects, a new
strategy to engineer diﬀerent kinds of nanocarriers for the sus-
tained, controlled, and targeted delivery of both therapeutic and
diagnostic agents at the same time has emerged.21 Indeed, our
group has demonstrated that, as with other kinds of nano-
particles, cubosomes can be simultaneously loaded with optical
imaging agents and anticancer drugs.16,19 Cubosome and hex-
osome formulations possess a number of properties that can be
exploited in nanomedicine but, most of all, (i) they have the right
size for theranostic applications, and (ii) they are biodegradable.
Moreover, these nanoparticles can be considered to be stealth
particles, because their PEO corona is expected to prevent the
adsorption of macromolecules on the nanoparticle surface. This
prevents the formation of the biomolecular corona, thus
reducing the clearance from the bloodstream via the mono-
nuclear phagocytic system (MPS).22 When considering cubo-
somes and hexosomes for cancer diagnostic and therapy (as in
the case discussed in this paper), it deserves also noticing that
their size is within the range required for the tumor tissues
passive targeting through the enhanced permeation mechanism
(EPR).23 We also proved that decoration of their surface with
targeting moieties capable of addressing them at cancer cells is
feasible, making these lipid-based nanoparticles even more
appealing for theranostic nanomedicine applications in
oncology.16
Over the past decade increasing eﬀorts have been devoted to
the synthesis of new organic chromophores or nanoparticles24,25
with strong absorption and emission bands for imaging appli-
cations, both in vitro and in vivo. In particular, considerable
attention has been addressed towards the development of
derivatives of 4,4-diuoro-4-bora-3a,4a-diaza-s-indacene (BOD-
IPY) because of their high molar extinction coeﬃcients and
quantum yields, excellent photostability and high solubility in
commonly used organic solvents. BODIPY derivatives have been
included into diﬀerent type of nanoparticles,26–33 belonging
both to the hard and the so matter realm.
Here, we report the formulation of MO-based hexosomes
loaded with both the model chemotherapeutic drug campto-
thecin and a pyrene-modied BODIPY uorophore (Py-BODIPY)
also stabilized by a mixture of Pluronic F108 (PF108) and folate-
conjugated PF108 (PF108-FA), and investigate their physico-
chemical and photophysical properties. Theoretical calcula-
tions were used to elucidate the origin of the peculiar
uorescent properties of Py-BODIPY and the localization of the
dye inside the nanoparticles.
2. Results and discussion
2.1. Pyrene-modied BODIPY (Py-BODIPY) synthesis and
solvatochromic properties
The typical emission of unsubstituted BODIPY chromophore
falls in the region 470–530 nm, but the position of the
maximum of luminescence can be modulated by substitution at
diﬀerent positions of the BODIPY skeleton, and in particular of
the meso-carbon atom. The strategy of functionalizing BODIPYs
on the meso-carbon with polyaromatic rings such as naphtha-
lene,34 anthracene,34 and phenanthrene,35 in order to improve23444 | RSC Adv., 2015, 5, 23443–23449the photophysical properties of the chromophore have been
widely adopted.
In particular, the BODIPY derivative containing a pyrene
group (Py-BODIPY) in themeso position was reported for the rst
time by Pen˜a-Cabrera and co-workers36 using the Liebeskind–
Sro¨gl cross-coupling reaction between 8-thiomethylBODIPY and
pyrene boronic acid, catalyzed by copper(I) thiophene-2-
carboxylate (CuTC). Herein, we succeeded in synthesizing
Py-BODIPY using the classic Lindsey method,37 i.e., acid-
catalyzed condensation of 1-pyrenecarboxaldheide with
pyrrole, followed by oxidation with DDQ and exposure to tri-
ethylamine and BF3$Et2O (Scheme 1 and ESI† for synthetic
details).
Although the method reported by Pen˜a-Cabrera avoids
the synthesis of dipyrromethanes precursors which mightThis journal is © The Royal Society of Chemistry 2015
Table 2 Average nanoparticle diameter (Dav), polydispersity index
(PDI), and z-potential of various hexosome formulations. HexFA,
indicate the hexosome formulation stabilized by the folate-conjugated
PF108, while the capitol letters B and C in the acronyms indicate
formulations loaded with Py-BODIPY and/or camptothecin,
respectively
Formulation Dav (nm) PDI z-potential (mV)
HexFA 168  1 0.20 33  1
HexCFA 170  1 0.20 36  1
HexBFA 177  1 0.22 32  1
HexCBFA 172  1 0.20 35  1
Paper RSC Advancesbe diﬃcult to purify, it requires the synthesis of both 8-thio-
methylBODIPY and the catalyst. The Lindsey method is more
straightforward to prepare Py-BODIPY as it requires two steps,
being the 1-pyrenecarboxaldheide commercially available.
Here, we studied the photophysical properties of Py-BODIPY
in diﬀerent solvents covering a variety of polarities larger than
that previously reported,38 and ranging from apolar hexane to
polar DMSO (Table 1). While the absorption spectrum of
Py-BODIPY showed negligible changes in the diﬀerent solvents
(ESI, Fig. S1†), its emission properties were strongly dependent
on the polarity of the solvent, with the maximum of the uo-
rescence emission ranging from 523 nm in hexane to 709 nm in
DMSO (Fig. 1).Fig. 2 Synchrotron SAXS diﬀraction patterns recorded at diﬀerent
temperatures of the hexosome formulation stabilized by the mixture
PF108/folate-conjugated PF108 and loaded with Py-BODIPY and
camptothecin (HexCBFA). TheMiller indices (hk) are reported on top of
the corresponding Bragg reﬂections.2.2. Nanoparticles physicochemical and photophysical
characterization
The hexosome nanoparticles investigated are engineered for
theranostic applications in oncology. Therefore, to confer on
them targeting properties towards tumor tissues, the stabiliza-
tion of the nanoparticles was achieved using a 80/20 mixture of
commercial PF108 and the folate-conjugate PF108 (PF108-FA).
The synthesis of PF108-FA and its use for the formulation of
targeted theranostic cubosomes were previously described in
ref. 16. Since tumor cells oen overexpress folate receptors, the
folate molecules conjugated to the terminal PEO moieties of
PF108 on the particle surface will actively favor the enrichment
of nanoparticles at cancer cells compared to healthy cells.
Hexosomes were also simultaneously loaded with Py-BODIPY,
for optical imaging purposes, and camptothecin, an anti-
cancer drug that, along with its analogues, was demonstrated to
be eﬀective in the treatment of a broad spectrum of tumors. The
loading eﬃciency of the dye and the drug (E%, expressed as
percentage of the amount of the drug and the dye present in the
formulation before dialysis, see ESI†) were 97% and 54%,
respectively. The physicochemical characterization of the hex-
osome formulation containing both the diagnostic and the
therapeutic agent (HexCBFA) was performed by DLS, SAXS, and
cryo-TEM. For the sake of comparison the other targeting hex-
osome formulations, empty (HexFA) as well as those containing
only the drug (HexCFA) or the dye (HexBFA), were also investi-
gated by DLS (see ESI† for Experimental details).
In general, DLS results reported in Table 2 conrm that the
80/20 mixture of PF108/PF108-FA was able to stabilize the
formulations as a nanometer-size particle dispersion with quite
a low polydispersity and highly negative z-potential. Moreover,
encapsulation of the uorophore and the drug, even when they
are formulated simultaneously, did not cause appreciable
alterations in the size, the PDI, and the z-potential of the
nanoparticles (Table 2).
The inner symmetry and the stability as a function of the
temperature of the HexCBFA formulation were determined by
synchrotron SAXS experiments. The diﬀraction patterns recor-
ded at 25, 37, and 50 C are reported in Fig. 2. All of them are
dominated by a strong reection peak followed, at higher q
values, by two weaker reections. The positions of these three
Bragg peaks, in the ratio 1 : O3 : 2, are always consistent withThis journal is © The Royal Society of Chemistry 2015that expected for a reverse hexagonal phase. With temperature
increasing, the lattice parameters, a, were found to be 59(1),
57(1), and 55(1) A, respectively, while the corresponding
radius of the water channels rw were 31(1), 30(1), and 29(1)
A, respectively. This is as generally observed for liquid crystal-
line systems.39 Nonetheless, the nanoparticles retain their
internal reverse hexagonal symmetry even at the highest
temperature (50 C).
Cryo-TEM observations of the same sample (Fig. 3) showed
the presence of quasi-spherical nanoparticles characterized by
curved striations and the absence of the small unilamellar
vesicles usually found in cubosomes formulations, either
attached to the nanoparticles or dispersed as single entities.
Curved striations are a characterizing feature of the hex-
osomes,40,41 and are related to the peculiar conguration
adopted by the close (hexagonally) packed and deformable
water tubes that constitutes the internal nanostructure.42
From a photophysical point of view, when the HexCBFA
formulation (dilution 1 : 30) was excited at 330 nm an emission
band with the maximum centered at 532 nm (Fig. 4) wasRSC Adv., 2015, 5, 23443–23449 | 23445
Fig. 3 Cryo-TEM image of the same sample investigated in Fig. 2.
Fig. 4 Emission spectra of Py-BODIPY in hexane (blue curve) (lexc ¼
350 nm) and of HexCBFA in water (dilution 1 : 30), lexc ¼ 330.
Fig. 5 Fluorescence microscopy of living HeLa cells treated with
HexFA and HexBFA nanoparticles (incubated for 4 h) showing cyto-
plasmic ﬂuorescence spots only inside the HexBFA-treated cells. Scale
bar ¼ 10 mm.
Fig. 6 Colocalization of Py-BODIPY with LipidTOX Red Neutral Lipid
Stain. HeLa cells were treated with HexBFA nanoparticles (incubated
for 4 h), ﬁxed with 4% PFA and stained with LipidTOX. (A) Cells are
displayed in separate images showing the ﬂuorescence of Py-BODIPY
(green), LipidTOX (red) and in a composite image (colocalization in
yellow). Scale bar ¼ 10 mm. (B) Magniﬁcation of the square in the
merged image as shown in (A) and ﬂuorescent intensity proﬁles of Py-
BODIPY and LipidTOX. The linear plot (white line), sampled crossing
over the cell cytoplasm and three lipid droplets, shows the ﬂuores-
cence intensity of Py-BODIPY-green and LipidTOX-red ﬂuorescence.
The Py-BODIPY proﬁle colocalizes perfectly with the LipidTOX proﬁle
thus indicating that Py-BODIPY stains neutral lipids in the lipid droplets.
RSC Advances Paperobserved, a position quite similar to that observed for the u-
orophore dissolved in hexane (lemiss ¼ 523 nm).
The photostability of the HexCBFA formulation was tested by
irradiating the sample under a UV-lamp (lexc ¼ 365 nm) for
24 h. No changes were observed in the emission properties of
the formulation in these conditions.
2.3. Internalization, viability, and Py-BODIPY localization
against HeLa cells
The uptake of the HexBFA nanoparticles was investigated by
uorescence microscopy (see ESI† for Experimental details).
The image in Fig. 5 clearly shows that cytoplasmic uorescent
signals were observed in the cytoplasm of living cells aer
HexBFA nanoparticle incubation, whereas no uorescence was
detected in HexFA-treated cells. Remarkably, rather than a
diﬀuse uorescence the microscopic observations revealed
intense uorescent spots dispersed throughout the cytoplasm.
Given the shape and the size of these spots and the apolar
nature of the dye, it could be inferred that the Py-BODIPY23446 | RSC Adv., 2015, 5, 23443–23449localizes in the lipid droplets. The latter are dynamic storage
organelles that represent an intracellular reservoir of neutral
lipids, such as triacylglycerols and cholesteryl esters, part of the
lipid metabolism and used for membrane lipid synthesis. We
recently demonstrated that monoolein-based nanoparticles
(cubosomes) treatment induces intracellular accumulation of
neutral lipids in the cytoplasmic lipid droplets.16 To investigate
whether the Py-BODIPY uorescence is localized in the lipid
droplets, HexBFA-treated cells, grown on coverslips, were xed
and labeled with LipidTOX, a red neutral lipid stain with an
extremely high aﬃnity for neutral lipid droplets. This treatment
resulted in the intracellular appearance of a colocalized
Py-BODIPY (green) and LipidTOX (red) uorescence, as shownThis journal is © The Royal Society of Chemistry 2015
Fig. 7 Viability, expressed as % of the control, induced by incubation
for 4 h with HexFA and HexBFA nanoparticles (1 : 500, 2 mL mL1) in
HeLa cells culture. Results were expressed as a mean  standard
deviation (SD) of three independent experiments involving quadru-
plicate analyses for each sample.
Fig. 9 Molecular orbital isosurfaces of HOMO1 (a), HOMO (b), and
LUMO (c) calculated for Py-BODIPY. Cutoﬀ value 0.05 e.
Paper RSC Advancesby yellow uorescence in the merged image and by intensity
uorescence proles (Fig. 6).
The two nanoparticle formulations, HexFA and HexBFA,
were also tested for cytotoxicity (MTT assay) in HeLa cells. Fig. 7
shows the viability, expressed as % of the control, induced in
HeLa cells aer 4 h incubation. Evidently, treatments with both
nanoparticle formulations did not induce a relevant reduction
in cell viability as compared with control cells (see ESI† for
Experimental details).2.4. Theoretical calculations
In order to correlate the photophysical properties of Py-BODIPY
and the environment experienced by the dye in the formulation,
theoretical calculations were carried out at Density Functional
Theory (DFT) level. The eﬀect of implicit solvation on the opti-
mised metric parameters (Fig. 8; ESI, Table S1†) was evaluated
at IEF-PCM level by considering the same solvents investigated
in paragraph 2.1 (see also Table 1). In all cases, the optimised
metric parameters were only marginally aﬀected (see ESI† for
Experimental details).Fig. 8 Ball and stick drawing of the structure of Py-BODIPY optimised
at DFT level in the gas phase. The numbering scheme for the BODIPY
core is also reported. Hydrogen atoms have not been depicted for
clarity.
This journal is © The Royal Society of Chemistry 2015In agreement with what was reported previously,38 the
HOMO1 and the LUMO are p-orbitals located on the BODIPY
moiety, while the HOMO is centred on the pyrenyl substituent
(Fig. 9), both in the gas phase and in solution.
Time-Dependent (TD) DFT calculations show that the singlet
electron transition at the lowest energy S0/ S1 (about 2.2 eV,
Table S1 and Fig. S3, ESI†) calculated for Py-BODIPY arises
entirely from a HOMO / LUMO monoelectronic excitation,
corresponding to a charge transfer (CT) process between the
pyrene and the indacene systems. Due to the p-nature of the
molecular orbitals (Fig. 9), in order for the overlap integral
between the wavefunctions of HOMO and LUMO to be diﬀerent
from zero, the deviation of s (the rotation of the pyrenyl ring, see
ESI† for Experimental details) from orthogonality is required.
Accordingly, this transition was calculated to be forbidden
when the pyrene and the indacene planes were forced to be
perpendicular. As a consequence of the CT nature of the tran-
sition, the S0/ S1 transition, which shows a very low oscillator
strength at the optimised geometry, is calculated to be moder-
ately solvatochromic in character (with a variation Dl in the
calculated absorption wavelength of about 25 nm on passing
from toluene to DMF).
The S0/ S2 transition (falling at about 3.0 eV, see Table S1
and Fig. S3, ESI†) is instead assigned to a HOMO1/ LUMO
excitation. Due to its non-polar character, this transition is
independent of the solvent (Dl ¼ 5 nm). Although diﬀerence in
the excitation energies between the two transitions (about
0.8 eV, see Table S1, ESI†) might be overestimated by TDDFT
calculations because of their diﬀerence in polarity, the struc-
tured experimental absorption band at about 500 nm can be
attributed to the convolution of the transitions leading to the S1
and S2 excited states. TDDFT calculations allow accounting for
the uorescence of Py-BODIPY. Indeed, it is conceivable that the
UV excitation from S0 to a Sk excited state is followed by an
internal conversion to the S2 excited state. The possibility of the
pyrene group to rotate (the libration vibration is calculated at
about 20 cm1 for the ground state), shown by the PES analysis
(see ESI and Fig. S2†), could be responsible for the vibrational
internal conversion S2 / S1. Hence, uorescence emission
would involve the S1/ S0 radiative relaxation. From a quali-
tative point of view, the polar nature of S1 nicely accounts for
the remarkable solvatochromism of the emission discussed
above. Indeed, in polar solvents (such as DMF, alcohols,
acetonitrile) the S1 singlet excited state is stabilised (E < 2.2 eV,
Table S1 and Fig. S3, ESI†) by up to 0.1 eV with respect to
nonpolar solvents (hexane, toluene), so that emission isRSC Adv., 2015, 5, 23443–23449 | 23447
RSC Advances Paperexpected to occur at lower energies, as found experimentally
(Fig. 1). Accordingly, the uorescent emission observed in the
hexosomes, similar to that detected in hexane, reects the non-
polar nature of the environment experienced by the imaging
agent (the hydrophobic MO chains), strongly supporting the
localization of the Py-BODIPY within the bilayer.
3. Conclusions
In this paper we showed that nanoparticles with a 2D hexagonal
nanostructure can be loaded with a pyrene-modied BODIPY
uorophore and the antineoplastic drug camptothecin and, at
the same time, stabilized using a mixture of PF108 and folate-
conjugated PF108, so that they possess targeting properties
toward tumor cells. The striking solvatochromism of the
modied BODIPY, emitting at energies directly dependent on
the polarity of the chemical environment, and the QM calcula-
tions performed, conrm the localization of the imaging agent
within the bilayer. Moreover, we demonstrated that these
nanoparticles are easily internalized by HeLa cells and that the
uorophore localizes within the lipid droplets. The cytotoxicity
experiments, performed using the HexBFA formulation at a
concentration of 75 mg mL1 of the dispersed phase (MO + block
copolymers, or 68 mg mL1 of MO), the same as used for the
uorescence microscopy experiments, proved that the proposed
formulation can be safely used for cellular imaging purposes.
Remarkably, these results are in good agreement with our
previous cytotoxicity tests performed on HeLa cells using
cubosomes formulations, and those obtained by other groups
working on similar nanoparticles and diﬀerent cellular
lines.43,44
Integration of therapeutics and imaging agents within a
single theranostic nanoparticle allows monitoring drug
delivery, release, and eﬃcacy, contributing to realize tailor-
made therapies that, besides the study of genetic variations
and biomarkers, exploit the development of imaging methods
for predicting and evaluating therapeutic responses.45 There-
fore, results here presented encourage the use of these nano-
particles in theranostic nanomedicine for personalized
diagnosis and treatment of tumors.
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Eﬀects of monoolein-based cubosome
formulations on lipid droplets and mitochondria
of HeLa cells
Angela Maria Falchi,*a Antonella Rosa,a Angela Atzeri,a Alessandra Incani,a
Sandrina Lampis,b Valeria Meli,b Claudia Caltagironeb and Sergio Murgia*b
Despite the remarkable development of nanoparticles for diﬀerent purposes, relatively little is known
about their interaction with biological systems and individual cells. Here the eﬀects of two monoolein-
based cubosome formulations stabilized by Pluronic F108 and F127 were investigated against HeLa cells.
Microscopy analysis on living cells loaded with organelle-speciﬁc ﬂuorescent probes was performed to
assess the formation of cytoplasmic lipid droplets after nanoparticle treatment. Mitochondrial membrane
potential and mitochondrial ROS generation were also investigated in relation to the capability of the
accumulated lipids to aﬀect mitochondrial functions. Values of the main cellular unsaturated fatty acids
were also measured to assess cell lipid proﬁle modulation. Results from this study show that the uptake of
both cubosome formulations induced modiﬁcation of the cell lipid proﬁle, lipid droplet accumulation,
mitochondrial hyperpolarization and mitochondrial ROS generation. These results shed some light on the
inﬂuence exerted by monoolein-based cubosome formulations on subcellular organelles and their
possible adverse eﬀects on cell functions.
Introduction
Monoolein (MO, glycerol monooleate) self-assembles in water,
forming a number of nanostructures, including two bicontinu-
ous cubic phases characterized by a diﬀerent space group: the
Ia3d, and the Pn3m.1 These amazing liquid crystalline nano-
structures are composed of a curved bilayer whose three-
dimensional folding originates two disconnected, continuous
water channels.2,3 They were ubiquitously found in Nature,
and several studies were dedicated to shed some light on their
role in the cell machinery.4–6 Since MO-based bicontinuous
cubic phases are nanostructures that can suitably host hydro-
phobic molecules with biological relevance, they were exten-
sively investigated in the past for their possible applications in
the pharmaceutical field.7–9 Remarkably, cubic phases can be
formulated as nanoparticle dispersions, known as cubosomes,
typically stabilized in water using amphiphilic polymers
having long polyethylene oxide (PEO) chains, such as Pluronics
or polysorbate 80.10–12 These liquid crystalline nanoparticles
are often proposed to be suitable drug delivery nanocarriers
and, recently, their possible application as theranostic nano-
medicine was discussed in several papers.13–15 However, little
information about in vitro cellular interactions and toxicity of
monoolein-based cubosomes has been reported so far, and
the lack of shared protocols precludes straightforward com-
parisons between these investigations. For example, focusing
on monoolein-based formulations exposed to adherent cells,
to the best of our knowledge only six papers (two from our
group, not including the present) have discussed the cytotoxi-
city of pristine cubosomes (i.e., not decorated with targeting
agents or loaded with drugs/imaging agents).13,16–20 In all
these cases, experiments were performed using diﬀerent cell
lines, at diﬀerent incubation times, and with formulations
having diﬀerent compositions (basically, they were prepared
using a diﬀerent monoolein/Pluronic ratio, sometimes using
diﬀerent types of Pluronic). It is worth noting that several
papers have reported on the haemolytic properties of monoo-
lein-based cubosome formulations tested on mouse blood,18,21
indicating 20 μg mL−1 of monoolein as the maximum tolerable
concentration.20 However, another recent investigation con-
ducted on human and porcine plasma has disputed these
results, attributing to the same formulation a very low haemo-
lytic activity.22 We have previously shown no toxic eﬀects of
monoolein-based nanoparticles (liposomes and cubosomes) at
short times against HeLa cells and 3T3 fibroblasts16,23 based
on an 80% viability threshold.
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All cell types have been found to readily take up the lipids
present in culture media and sequester them into lipid dro-
plets (LDs). LDs are cytoplasmic organelles that consist of a
hydrophobic core of neutral lipids (such as triglycerides and
cholesterol esters) encased by a phospholipid monolayer har-
boring a set of enzymes and regulatory proteins that catalyze
the highly metabolically controlled synthesis and mobilization
of fat stores.24 LDs, found in almost all cells under physiologi-
cal or pathological conditions, are heterogeneous not only in
size but also in the lipid content and the composition of their
protein coat.25 The most widely accepted model for LD for-
mation hypothesizes that they arise in the endoplasmic reticu-
lum (ER) through the accumulation of neutral lipid at specific
sites between the leaflets of the phospholipid bilayer (ER
budding model).24 Dynamical interactions between LDs and
organelles other than ER, including mitochondria and peroxi-
somes, have been suggested to facilitate the exchange of pro-
teins and lipids in cells, while interactions between the ER
and mitochondria are crucial for processes such as lipid syn-
thesis, storage and transport as well as mitochondrial func-
tions (calcium homeostasis and apoptosis).26,27
In the present study, we used organelle-specific dyes to
explore the changes occurring in lipid droplets and mitochon-
dria of living HeLa cells when exposed to treatment with
monoolein-based cubosomes stabilized by Pluronic F108 or
Pluronic F127. Analyses were carried out to examine lipid
droplet content, mitochondria membrane potential, reactive
oxygen species (ROS), and cellular lipid profile at 4 and 24 h
after nanoparticle treatment. Our results demonstrate that the
uptake of both cubosome formulations induces a modification
in the cellular lipid profile, accumulation of lipid droplets
associated with a significant dysfunction of mitochondria,
including mitochondrial hyperpolarization and mitochondrial
ROS generation.
Results and discussion
Cubosome characterization
Colloidal dispersions of a bicontinuous cubic phase (cubo-
somes) were prepared by dispersing via sonication melted
monoolein (MO) either in a Pluronic F108 (PF108) or in a
Pluronic F127 (PF127) aqueous solution. These nanoparticle
formulations were then characterized for particle size and
morphology, as well as for their inner structure. The cryo-TEM
images of MO-based PF127 and PF108 stabilized cubosomes
(MO/PF127 and MO/PF108) are shown in Fig. 1A and B. These
images show various nanoparticles revealing the regular alter-
nation of bright spots (water channels) and dark matrix (lipid
bilayer) classically observed in the presence of a cubic arrange-
ment of the interface, along with the vesicular material that
typically co-exists with the cubosomes in these kinds of formu-
lations.16 On the basis of repeated observations, the samples
under investigation via cryo-TEM were found to be a dispersion
of cubosomes having diameter in the range of 100–200 nm, in
striking agreement with DLS analysis (Table 1). SAXS definitely
confirmed the inner cubic structure of both cubosome formu-
lations. As reported in Table 1, the diﬀraction patterns showed
the Bragg peaks of the bicontinuous cubic double diamond
and primitive phases (with space groups Pn3m and Im3m,
respectively, see also Fig. 1C and D). It deserves noticing that
the simultaneous presence of these two phases has already
been described for cubosome formulations having compo-
sition similar to those investigated here,28 and their occur-
Fig. 1 Cryo-TEM images of MO-based cubosomes stabilized by PF127 (A) and PF108 (B). I(q) vs. q data obtained by SAXS of the cubosome formu-
lation stabilized by PF127 (C) and PF108 (D). The Miller indices are reported on top of the corresponding Bragg peaks along with the indication of the
space group.
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rence is explained with the non-uniform partition of the Pluro-
nic. Indeed, during the dispersion process the dispersant pre-
ferentially localizes at the cubosome surface, originating
Pluronic-depleted regions characterized by double diamond
symmetry.29
Accumulation of lipids in the lipid droplets
Several studies have shown LD accumulation after treatment
with free fatty acids30 or associated with oxidative stress
induced by nanoparticle treatment.31,32 Indeed, after the
internalization in the cells, unsaturated fatty acids such as
oleic acid (OA) can be either esterified and stored as neutral
lipids inside LDs or become part of the cellular membranes
or, after activation to fatty acyl-CoAs, oxidized in mitochondria
for energy production.30 Here, to investigate LD accumulation,
HeLa cells were treated with cubosome formulations (5 µL in
1 mL of medium) at 4 and 24 h and, after nanoparticle wash-
out, co-loaded with Nile Red (NR) and Hoechst probes, to stain
LDs and the nucleus, respectively.
In untreated control cells the number of small LDs,
detected as punctuated green fluorescent cytoplasmic struc-
tures, was very diﬀerent from cell to cell. Upon short exposure
to cubosomes, the number of lipid droplets dispersed through-
out the cytoplasm and their size increased in a remarkable
way and droplets appeared larger and more numerous in
all cells (Fig. 2A), suggesting that LD accumulation results
from the synthesis of neutral lipids from nanoparticle-derived
monoolein.
When compared to untreated control cells, an increase in
the IOD (Integrated Optical Density) per cell of 7.9 (p < 0.001)-
and 3.1 (p < 0.001)-fold was estimated for, respectively,
MO/PF127 and MO/PF108, indicating a statistically signifi-
cantly increased production of LDs (Fig. 2B). Subsequently,
HeLa cells were grown in the presence of MO dissolved in
DMSO and Pluronic aqueous solutions (administered at the
same concentrations as MO and Pluronics present in the cubo-
some formulations) and OA (18:1 n-9) (used as the positive
control at the non-cytotoxic concentration of 100 µM in
DMSO). At short times, MO and OA treatments caused 1.3 (p <
0.05)- and 2.8 (p < 0.001)-fold increase, respectively, in IOD per
cell in comparison with untreated cells, whereas Pluronic solu-
tions showed the same IOD per cell as the control (Fig. 2B). At
longer exposure time (24 h), diﬀerently from MO- and OA-
treated cells where the IOD did not change, the IOD of
MO/PF127 and MO/PF108-treated cells increased by 25.6 (p <
0.001)- and 31.5-fold (p < 0.001), respectively. Because of the
huge cubosome uptake, cells appeared to be full of lipids
inside the cytoplasm with many large droplets aggregated in
several clusters resembling grapes (Fig. 2A and B).
While the LD formation induced by long-chain unsaturated
fatty acids such as OA is a well-known phenomenon, data
reported here proved that LD formation also occurs upon MO
and MO-based cubosome treatment. Compared with MO-
treated cells, statistically significantly increased production of
lipid droplets was detected after cubosome exposure, thus
suggesting a strong internalization ability of both MO-based
cubosome formulations. Since the amount of MO adminis-
tered was exactly the same, the diﬀerences could be ascribed
to diﬀerent uptake mechanisms. Indeed, while nanoparticles
can be transported into the cells via endocytosis, the fatty acid
uptake across the lipid bilayer of the plasma membrane was
proposed to proceed by diﬀusion or through membrane-
associated proteins (acting as fatty acid transporters).33,34
Remarkably, statistically significant diﬀerences (p < 0.001)
between the two cubosome formulations were observed in the
IOD only at short time treatments.
Modification of the lipid cell profile
The same MO/PF108 and MO/PF127 cubosome formulations
and MO, OA, and Pluronic solutions previously described were
then tested to assess their eﬀects on the lipid composition of
HeLa cells. After 4 and 24 h of incubation, the cell lipid frac-
tion was extracted and the variations in the levels of unsatu-
rated fatty acids and cholesterol were analyzed with respect to
untreated control cells. The unsaturated fatty acid composition
(expressed as µg per plate) and the chromatographic profile of
HeLa control cells obtained by HPLC are shown in Fig. 3. The
cell content of the most abundant unsaturated fatty acids was
detected as follows: 78.19, 19.87, 6.38, 4.89, 3.11, and 3.05 µg
per plate for 18:1 isomers (OA and 18:1 n-7), 16:1 n-7, arachi-
donic acid (20:4 n-6), docosahexaenoic acid (DHA, 22:6 n-3),
eicosapentaenoic acid (EPA 20:5 n-3), and 18:2 n-6, respect-
ively; minor amounts were measured for 18:3 n-3, 20:3, and
22:4 n-6. The incubation of HeLa cells with PF108 or PF127
solution did not induce changes in unsaturated fatty acid
levels, with treated cells showing a profile similar to that of
control cells at both incubation times (data at 4 h are shown in
Fig. 3A).
Fig. 4 shows the values of the most abundant unsaturated
fatty acids 16:1 n-7, 20:4 n-6, DHA, OA, and cholesterol
(expressed as % of the control) measured in HeLa cells after 4
(Fig. 4A) and 24 h (Fig. 4B) of incubation in the presence of
cubosomes, MO, and OA. The incubation of cells at 4 h treat-
ment with the compounds induced a significant increase in
the cell level of OA, which reached values approximately 3, 3,
2, and 2 times higher than that of the control cells in MO/
PF108, MO/PF127, MO and OA treated cells, respectively. Treat-
ments were not associated with changes in the levels of all the
other unsaturated fatty acids. Experiments performed at 24 h
of incubation time revealed a further increase of the OA levels
Table 1 Space group, lattice parameter (a), mean diameter (Dav), poly-
dispersion index (PDI), and ζ-potential of the cubosome nanoparticles
stabilized with either PF108 or PF127
Cubosome
stabilizers
Space
group a (Å) Dav (nm) PDI
ζ-Potential
(mV)
PF108 Pn3m 101 ± 4 133 ± 1 0.11 −28 ± 2
Im3m 137 ± 4
PF127 Pn3m 98 ± 3 136 ± 2 0.14 −19 ± 1
Im3m 136 ± 6
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(5 times higher than the control) in cells treated with cubo-
some formulations, while levels of all the other unsaturated
fatty acids remained substantially unaltered with respect to the
control. Remarkably, the levels of OA recorded in MO and OA
treated cells were very similar to those observed at 4 h-treated
HeLa cells. This result parallels the finding discussed in the
previous paragraph concerning the lipid droplet accumulation
and, similarly, can be reconciled taking into account the
diﬀerent uptake mechanisms. Using HPLC, the total chole-
sterol level was measured in control cells as the mean content
of 72.52 ± 0.55 µg per plate. Fig. 4 also shows the values of
cholesterol measured in the control and 4 and 24 h-treated
HeLa cells. The diﬀerent treatments did not seem to aﬀect the
level of cholesterol.
Mitochondrial membrane potential
Mitochondria play a central role in normal cell functions such
as energy supply and in cell death by inducing apoptosis.
Changes in the mitochondrial membrane potential (mitoMP)
represent one of the adaptation processes to a variety of
environmental factors that regulate the increased energy
demands, cell growth and diﬀerentiation, or cellular stress. In
mitochondria, mitoMP is produced by the electron transport
chain as it pumps H+ ions into the membrane space,
Fig. 2 Lipid droplet accumulation induced in HeLa cells by cubosome treatment. (A) Representative composite color images of HeLa cells exposed
to the monoolein (MO), MO/PF127 and MO/PF108 cubosomes at 4 and 24 h of incubation time. Membranes (red) and lipid droplets (green) were
stained with Nile Red (colocalization in yellow). Scale bar = 20 µm. (B) Results of the lipid droplet formation at 4 and 24 h of incubation time. Oleic
acid (OA) was used as the positive control at the non-cytotoxic concentration of 100 µM. Data are expressed as mean ± SD from four independent
experiments. Statistically signiﬁcant diﬀerences are indicated by * (p < 0.05), *** (p < 0.001) by t-test vs. untreated-control cells.
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thus creating an electrochemical proton gradient which drives
ATP synthesis. Variations of mitoMP are usually measured
in living cells with the cationic fluorescent dye TMRM,
which accumulates in the mitochondrial matrix driven by the
voltage gradient across the inner mitochondrial membrane.
Using the TMRM probe, control cells showed morphologically
Fig. 3 Fatty acid composition and chromatographic proﬁle of HeLa cells. Values of the unsaturated fatty acids (16:1 n-7, 18:1, 18.2 n-6, 18:3 n-3,
20:3, 20:4 n-6, 20:5 n-3, 22:4 n-6, 22:6 n-3, expressed as µg per plate) measured in control cells and after 4 h of incubation in the presence of
PF127 and PF108 solutions (A) and the corresponding HPLC chromatographic proﬁle of the control HeLa cells (B). Data are expressed as mean ± SD
from four independent experiments (involving duplicate analyses for each sample).
Fig. 4 Lipid proﬁle modulation in cubosome-treated cells. The values of the main unsaturated fatty acids, 16:1 n-7, 18:1 (OA), 20:4 n-6, 22:6 n-3,
and cholesterol (expressed as % of the control) measured in HeLa control cells and after 4 (A) and 24 h (B) of incubation in the presence of MO/
PF127 and MO/PF108 cubosomes, MO, and OA (used as the positive control). Data are expressed as mean ± SD from four independent experiments
(involving duplicate analyses for each sample). Statistically signiﬁcant diﬀerences, using one-way analysis of variation (one-way ANOVA) and the
Bonferroni post test (GraphPad INSTAT software, San Diego, CA), are indicated by ** (p < 0.01), *** (p < 0.001) vs. untreated-control cells.
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smooth and variously stained mitochondrial filaments
(Fig. 5A).
Following short term incubation of HeLa cells with both
cubosome formulations and MO, a significant hyperpolariz-
ation of the mitochondrial membrane potential was observed
as compared with untreated-control cells (Fig. 5B and C).
Moreover, MO/PF127-treated cells showed a larger mitoMP
(p < 0.05) than MO/PF108- and MO-treated cells. In contrast,
analysis of mitoMP in cells treated with Pluronic solutions
showed the same mitoMP as the control. At long time treatment,
diﬀerently from MO-treated cells, a significant decrease of
mitoMP (p < 0.05) was detected in both cubosome-treated cells.
On co-loading cells with TMRM and Bodipy 493/503, it was
observed that, in cubosome-treated cells, the cytoplasmic dis-
tribution of mitochondria (the so-called mitochondrial net-
working) was considerably modified, and unlike MO-treated
cells where the mitochondrial network appeared to be regular
(Fig. 5D), clusters of mitochondria were confined in various
areas of the cytoplasm and excluded by the large droplets
(Fig. 5E and F). Therefore, the loss of mitoMP associated with
altered mitochondrial morphology could suggest that, at long
time treatment, mitochondrial dysfunction arises from lipid
accumulation.35
Mitochondrial ROS generation
The mitochondrion is the major free radical-producing com-
partment of the cell, representing, at the same time, an impor-
tant target for the reactive oxygen species (ROS) action.
Mitochondrial ROS production usually occurs during electron
transport along the respiratory chain complexes, and same
pathophysiological conditions can increase mitochondrial
ROS generation such as an enhancement of the mitochondrial
membrane potential.36 To specifically investigate the eﬀect of
nanoparticles on mitochondrial ROS generation, control and
treated cells were loaded with the mitochondrial superoxide
indicator MitoROS Red in combination with the mitochondria-
specific probe MitoTracker Green with the aim of verifying the
mitochondrial origin of ROS and correlating mtROS with
changes in the mitochondrial morphology. A significant and
progressively increased ROS production was detected in cells
treated with both types of cubosomes as compared with the
control and MO-treated cells (Fig. 6A–C). ROS production
increased by 1.3 (p < 0.01)- and 1.9-fold (p < 0.001) at short
term treatment and by 2.3- and 2.4-fold (p < 0.001) at long
time exposure to, respectively, MO/PF108 and MO/PF127 cubo-
somes. The mitochondrial origin of ROS was confirmed by
their co-localization with MitoTracker Green. It is worth men-
tioning that, in cells with high mtROS levels, mitochondria
appeared fragmented (Fig. 6D), suggesting involvement of the
mitochondrial permeability transition pore (mPTP) and the
inner membrane anion channel (IMAC) in maintaining
healthy mitochondria homeostasis.37
Analysis of the mtROS level in HeLa cells treated with Pluro-
nic solutions showed diﬀerent results (Fig. 6A). Whereas in
PF108 solution-treated cells, mtROS production was not dis-
similar from the control and MO-treated cells, cells treated
with a PF127 solution showed a significant mtROS increase at
both 4 h and 24 h treatment. This eﬀect is in agreement with
that reported in a previous study where Pluronic P85 co-loca-
lized with mitochondria and caused mitochondria impairment
accompanied by ROS production.38
Nuclear staining and externalization of phosphatidylserine
LD and mitoMP evaluation was performed on cubosome-
treated cells with no signs of morphological damage and/or
chromatin condensation (Fig. 7A). Chromatin condensation
was determined by nuclear staining with Hoechst 33258. After
4 h cubosome treatment along with healthy cells, we detected
Fig. 5 Eﬀect of cubosome treatment on mitochondrial membrane
potential and mitochondrial network appearance. (A, B) Representative
images of the control (A) and short-term cubosome-treated (B) cells
stained with the mitochondria-speciﬁc dye TMRM. Scale bar = 20 µm.
(C) Analysis of mitochondrial membrane potential (mitoMP) evaluated by
TMRM ﬂuorescence intensity (arbitrary units) in the control and treated
cells. Data are expressed as the mean ± SD from four independent
experiments. Statistically signiﬁcant diﬀerences are indicated by *(p <
0.05), ***(p < 0.001) by t-test vs. untreated-control cells and among
diﬀerently treated cells. (D–F) Representative composite color images of
HeLa cells, co-loaded with TMRM (red) and Bodipy 493/503 (green),
after 24 h of incubation time with MO (D), MO/PF127 (E) and MO/PF108
(F) cubosomes. Scale bar = 10 µm.
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Fig. 6 Mitochondrial ROS generation. (A) Analysis of mitochondrial ROS evaluated by MitoSOX ﬂuorescence intensity (arbitrary units) in untreated-
control and treated cells. Data are expressed as mean ± SD from four independent experiments. Statistically signiﬁcant diﬀerences are indicated by
*(p < 0.05), **(p < 0.01), ***(p < 0.001) by t-test vs. untreated-control cells and among diﬀerently treated cells. (B, C) Representative images of
MitoSOX Red ﬂuorescence in untreated (B) and short-term cubosome-treated (C) cells. (D) Composite color image of cubosome-treated cells co-
loaded with MitoSOX Red (red) and MitoTracker Green (green), co-localization in yellow-orange. Scale bar = 10 µm.
Fig. 7 Cells undergoing apoptosis with chromatin condensation and externalized PS. (A–C) Merged color images of cubosome-treated cells co-
loaded with TMRM (red), Bodipy 493/503 (green) and Hoechst 33258 (HOE, blue) probes. (A) Healthy cells showing polarized mitochondria, lipid
droplet accumulation and no signs of chromatin condensation. (B, C) Round cells, full of cytoplasmic lipids, showing chromatin condensation (HOE-
positive) and depolarized mitochondria (TMRM-negative). Arrows indicate some round cells showing still polarized mitochondria. (D–F) Phase con-
trast (D) and relative ﬂuorescence image (E) of cells showing distinct round domains positive for FITC-Annexin V with nuclei negative for propidium
iodide (PI). (F) Apoptotic cells positive for FITC-Annexin V and PI. Scale bars = 10 µm.
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the presence of clusters of round cells (still attached at the
dish) with the cytoplasm full of lipids, showing condensed
nuclei and low or completely missing TMRM fluorescence,
indicating mitochondrial depolarization (Fig. 7B and C). To
verify whether these round cells were undergoing apoptosis,
untreated control and cubosome-treated cells were co-stained
with FITC-conjugated Annexin V and propidium iodide (PI). As
untreated-control cells were largely negative for externalized
phosphatidylserine (PS) and nuclear condensation, in cells
treated with cubosomes we were able to observe and dis-
tinguish diﬀerently labeled cells: (a) healthy cells (∼80%),
negative for both Annexin-FITC and PI (Fig. 7A); (b) cells
undergoing apoptosis (∼15%), with exposed PS Annexin posi-
tive and PI negative (Fig. 7D and E); (c) apoptotic cells (∼5%),
positive for both Annexin-FITC and PI (Fig. 7F). This result
showed the slight impact of the cubosomes on the cells and,
at the same time, confirmed that lipid loading might induce
apoptosis in cells.
MTT assay
The eﬀects of cubosome formulations, MO, PF127 and PF108
solutions were evaluated against HeLa cells at 4 and 24 h
according to the MTT assay, which is sensitive to mitochon-
drial activity and is used to evaluate cell apoptosis and cell
division inhibition. The MTT value of non-treated control cells
was set to 100% and the values of treated cells were expressed
as a percent of the control. As shown in Fig. 8, a slight
decrease of MTT reduction was observed with both cubosome
formulations (but also with MO and Pluronic solutions) in the
first 4 h of incubation time. Remarkably, at long term exposure
(24 h), the absorbance of cubosome-treated cells increased
and was not diﬀerent from control cells, whereas treatment
with MO and both Pluronic solutions showed the same
decrease as MTT reduction at short time. This unexpected
result may be due to variation in the redox status of the cells
and/or mitochondrial membrane hyperpolarization and/or
interference of the MTT reaction with the large amount of LDs
in the cell cytoplasm. Indeed various lines of evidence suggest
that MTT formazan deposits accumulate in the lipid dro-
plets.39,40 According to MTT results further supported by fluo-
rescence analysis, HeLa cells appeared healthy beside
mitochondrial dysfunction and lipid droplet accumulation,
suggesting no relevant toxic eﬀect of cubosome treatment at
these incubation times and this concentration.
Conclusion
Here, the eﬀects caused by two diﬀerent cubosome formu-
lations on HeLa cells were compared. The formulations were
prepared using the same building block (monoolein), but were
stabilized by two diﬀerent Pluronics. By employing multiple
labeling with organelle-specific dyes, we provide a helpful pro-
cedure to investigate nanoparticle–cell interactions. Results
evidenced that both cubosome formulations influenced the
cell behavior and, particularly, organelles such as lipid dro-
plets and mitochondria. In long time experiments the diﬀer-
ences between the two cubosome formulations were levelled
out, but significant diﬀerences were observed at short time
treatments.
Physicochemical investigations demonstrated that, from a
morphological point of view, two almost indistinguishable for-
mulations were compared. Moreover, the lipid profile con-
firmed that the same amount of formulation was taken up by
the cells. Therefore, the detected diﬀerences can be entirely
ascribed to the diﬀerent Pluronic used to stabilize the cubo-
some formulations, and could be explained in terms of the
diﬀerent hydrophobicity of these block copolymers, as exem-
plified by their Hydrophilic Lipophilic Balance values (HLB
equal to 22 and 27 for PF127 and PF108, respectively).41
Results concerning the Pluronic solutions evidenced diﬀerent
mitochondrial ROS production depending on the dispersant
used, reinforcing this hypothesis. The MTT test proved the low
toxicity of these formulations against HeLa cells at the concen-
tration used in this investigation (165 μg mL−1 of monoolein).
This finding agrees with others previously reported on the
same cellular line.17
Taking into consideration the close advent on the market of
various nanotechnologically based products, we strongly
believe that the presented results may be useful to understand
the impact of cubosome formulations in biological tissues and
their possible hazardous nature.
Experimental
Cubosome preparation
Cubosomes were prepared by dispersing the appropriate
amount of melted monoolein (MO) in an aqueous solution of
Pluronic (F108 or F127) using an ultrasonic processor UP100H
Fig. 8 Results of the MTT assay of HeLa cells exposed to treatment
with cubosomes, monoolein and Pluronic solutions. The MTT value of
non-treated control cells was set to 100% and the values of treated cells
were expressed as a percent of the control. Data are expressed as the
mean ± SD from three independent experiments (involving triplicate
analyses for each sample). Statistically signiﬁcant diﬀerences are indi-
cated by **(p < 0.01) and ***(p < 0.001) vs. untreated-control cells by
t-test.
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by Dr Hielscher, cycle 0.9, amplitude 90%, for 10 minutes. The
sample volume was 4 mL with 96.4 wt% of water, 3.3 wt% of
MO and 0.3 wt% of Pluronic (F108 or F127). MO (RYLO MG 19
PHARMA, glycerol monooleate, 98.1 wt%) was kindly provided
by Danisco A/S, DK-7200, Grinsted, Denmark. Pluronic F108
(PEO132–PPO50–PEO132) and Pluronic F127 (PEO100–PPO65–
PEO100) were purchased from Sigma-Aldrich. Distilled water
passed through a Milli-Q water purification system (Millipore)
was used to prepare the samples.
Cryogenic-transmission electron microscopy (cryo-TEM)
Vitrified specimens were prepared in a controlled environment
vitrification system (CEVS) at 25 °C and 100% relative humid-
ity. A drop of the sample was placed on a perforated carbon
film-coated copper grid, blotted with filter paper, and plunged
into liquid ethane at its freezing point. The vitrified specimens
were transferred to a 626 Gatan cryo-holder, and observed at
120 kV acceleration voltage in a FEI Tecnai T12 G2 trans-
mission electron microscope at about −175 °C in the low-dose
imaging mode to minimize electron-beam radiation-damage.
Images were digitally recorded with a Gatan US1000 high-
resolution CCD camera.
Small-angle X-ray scattering (SAXS) experiments
Small-angle X-ray scattering was recorded with an S3-MICRO
SWAXS camera system (HECUS X-ray Systems, Graz, Austria).
Cu Kα radiation of wavelength 1.542 Å was provided by a GeniX
X-ray generator, operating at 50 kV and 1 mA. A 1D-PSD-50 M
system (HECUS X-ray Systems, Graz, Austria) containing 1024
channels of width 54.0 µm was used for the detection of scat-
tered X-rays in the small-angle region. The working q-range
(Å−1) was 0.003 ≤ q ≤ 0.6, where q = 4π sin(θ)λ−1 is the scatter-
ing wave vector. Thin-walled 2 mm glass capillaries were used.
The lattice parameter a of the cubic phase was determined
using the relation a = d(h2 + k2 + l2)1/2 from linear fits of the
plots of 1/d versus (h2 + k2 + l2)1/2, where d = 2π/q and h, k, and
l are the Miller indices.
Dynamic light scattering (DLS)
Particle size and ζ-potential determinations of the nano-
particles were performed with a ZetaSizer Nano ZS (Malvern
Instruments, Malvern, UK) at a temperature of 25 ± 0.1 °C.
Samples were backscattered by a 4 mW He–Ne laser (operating
at a wavelength of 633 nm) at an angle of 173°. Diluted
samples (1 : 50) were housed in disposable polystyrene cuvettes
of 1 cm optical path length with water as the solvent. At least 2
independent samples were taken, each of which was measured
3–5 times. The width of the DLS hydrodynamic diameter distri-
bution is indicated by PDI (polydispersion index).
Cell culture and treatments
The human cervical carcinoma cell line HeLa (ATCC collec-
tion), chosen as model cancer cells, was grown in phenol red-
free Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen,
USA) with high glucose, supplemented with 10% (v/v) fetal
bovine serum, penicillin (100 U mL−1) and streptomycin (100
µg mL−1) (Invitrogen) in a 5% CO2 incubator at 37 °C. Cells
were seeded in 35 mm dishes and experiments were carried
out two days after seeding when cells had reached 90% con-
fluency. MO-based cubosomes were added to the cells at a con-
centration of 1 : 200 (5 µL in 1 mL of fresh medium) and
incubated at 37 °C for 4 and 24 h. Treatments were also per-
formed with oleic acid (OA) in DMSO (100 µM), MO in DMSO
(463 µM) and Pluronic F108 and F127 aqueous solutions (205
µM and 238 µM, respectively) equimolar respectively with the
lipid and surfactant present in the cubosome formulations.
OA and MO stock solutions in DMSO were 1000-fold concen-
trated to not exceed the 0.1% concentration of vehicle in the
medium. The same concentration of vehicle was added to
control cells when required by experimental design. For live
cell imaging, fresh serum-free medium was used to remove the
extracellular particle suspension. Then, cells were loaded with
fluorescent probes and, after the incubation time, the latter
were washed before the imaging session.
Fluorescence microscopy
Cells were stained with the following probes: 300 nM Nile Red
(NR) (9-diethylamino-5H-benzo[a]phenoxazine-5-one) for
15 min; 25 nM tetramethylrhodamine methyl ester perchlorate
(TMRM) for 30 min; 5 µM MitoSox Red for 10 min; 100 nM
MitoTracker Green FM (MitoTracker) for 30 min; 38 µM Bodipy
493/503 for 30 min; 650 nM Hoechst 33258 for 30 min. NR was
from Fluka (Buchs, SG, Switzerland); TMRM, MitoTracker
Green, MitoSox Red and Bodipy 493/503 were from Molecular
Probes (Eugene, OR, USA); Hoechst from Sigma-Aldrich
(St. Louis, MO, USA). Microscopy observations were made
using a Zeiss (Axioskop) upright fluorescence microscope
(Zeiss, Oberkochen, Germany) equipped with 10×, 20× and
40×/0.75 NA water immersion objectives and a HBO 50 W
L-2 mercury lamp (Osram, Berlin, Germany). Twelve-bit-deep
images were acquired with a monochrome cooled CCD camera
(QICAM, Qimaging, Canada) with variable exposure. For the
observation of TMRM and MitoSOX, filters were: ex 546 ±
6 nm, em 620 ± 60 nm. For MitoTracker Green, Bodipy 493/503
and Annexin V-FITC, filters were: ex 470 ± 20 nm, em 535 ±
40 nm. For Hoechst 33258, filters were: ex 360 ± 20 nm, em
460 ± 25 nm. For Nile Red, filters were: ex 470 ± 20 nm, em
535 ± 40 nm for nonpolar lipids; ex 546 ± 6 nm, em
620 ± 60 nm for total lipids.
Lipid droplet quantification
Fluorescent-based detection of the lipid droplet number,
volume and cellular distribution is usually achieved in live
cells with NR and Bodipy 493/503. NR is an ideal probe for the
detection of lipids, as it exhibits high aﬃnity, specificity and
sensitivity to the degree of hydrophobicity of lipids. The latter
feature results in a shift of the emission spectrum from red to
green in the presence of polar and non-polar lipids respect-
ively.42 For this reason, on staining living cells with NR, the
cytoplasmic membranes are stained in red whereas neutral
lipids of LDs are stained in green. Fluorescence images of NR-
stained cells were acquired at 10× under a fluorescence micro-
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scope. Measurements concerned the amount of LD content
that was evaluated by the fluorescence intensity of NR-green
emission. IOD (Integrated Optical Density) per cell was calcu-
lated using Image ProPlus software. Alternatively, LDs were
stained with Bodipy 493/503. This nonpolar dye for neutral
lipid staining was used when cells were co-loaded with TMRM
or MitoSOX Red for simultaneous observations of LDs with
mitochondria or mitochondrial ROS, respectively.
Detection of mitochondrial membrane potential and
mitochondria-derived ROS
TMRM is a red potential-sensitive probe that is concentrated
inside mitochondria by their negative membrane potential.
MitoTracker Green FM is a green selective dye that localizes to
the lipid environment of the mitochondria. MitoSOX Red is a
live-cell permeant fluorogenic probe that is selectively targeted
to the mitochondria of live cells. Once in the mitochondria,
MitoSOX Red is oxidized by superoxide anions and exhibits
red fluorescence. In order to analyze the mitochondrial mem-
brane potential (mitoMP) and the mitochondrial production
of superoxide anions (mtROS), cells were incubated with
TMRM or MitoSOX and, after removal of the probes from the
medium, images of living cells were captured under a fluo-
rescence microscope. The fluorescence intensities of TMRM
and MitoSOX were assumed to be a conventional estimate of
mitoMP and mtROS concentrations, respectively. Using Image
ProPlus software, the fluorescence intensity of TMRM and
MitoSOX was measured around the perinuclear area where
mitochondria are densely packed. Mitochondrial fragmenta-
tion was morphologically assessed.
Imaging
Fluorescence intensity measurements, made on a single cell
basis, were performed with Image ProPlus software (Media
Cybernetics, Silver Springs, MD) in the following way: cells
were seeded in 35 mm dishes and, after nanoparticle treat-
ment, loaded with fluorescent probes. Ten randomly selected
fields were acquired from each dish using a 10× objective. Data
of the fluorescence intensity of NR, TMRM or MitoSOX were
expressed as the mean ± standard deviation (SD) of four inde-
pendent experiments. Statistical evaluations were done by
Student’s t-test. The diﬀerences were considered to be signifi-
cant at p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***).
Nuclear and Annexin V-FITC staining
Cells were co-loaded with the DNA fluorochrome Hoechst
33258 together with all dyes. This probe is a water-soluble
nuclear dye commonly used to distinguish apoptotic nuclei
(characterized by nuclear condensation of chromatin and/or
nuclear fragmentation) from healthy ones. To visualize the
externalized phosphatidylserine (PS) as an early apoptosis
marker, treated cells were incubated with FITC-conjugated
Annexin V and propidium iodide (PI) for 10 min at room temp-
erature according to the Instruction Manual for the kit
(Annexin V-FITC Apoptosis detection kit, Sigma-Aldrich).43
FITC-conjugated Annexin V and PI were detected as green and
red fluorescence, respectively. Fluorescence images were
acquired at 10× and viable and non-viable cells were counted
in each field (5 fields per well) using Image ProPlus. Results
are expressed as the percent ratio of damaged versus total
number of cells.
Extraction and analyses of cell lipid components
Total lipids were extracted from HeLa cell pellets using the
Folch procedure.44 The CHCl3 fraction, containing the lipids,
from each cell sample was dried down and dissolved in EtOH.
Separation of cholesterol and unsaturated fatty acids was
obtained by mild saponification.45 The hexane phase contain-
ing the unsaponifiable fraction (cholesterol) was collected and
the solvent was evaporated. A portion of the dried residue, dis-
solved in MeOH, was injected into the high-performance
liquid chromatography (HPLC) system. The hexane phase
(saponifiable fraction) with fatty acids, dissolved in CH3CN
with 0.14% CH3COOH (v/v), was injected into the HPLC
system. The recovery of fatty acids and cholesterol during the
saponification was calculated using an external standard
mixture prepared by dissolving 1 mg of triolein, trilinolein,
and cholesterol in EtOH and processed as samples. All solvent
evaporation was performed under vacuum. Analyses of chole-
sterol and unsaturated fatty acids were carried out with an
Agilent Technologies 1100 HPLC (Agilent Technologies, Palo
Alto, CA) equipped with a diode array detector as previously
described.45 Identification of lipid components was made
using standard compounds and the conventional UV spectra,
generated using the Agilent OpenLAB CDS Chemstation
C.01.04. Calibration curves of all of the compounds were con-
structed using standards and were found to be linear, with cor-
relation coeﬃcients >0.995. Cholesterol, triolein, trilinolein,
standards of fatty acids, high-purity solvents, and Desferal
were purchased from Sigma-Aldrich. Data are expressed as
mean ± SD from four independent experiments (involving
duplicate analyses for each sample). Statistically significant
diﬀerences, using one-way analysis of variation (one-way
ANOVA) and the Bonferroni post test (GraphPad INSTAT soft-
ware, San Diego, CA), are indicated by *(p < 0.05), **(p < 0.01)
and ***(p < 0.001).
MTT assay
HeLa cells were seeded in 24-well plates (3 × 104 cells per well),
cultured overnight and then treated with the cubosomes, MO
and Pluronic solutions for 4 and 24 h at the same concen-
trations as those described in the “Cell culture and treat-
ments” section. After removal of the extracellular particle
suspension with fresh serum-free medium, cells were incu-
bated with MTT (3(4,5-dimethylthiazolyl-2)-2,5-diphenyltetra-
zolium bromide) (0.5 mg mL−1) for 2 h at 37 °C, and then
lysed with DMSO. Absorbance was measured at 570 nm using
an Infinite auto 200 microplate reader (Infinite 200, Tecan,
Austria). Results are shown as percent of cell viability in com-
parison with non-treated control cells. Data are expressed as
mean ± SD from three independent experiments (involving
triplicate analyses for each sample). Statistical evaluations
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were done by Student’s t-test. The diﬀerences were considered
to be significant at p < 0.05 (*), p < 0.01 (**) and p < 0.001
(***).
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A B S T R A C T
Monoolein-based cubosomes are promising drug delivery nanocarriers for theranostic purposes.
Nevertheless, a small amount of research has been undertaken to investigate the impact of these
biocompatible nanoparticles on cell lipid proﬁle. The purpose of the present investigation was to explore
changes in lipid components occurring in human carcinoma HeLa cells when exposed to short-term
treatments (2 and 4 h) with monoolein-based cubosomes stabilized by Pluronic F108 (MO/PF108). A
combination of TLC and reversed-phase HPLC with DAD and ELSD detection was performed to analyze
cell total fatty acid proﬁle and levels of phospholipids, free cholesterol, triacylglycerols, and cholesteryl
esters. The treatments with MO/PF108 cubosomes, at non-cytotoxic concentration (83 mg/mL of MO),
affected HeLa fatty acid proﬁle, and a signiﬁcant increase in the level of oleic acid 18:1 n-9 was observed
in treated cells after lipid component saponiﬁcation. Nanoparticle uptake modulated HeLa cell lipid
composition, inducing a remarkable incorporation of oleic acid in the phospholipid and triacylglycerol
fractions, whereas no changes were observed in the cellular levels of free cholesterol and cholesteryl
oleate. Moreover, cell-based ﬂuorescent measurements of intracellular membranes and lipid droplet
content were assessed on cubosome-treated cells with an alternative technique using Nile red staining. A
signiﬁcant increase in the amount of the intracellular membranes and mostly in the cytoplasmic lipid
droplets was detected, conﬁrming that monoolein-based cubosome treatment inﬂuences the synthesis
of intracellular membranes and accumulation of lipid droplets.
ã 2015 Elsevier Ireland Ltd. All rights reserved.
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Nanoparticles (NPs) are a class of functional materials
characterized by size-dependent properties, generally deﬁned as
engineered structures with at least one dimension less than
100 nm (Kroll et al., 2009), for which applications in medicine as
therapeutic drug delivery and/or medical imaging systems have
been predicted (Faraji and Wipf, 2009; Kroll et al., 2009; Panariti el
al., 2012). Relevant examples include micelles, liposomes, solid
lipid, polymeric, silicon-based, gold, or iron oxide NPs, as well as
dendrimers, and quantum dots (Faraji and Wipf, 2009; Panariti el
al., 2012). Lipid-based reverse cubic bicontinuous liquid crystalline
phases possess a three-dimensional structure consisting of non-
intersecting bilayers folded on an inﬁnite periodic minimal surface
characterized by a cubic symmetry and organized to form two
disconnected, continuous water channels (Hyde, 1989). They were
broadly investigated for pharmaceutical purposes in the past as
their nanostructure can incorporate molecules of biological* Corresponding author. Fax: +39 070 6754032.
** Corresponding author. Fax: +39 070 6754003.
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0009-3084/ã 2015 Elsevier Ireland Ltd. All rights reserved.relevance (Caboi et al., 2001; Murgia et al., 2001). Remarkably,
these peculiar cubic phases can be dispersed in water originating
nanoparticles known as cubosomes (Larsson, 1983; Larsson and
Tiberg, 2005), often pictured as the non-lamellar counterpart of
liposomes. Cubosomes can be easily prepared sterically stabilizing
a dispersion of monoolein (MO, Fig. 1A) in water by Pluronic series.
By virtue of peculiar characteristics such as high mechanical
rigidity, high hydrophobic volume, and the possibility of being
biodegraded in vivo through enzyme-catalyzed reactions (carbox-
ylesterases and phosphatases) (Hinton et al., 2014; Mulet et al.,
2013), monoolein-based cubosomes were recently proposed for
application in theranostic nanomedicine (Caltagirone et al., 2014;
Murgia et al., 2013).
Several investigations were conducted on the in vitro cytotox-
icity of MO-based nanoparticles, and results were found related to
cell line, incubation time, dose, and formulation type (Falchi et al.,
2015; Hinton et al., 2014; Murgia et al., 2010, 2015; Tran et al.,
2015). Previous studies also provided evidence that, as result of
their internalization, MO-based cubosomes induce accumulation
of lipids in treated cells, causing the increase (both in size and
number) of the cytoplasmic lipid droplets (LDs) (Caltagirone et al.,
2014; Falchi et al., 2015; Murgia et al., 2015). LDs are
Fig. 1. Chemical structures of monoolein (MO) (A) and pluronic PF108 (B). Cryo-TEM images of MO/PF108 cubosomes (Falchi et al., 2015) (C).
A. Rosa et al. / Chemistry and Physics of Lipids 191 (2015) 96–105 97macromolecular lipid assemblies consisting of neutral lipids, such
as triacylglycerols, diacylglycerols, cholesterol esters, and choles-
terol, surrounded by a monolayer of phospholipids and associated
proteins (Bartz et al., 2007; Khatchadourian and Maysinger, 2009;
Przybytkowski et al., 2009; Suzuki et al., 2012). LDs are now
regarded as metabolically active organelles, with a particular
structure and organization, engaged in a wide range of activities
and formed, under physiological conditions, when free (unesteri-
ﬁed) fatty acids from exogenous or endogenous sources are
available inside the cells (Khatchadourian and Maysinger, 2009;
Przybytkowski et al., 2009; Suzuki et al., 2012). Their main
functions includes lipid storing and supplying for various cellular
needs (b-oxidation, membrane biogenesis, and lipoprotein syn-
thesis) (Suzuki et al., 2012).
Remarkably, although numerous articles were devoted to
validate cubosome relevance in nanomedicine, only a small
amount of research was undertaken to investigate the impact of
these nanoparticles on the cell lipid proﬁle (Falchi et al., 2015).
The present investigation aimed to ﬁll this gap by exploring
the changes in lipid components occurring in HeLa cells
when exposed to short-term treatments with MO-based cubo-
somes stabilized by Pluronic F108 (MO/PF108). The effect of
nanoparticles (at 2 and 4 h of incubation) on HeLa cell viability
was preliminary evaluated by the MTT assay. MO/
PF108 cubosomes, at non-cytotoxic concentration, were then
tested to evaluate their effect on lipid component proﬁle, with
particular regard to triacylglycerols (TAG), phospholipids (PL),
free cholesterol (FC), cholesteryl esters (CE), and total fatty acid
composition. In situ ﬂuorescent quantiﬁcation of cytoplasmic
membranes and LDs after cubosome treatment was also
assessed in living cells loaded with Nile red, a ﬂuorescent
hydrophobic probe for the detection of polar and non-polar lipids
(Greenspan et al., 1985).
2. Materials and methods
2.1. Materials
Monoolein (RYLO MG 19 PHARMA, glycerol monooleate, 98.1 wt
%; MO) was kindly provided by Danisco A/S, DK-7200, Grinsted,
Denmark. Pluronic F108 (PEO132–PPO50–PEO132) (Fig. 1B), choles-
terol, cholesteryl oleate (CO), cholesteryl arachidonate, standards
of fatty acids, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT), 1,2-dipalmitoyl-sn-glycero-3-phosphocho-
line (PC 16:0/16:0), 1,2-dioleoyl-sn-glycero-3-phosphocholine (PC
18:1/18:1), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(PC 16:0/18:1), 1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocho-
line (PC 18:1/16:0), 2-linoleoyl-1-palmitoyl-sn-glycero-3-phos-
phocholine (PC 16:0/18:2), 2-arachidonoyl-1-palmitoyl-sn-
glycero-3-phosphocholine (PC 16:0/20:4), 1,2-dilinoleoyl-sn-glyc-
ero-3-phosphocholine (PC 18:2/18:2), 1,2-dieicosapentaenoyl-sn-
glycero-3-phosphocholine (PC 20:5/20:5), trilinolein (LLL), triolein
(OOO), 1,3-dioleoyl-2-palmitoyl-glycerol (OOP), trilinolenin
(LnLnLn), 1,2-dilinoleoyl-3-palmitoyl-rac-glycerol (LLP), 1,2-dili-
noleoyl-3-oleoylrac-glycerol (LLO), 1,2-dioleoyl-3-linoleoy-rac-glycerol (OOL), and Desferal (deferoxamine mesylate salt), were
purchased from Sigma–Aldrich (Milan, Italy). The code letters used
for the fatty acid in TAG are: L, linoleic; Ln, linolenic; O, oleic; P,
palmitic. All solvents used, of the highest available purity, were
also from Sigma–Aldrich. All of the other chemicals used in this
study were of analytical grade. Cell culture materials were
purchased from Invitrogen (Milan, Italy).
2.2. Cubosome preparation and characterization
Cubosomes were prepared by dispersing the appropriate
amount of melted MO in a solution of Pluronic F108 using an
ultrasonic processor UP100H by Dr. Hielscher, cycle 0.9, ampli-
tude 90%, for 10 min. The sample volume was 4 mL with 96.4 wt%
of water, 3.3 wt% of MO and 0.3 wt% of Pluronic F108 (Falchi et al.,
2015). Distilled water passed through a Milli-Q water puriﬁcation
system (Millipore) was used to prepare the samples. MO/
PF108 cubosomes (Fig. 1C) were characterized for particle size,
morphology, and inner structure as previously reported (Falchi
et al., 2015).
2.3. Cell Culture
Human carcinoma HeLa cell line (ATCC collection) was grown in
phenol red-free Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Invitrogen, USA) with high glucose, supplemented with 10% (v/v)
fetal bovine serum, penicillin (100 U mL1), and streptomycin
(100 mg mL1) (Invitrogen) in a 5% CO2 incubator at 37 C.
2.4. Cytotoxic activity (MTT assay)
The cytotoxic effect of the nanoparticle formulation MO/
PF108 was evaluated in HeLa cells by the MTT assay (Rosa et al.,
2013; Schiller et al., 1992). HeLa cells were seeded in 24-well plates
at density of 3  104 cells/well in 500 mL of serum-containing
media. Experiments were carried out two days after seeding when
cells had reached 90% conﬂuence. Cubosomes were added to the
cells at concentrations of 1:400 and 1:200 (2.5 mL and 5 mL in 1 mL
of serum-free medium, respectively) and incubated at 37 C for 2 h
and 4 h. A 50 mL portion of MTT solution (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) (5 mg/mL in H2O) was
then added and left for 2 h at 37 C. The medium was aspirated,
500 mL of DMSO was added to the wells, and colour development
was measured at 570 nm with an Inﬁnite 200 auto microplate
reader (Inﬁnite 200, Tecan, Austria). The absorbance is propor-
tional to the number of viable cells. All measurements were
performed in quadruplicate and repeated at least three times.
Results are shown as percent of cell viability in comparison with
non-treated control cells.
2.5. Lipid proﬁle modulation in HeLa cells
HeLa cells were plated in Petri dishes at a density of about
106 cells/10 mL of complete medium and were used for fatty acid
proﬁle modulation experiments at 2 days post-seeding when cells
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a concentration of 1:400 (25 mL in 10 mL of fresh medium) and
incubated at 37 C for 2 h and 4 h. Cells were also incubated for 4 h
at 37 C with a water solution of Pluronic F108 equimolar with the
surfactant present in the cubosome formulation. After treatment,
the cells were scraped and centrifuged at 1200 g at 4 C for 5 min.
After centrifugation, pellets were separated from supernatants and
used for lipid extraction and analyses (Rosa et al., 2013).
2.6. Extraction and preparation of lipid components
2.6.1. Determination of MO in cubosomes
Aliquots (10 mL) of the MO/PF108 nanoparticle preparation
were dissolved in 300 mL of CH3CN with 0.14% CH3COOH (v/v), and
aliquots of the samples were injected into the HPLC system for the
quantiﬁcation of MO.
2.6.2. Extraction of HeLa cell lipids
Total lipids were extracted from HeLa cell pellets using the
Folch et al. procedure (Folch et al., 1957) by the addition of 12 mL of
the mixture CHCl3/MeOH 2:1. After the addition of 4 mL of H2O,
samples were left in the dark at room temperature for 1 h, then
were centrifuged for 1 h at 900 g. The CHCl3 fraction, containing the
lipid compounds, was separated from the MeOH/H2O mixture, and
stored at 80 C before further analysis. Aliquots of the lipid
extracts were subjected to mild saponiﬁcation and TLC analysis.
Another aliquot of the CHCl3 fraction, from each cell sample, was
dried down, dissolved in 300 mL of MeOH, and injected into the
HPLC system for the analysis of lipid components: MO, phospho-
lipids (PL), free cholesterol (FC), triacylglycerols (TAG) and
cholesteryl esters (CE).
2.6.3. Saponiﬁcation of HeLa cell lipids
An aliquot of the CHCl3 fraction from each cell sample was
collected, dried down, and dissolved in 5 mL of EtOH. Separation of
fatty acids was obtained by mild saponiﬁcation (Rosa et al., 2013)
as follows: 100 mL of Desferal solution (25 mg/mL of H2O),1 mL of a
water solution of ascorbic acid (25% w/v), and 0.5 mL of 10 N KOH
were added to lipids in EtOH solution. The mixtures were left in the
dark at room temperature for 14 h. After the addition of n-hexane
and of H2O to the mixtures, samples were acidiﬁed with 37% HCl to
pH 3–4 and then centrifuged for 1 h at 900g. The hexane phase
with fatty acids was collected and the solvent was evaporated. A
portion of the dried residue was dissolved in 300 mL of CH3CN with
0.14% CH3COOH (v/v), and aliquots of the samples were injected
into the HPLC system. The recovery of fatty acids during the
saponiﬁcation was calculated using an external standard mixture
prepared dissolving 1 mg of triolein and trilinolein, in 5 mL of EtOH
and processed as samples. All solvent evaporation was performed
under vacuum.
2.6.4. Qualitative proﬁle of HeLa cell lipids by TLC
An aliquot of the CHCl3 fraction obtained from control and
treated cells (2 h) was subjected to TLC analysis for a preliminary
evaluation of the HeLa cell lipid classes. The lipids were separated
on TLC plates in hexane:diethyl ether:acetic acid (80:20:1, v/v) for
40 min. Lipid classes were visualized by iodine vapor. Neutral lipid
classes were identiﬁed according to TLC standards.
2.7. HPLC analysis of lipid compounds
Analyses of lipid compounds extracted from HeLa cells and MO
in cubosomes were carried out with an Agilent Technologies
1100 liquid chromatograph (Agilent Technologies, Palo Alto, CA)
equipped with a diode array detector (DAD) and with an Agilent
Technologies 1260 Inﬁnity ELSD. Analyses of unsaturated (detectedat 200 nm with DAD) and saturated (ELSD detection) free fatty
acids, obtained from cell lipid saponiﬁcation, and MO (at 200 nm)
in cubosome dispersion, were carried out with a XDB–C18 Eclipse
(150  4.6 mm, 3.5 mm particle size) (Agilent Technologies)
equipped with a Zorbax XDB–C18 Eclipse (12.5  4.6 mm, 5 mm
particle size) guard column (Agilent Technologies), with a mobile
phase of CH3CN/H2O/CH3COOH (75/25/0.12, v/v/v), at a ﬂow rate of
2.3 mL/min (Rosa et al., 2013). The temperature of the column was
maintained at 37 C. Analyses of MO, PL, FC, TAG, and cholesteryl
oleate (CO) in the lipid extracts obtained from cell pellets were
carried out with 1100 HPLC-ELSD. Separation was performed with
an Inertsil ODS-2 column, 150  4.6 mm, 5 mm particle size
(Superchrom), and MeOH as the mobile phase, at a ﬂow rate of
0.7 mL/min for MO, PL, and FC, and 2 mL/min for TAG and CO. The
column temperature was set at 37 C. ELSD detector settings were:
evaporator temperature 40 C, nebulization temperature 40 C,
with nitrogen as the nebulizing gas at a ﬂow of 1 L/min. Recording
and integration of the chromatogram data was carried out through
an Agilent OpenLAB Chromatography data system. The identiﬁca-
tion of cell lipid components was made using standard compounds
and conventional UV spectra. Calibration curves of all of the
compounds were constructed using standards and were found to
be linear (DAD) and exponential (ELSD), with correlation
coefﬁcients >0.995.
2.8. Fluorescent quantiﬁcation of cytoplasmic membranes and LDs in
HeLa cells
2.8.1. Fluorescence microscopy
Cells were seeded in 35 mm dishes and experiments were
carried out two days after seeding when cells had reached 90%
conﬂuence. MO-based cubosomes were added to the cells at a
concentration of 1:400 (2.5 mL in 1 mL of fresh medium) and
incubated at 37 C for 2 and 4 h. Cells were also incubated for 4 h at
37 C with a water solution of Pluronic F108 equimolar with the
surfactant present in the cubosome formulation. For live cell
imaging, cells were stained with 300 nM Nile red (NR) (9-
diethylamino-5H-benzo[a]phenoxazine-5-one) for 30 min and,
after incubation time, the probe was washed out before imaging
session. Microscopy observations were made using a Zeiss
(Axioskop) upright ﬂuorescence microscope (Zeiss, Oberkochen,
Germany) equipped with 10, 20 and 40/0.75 NA water
immersion objectives and a HBO 50 W L-2 mercury lamp (Osram,
Berlin, Germany). Twelve-bit-deep images were acquired with a
monochrome cooled CCD camera (QICAM, Qimaging, Canada) with
variable exposure. For observation of NR, ﬁlters were: ex 470  20,
em 535  40 for non-polar/neutral lipids; ex 546  6, em
620  60 for polar lipids.
2.8.2. Measurements
NR is a ﬂuorescent hydrophobic probe for the detection of
neutral lipids or mixtures of lipids and proteins that create a
hydrophobic environment (Greenspan et al., 1985). It is charac-
terized by a shift of emission from red to green in the presence of
polar and non-polar lipids respectively. Accordingly, cytoplamic
membranes, typically composed of PL, are stained in red whereas
neutral lipids such as CE or TAG are stained in green. Images of
NR-loaded cells were acquired with 10x objective and color
composite images were generated after background subtraction.
Mean values of red and green ﬂuorescence intensity were
recorded from Histogram data. Measurements, made on single
cell basis, concerned the amount of cytoplasmic membranes and
neutral lipids, evaluated by the ﬂuorescent intensity of the NR-red
and NR-green emission, respectively. Measurements were per-
formed with Image Pro Plus software (Media Cybernetics, Silver
Springs, MD).
Fig. 2. Viability, expressed as percentage of the control, induced in HeLa cells by
incubation for 2 h and 4 h in the presence of MO/PF108 cubosomes (concentrations
1:400 and 1:200, corresponding to 83 and 166 mg/mL of MO, respectively). Data are
expressed as a mean  standard deviation (SD) of three independent experiments
involving quadruplicate analyses for each sample.
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Evaluation of statistical signiﬁcance of differences was per-
formed using Graph Pad INSTAT software (GraphPad software, San
Diego, CA, USA). Comparison between groups was assessed by one-
way analysis of variance (one-way ANOVA) followed by the
Bonferroni Multiple Comparisons Test. Data were expressed as a
mean  standard deviation (SD) of three independent experiments
involving duplicate/quadruplicate analyses for each sample.
3. Results
3.1. Determination of MO level in cubosome formulation
Before any biological evaluation was performed, the amount of
MO in cubosome formulation was monitored by HPLC determina-
tion. A MO level of 33.14  2.56 mg/mL was determined in
cubosome dispersion. Experiments in HeLa cells were performed
using two concentrations of MO/PF108 cubosomes, 1:400 and
1:200, corresponding to 82.85  6.41 and 165.69  12.82 mg/mL of
MO, respectively.
3.2. Cytotoxic activity (MTT assay)
MO-based cubosomes prepared with PF108 were tested for
cytotoxicity (MTT assay) in HeLa cells. Fig. 2 shows the viability,Fig. 3. Fatty acid chromatographic proﬁle of control HeLa cells obtained by HPLC analys
PF108 cubosomes on HeLa fatty acid proﬁle measured by HPLC analysis with DAD (20expressed as percentage of the control, induced in HeLa cells after
2 and 4 h of incubation in the presence of two concentrations of
the nanoparticle formulation MO/PF108 (1:400 and 1:200).
Treatment with nanoparticle formulation at dose 1:400 did not
induce a relevant reduction in cell viability in comparison with
control cells at both incubation times. Cubosomes at dose
1:200 was not toxic at 2 h-incubation time, nevertheless a slight
decrease in HeLa cell viability was observed at 4 h-incubation
time as previously reported (Falchi et al., 2015).
3.3. Effect of MO/PF108 cubosomes on total fatty acid proﬁle of HeLa
cells
Freshly prepared MO/PF108 cubosomes were then tested
in HeLa cells at the concentration 1:400 (83 mg/mL of MO) to
assess their effects on cell lipid composition. Also PF108 solution
was tested to evaluate its effect on the HeLa cell lipids. After 2 and
4 h incubation, lipid fraction was extracted from cell pellets and
an aliquot was subjected to mild saponiﬁcation, in order to
observe the effect of MO-based cubosomes on the total fatty
acid proﬁle. Fig. 3A shows the fatty acid chromatographic
proﬁle of HeLa control cells obtained by HPLC analysis with
DAD (at 200 nm for unsaturated fatty acid determination) and
ELSD (for saturated fatty acids) detection. The content of the most
abundant fatty acids in HeLa control cells, detected by HPLC
analysis, is reported in Table 1. HeLa control cells showed a lipid
composition characterized by a high level of 18:1 isomers
(104.99  8.23 mg/plate; mainly oleic acid 18:1 n-9, OA), while
16:0 (29.59  2.58 mg/plate), and 22:6 n-3 (11.01  0.16 mg/plate)
represented the most abundant fatty acids among saturated and
polyunsaturated, respectively. High amounts of 18:2 n-6 and 20:4
n-6 were also measured. Values of the fatty acids measured in
HeLa cells after 4 h of incubation in the presence of PF108 solution
are also reported in Table 1. The incubation (4 h) of HeLa cells with
PF108 solution did not induce changes in fatty acid levels, with
treated cells showing a proﬁle similar to that of control cells, as
previously observed (Falchi et al., 2015). Fig. 3B–C show the
chromatographic proﬁle, obtained by DAD and ELSD detection, of
HeLa cells after 2 h-incubation with MO/PF108 cubosomes with
respect to untreated-control cells. The values of the main
unsaturated fatty acids 16:1 n-7, 20:4 n-6, 20:5 n-3, 22:6 n-3,
16:0, and OA (expressed as mg/plate) measured in HeLa cells after
2 and 4 h of incubation in the presence of MO/PF108 cubosomes
are reported in Table 1. The incubation of HeLa cells with theis with DAD (at 200 nm) and ELSD detection (A). Effect of 2 h-treatment with MO/
0 nm) (B) and ELSD (C) detection.
Table 1
Fatty acid composition (expressed as mg/plate), obtained by HPLC analysis, of control HeLa cells (Ctrl), cells treated with Pluronic F108 (PF108) (4 h of incubation) and MO/
PF108 cubosomes (2 and 4 h of incubation).
Fatty acid Ctrl cells PF108 treated cells
(4 h)
Cubosome treated cells
(2 h)
Cubosome treated cells
(4 h)
16:0 29.79  2.58 30.24  3.40 30.88  1.84 28.83  2.59
16:1 n-7 2.48  0.12 2.59  0.07 2.99  0.70 2.79  0.72
18:1 n-7 + 18:1 n-9 104.99  8.23 118.08  0.60 163.63  40.10** 180.85  23.50***
18:2 n-6 5.53  0.01 5.21  0.17 6.06  0.18 6.19  0.32
18:3 n-3 0.68  0.01 0.82  0.03 0.63  0.17 0.71  0.14
20:3 n-3 + 20:3 n-6 1.57  0.11 1.61  0.01 1.64  0.20 1.65  0.40
20:3 n-9 1.55  0.33 2.02  0.14 1.57  0.39 1.71  0.47
20:4 n-6 6.50  0.02 6.91  0.04 6.72  1.17 6.56  0.52
20:5 n-3 2.92  0.01 3.17  0.07 2.97  0.60 2.88  0.27
22:4 n-6 Trace Trace Trace Trace
22:5 n-3 2.31  0.07 2.09  0.05 2.24  0.25 2.03  0.06
22:6 n-3 11.01  0.16 12.95  0.01 10.75  1.72 10.91  1.71
Results are expressed as a mean  standard deviation (SD) of three independent experiments involving duplicate analyses for each sample. **P < 0.01; *P < 0.05 versus Ctrl.
100 A. Rosa et al. / Chemistry and Physics of Lipids 191 (2015) 96–105MO/PF108 nanoparticles induced a signiﬁcant increase in the
cell level of OA, which reached values approximately 1.5 and
1.7 times higher than that of control cells at 2 and 4 h of
incubation, respectively. The treatment did not seem to affect the
levels of the other saturated and unsaturated fatty acids, with
respect to control cells.Fig. 4. Chromatographic proﬁle, obtained by HPLC-ELSD analysis, of polar lipids monoole
and cells treated for 2 h with MO/PF108 cubosomes; a standard mix composed by MO, FC
18:1/16:0, ECN 32; PC 16:0/18:2, ECN 30; PC 16:0/20:4, PC 18:2/18:2, ECN 28; PC 20:5/20:
control) and values of FC/PL ratio measured in HeLa control cells (Ctrl) and after 2 h and 4
as a mean  standard deviation (SD) of three independent experiments involving dupl3.4. Effect of MO/PF108 cubosomes on HeLa cell polar lipids
Another aliquot of the lipid fraction extracted from cell pellets
was subjected to a simple chromatographic method using a
reversed-phase HPLC analysis combined with evaporative light
scattering detection (HPLC–ELSD) for the analyses of the polarin (MO), phospholipids (PL) and free cholesterol (FC) measured in control HeLa cells
, and a mixture of phosphatidylcholines (PC 16:0/16:0, PC 18:1/18:1, PC 16:0/18:1, PC
5, ECN 20), is reported for comparison (A). FC values (expressed as percentage of the
 h of incubation in the presence of MO/PF108 cubosomes (B). Results were expressed
icate analyses for each sample. ***P < 0.001; **P < 0.01 versus Ctrl.
Fig. 5. Identiﬁcation of HeLa cell lipid classes, separated on silica gel thin-layer
chromatography using hexane–diethyl ether–acetic acid (80:20:1) as a solvent.
Lane 1, standards. From top to bottom: mix of triacylglycerols (TAG) and
phosphatidylcholines (PC). Lane 2, standard of free cholesterol (FC). Lane 3,
standard of cholesteryl arachidonate. Lane 4, standard of cholesteryl oleate (CO).
Lane 5, control HeLa cells. Lane 6, HeLa cells treated for 2 h with MO/
PF108 cubosomes. Polar phospholipids remained at the origin in this solvent
system. Lipids were visualized with iodine vapors.
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chromatographic separation allowed to separate phospholipids
on the basis of equivalent carbon number (ECN) (¼CN2n, where
CN is the number of acyl group carbons and n the number of double
bonds) (Walczak et al., 2015) and lipids containing fatty acids with
the same ECN co-eluted. Phosphatidylcholines (PC) represent the
predominant polar lipid class (53%) in HeLa cell membranes (Li and
Yuan, 2011; Yu et al., 2014), therefore the identiﬁcation of PL was
made on the basis of the retention time of standard PC. Fig. 4A
shows the chromatographic proﬁle of polar lipids of HeLa control
cells and cells treated for 2 h with MO/PF108 cubosomes obtained
by HPLC-ELSD. The chromatographic proﬁle of a standard mix
composed by MO, cholesterol, and a mixture of unsaturated and
saturated PC, is also reported as reference in Fig. 4A. In our
experimental conditions, control HeLa cells showed a lipid proﬁle
characterized by two main peaks of PL at 9.8 and 12.5 min
(corresponding to ECN 28/30 and 32, respectively), and the peak of
FC was detected at 14.5 min. The 2 h-treatment with MO/
PF108 cubosomes induced in HeLa cells a change in the proﬁle
of polar lipids, in particular it was observed a marked increase in
the area of the peak corresponding to PL containing OA (PC 181:1-
18:1, PC 18:1-16:0, and PC 16:0-18:1) (Fig. 4A) with respect to the
other peaks, and a similar trend was observed at 4 h-incubation.
Fig. 4B shows the levels of FC (expressed as percentage of the
control) and the values of the ratio FC/PL containing OA measured
in HeLa control cells and after 2 h and 4 h of incubation in the
presence of MO/PF108 cubosomes. The determination of the ratio
FC/PL represented a useful approach to bypass eventual differences
in cell number and nanoparticle uptake rate among experiments.
The FC level was measured in control cells as mean content of
67.87  8.18 mg/plate, and a value of 122.56  12.73 mg/plate was
determined for PL containing OA (quantiﬁed as PC 18:1-18:1). Both
treatments with MO-based nanoparticles did not signiﬁcantly
affect FC level in HeLa cells, while a signiﬁcant decrease of the FC/
PL ratio value was observed at both the incubation times, due to a
synthesis of phospholipids containing OA, which conﬁrmed the
signiﬁcant increase of the OA amount measured in treated cells
after lipid saponiﬁcation. HeLa cells treated with PF108 solution
showed the same FC level and FC/PL ratio of control cells (data not
shown). The cell uptake of MO/PF108 cubosomes was also
evaluated by monitoring the intracellular amount of MO. MO
values of 5.95  3.11 and 9.84 1.22 mg/plate were determined in
treated HeLa cell pellets after 2 and 4 h of incubation, respectively.
3.5. Effect of MO/PF108 cubosomes on neutral lipids of HeLa cell
Initially, we set out to characterize the neutral lipid composition
of HeLa cells in the absence or in the presence of MO/
PF108 nanoparticles by TLC. Polar phospholipids remained at
the origin in this solvent system and represented the main lipid
classes in control and treated cells (Fig. 5). Control HeLa cells
showed the bands of FC and CE, the latter migrated in the
correspondence of cholesteryl oleate (CO), while the band of TG
was not detectable in these experimental conditions, as previously
observed (Galli et al., 1999). The treatment with MO/
PF108 nanoparticles induced an evident increase in the level of
TAG with respect to controls, as shown in Fig. 5 for cells at 2 h-
incubation. Then, we used HPLC-ELSD to identify and quantify the
dominant CE and TAG species. Fig. 6A shows the chromatographic
proﬁle of lipids extracted from control and treated HeLa cells
(2 and 4 h) obtained by HPLC-ELSD analysis at 2 mL/min with
MeOH as eluent. This chromatographic condition allowed to
separate cell polar lipids (PL and FC) from neural lipids (CE and
TAG) that eluted at higher retention times. Peak identiﬁcation and
improvement of separation was based on standards-individually
and as part of several mixtures prepared speciﬁcally to conﬁrmretention times. The reversed phase mode allowed also to separate
TAG on the basis of ECN (Lísa and Holcapek, 2008). Two main peaks
were detected: peak 1 at 45 min identiﬁed as CO (Fig. 6B), and peak
2 at 43 min, identiﬁed as TAG containing OA (OOO/POO, ECN 42)
(Fig. 6C). A mean value of 26.74  0.27 mg/plate was measured for
CO in control HeLa cells and similar values was detected in treated
cells. The treatment with MO-based nanoparticles induced a
signiﬁcant increase in the level of TAG contain OA (Fig. 6D) that
reached a value of 37.13  0.06 mg/plate at 4 h-incubation. HeLa
cells incubated for 4 h with PF108 solution exhibited the same
neutral lipid proﬁle of control cells (data not shown).
3.6. Intracellular membranes and lipid droplets
Nile red (NR) is a ﬂuorescent lipophilic dye characterized by a
shift of emission from red to green according to the degree of
hydrophobicity of lipids. NR ﬂuoresces intensely in red in the
presence of phospholipids constituting the membranes of the
membrane-enclosed organelles (mitochondria, endoplasmic re-
ticulum, Golgi Apparatus, endosomes and lysosomes), whereas
neutral lipids, present in the LDs, are stained in green (Greenspan
et al., 1985). Beside this property, quantitative ﬂuorescent
measurements were performed on whole cell to highlight
variations of polar and neutral lipids after nanoparticle treatment
in comparison with untreated control cells. Analysis of NR-loaded
cells after cubosome treatment at 2 and 4 h incubation time
(Fig. 7A) indicated a signiﬁcant increase of polar and neutral lipids
at both incubation times (Fig. 7B). Accordingly, the uptake of MO-
based cubosomes gave rise to a signiﬁcant increase of both
cytoplasmic membranes and LDs. However, comparing the effects
from two incubation times, whereas no variations in the amount of
cytoplasmic membrane were detected, signiﬁcant differences
were found in the neutral lipids, indicating that the excess of
lipids was rather stored into lipid droplets. Cell treated with
PF108 solution showed the same level of cytoplasmic membranes
and LDs as the control (data not shown). The ratio of red and green
emission, previously used in the microscopy investigations to
evaluate qualitative variations between polar and non-polar lipids
(Diaz et al., 2008), was also applied in order to conﬁrm the
observed changes in the intracellular amount of polar and neutral
lipids after cubosome treatment. Red/green ratio ranged from
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2 and 4 h, respectively, indicating a progressive accumulation of
hydrophobic lipids in the lipid droplets, so conﬁrming the
previously demonstrate increased of OA-containing TAG.
4. Discussion
NPs offer an extraordinary opportunity for application in
pharmacology and medicine. However, NPs should no longer be
viewed only as simple carriers for biomedical applications, since
they can also play an active role in mediating biological effects
(Kroll et al., 2009; Panariti et al., 2012; Przybytkowski et al., 2009).
Actually, NPs interaction with living systems is currently originat-
ing growing interest under the perspective of improving drug
delivery as well as implementing nanotechnologies in a safe way
(Lesniak et al., 2013). Plainly, safe and effective utilization of such
systems requires that they do not result in an adverse biological
response. Lipid-based nanoparticles (LNPs) are well tolerated in
living systems, since they are made from physiological compounds
leading to the metabolic pathways (Severino et al., 2012), and
among them MO-based cubosomes are innovative, promising drug
delivery nanocarriers (Larsson, 1983; Larsson and Tiberg, 2005;
Murgia et al., 2013; Caltagirone et al., 2014; Hinton et al., 2014).
Particularly, MO, their main molecular constituent, is a well-Fig. 6. Chromatographic proﬁle of lipid classes (phospholipids, PL; free cholesterol, 
PF108 cubosomes obtained by HPLC-ELSD analysis at 2 mL/min and details of the main 
oleate (CO) (B) and peak 2 as triacylglycerols containing OA (C). Values of TAG and CO me
deviation (SD) of three independent experiments involving duplicate analyses for eachknown lipid molecule commonly used as emulsifying agent and
food additive. It is considered as a nontoxic, biodegradable, and
biocompatible material classiﬁed as “generally recognized as safe”
(GRAS) (Lim et al., 2014). However, the interaction of MO-based
cubosomes with cell lipids is an essential focus in assessing and
understanding toxicity and compatibility. Surprisingly, the litera-
ture on the impact of MO-based cubosomes on cell lipid proﬁle is
negligible (Falchi et al., 2015), despite the number of publications
devoted to explore their potential applications for therapeutic
and theranostic purposes (Caltagirone et al., 2014; Hinton et al.,
2014; Mulet et al., 2013; Murgia et al., 2013, 2015).
Here, we investigated the changes in cellular lipid composition
(total fatty acid proﬁle, PL, FC, TAG, and CE) occurring in human
carcinoma HeLa cells when exposed to short-term treatments
(2 and 4 h) with MO/PF108 cubosomes. The treatments with a non-
cytotoxic concentration of MO/PF108 cubosomes, corresponding to
83 mg/mL of MO, signiﬁcantly modulated HeLa cell lipid proﬁle.
After the addition to the culture media, MO/PF108 nanoparticles
were immediately taken up by HeLa cells, inducing from 2 h-
incubation a remarkable incorporation of OA in the phospholipid
and triacylglycerol fractions, and accumulation of triacylglycerols
in the LDs. The cellular uptake of MO/PF108 cubosomes was also
conﬁrmed by the signiﬁcant increase in the level of OA observed
from 2 h incubation in treated cells after lipid componentFC) measured in control HeLa cells and cells treated for 2 h and 4 h with MO/
peaks 1 and 2 detected at 45 and 43 min (A). Identiﬁcation of peak 1 as cholesteryl
asured in control and treated cells (D); results were expressed as a mean  standard
 sample. **P < 0.01 versus Ctrl.
Fig. 7. The panel shows representative images of red (cytoplasmic membranes), green (lipid droplets, LDs) and merged emissions of untreated-control and cubosome-treated
HeLa cells loaded with Nile red (A). NR-ﬂuorescent quantiﬁcation of cytoplasmic membranes and lipid droplets of cells exposed to cubosome treatment for 2 and 4 h (B). The
percent of treated cells was normalized to the control cells. Results were expressed as a mean  standard deviation (SD) of three independent experiments involving duplicate
analyses for each sample. ***P < 0.001; **P < 0.01 versus Ctrl. xxxP < 0.001 versus 2 h incubation time. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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general, a mechanism of endocytosis, by which localised regions
of the plasma membrane wrap around the material to be
internalized, fold in and detach to form endocytotic vesicles (Oh
and Park, 2014; Panariti et al., 2012). After incorporation in the
endolysosomal compartments, LNPs are susceptible to rapid
enzymatic hydrolysis mediated by lysosomal lipases (Maier
et al., 2013). Presumably, after the addition to the culture media,
MO/PF108 nanoparticles were immediately taken up by HeLa cells
by endocytosis, and OA, maybe derived from the lipolysis of MO in
the endolysosomal compartments, was utilized for the synthesis of
phospholipids and triacylglycerols incorporating OA. At short
term-incubation, the OA increase in treated cells was mainly
derived from an intracellular hydrolysis process of MO more than
from the MO hydrolysis in the external medium. In fact, the extent
of hydrolysis phenomena in MO/water based systems resulted
negligible at short incubation times (Murgia et al., 2002). The OA
increase measured in MO/PF108 treated HeLa cells at 2 and 4 h of
incubation corresponded approximately to the 10% and 12% of theOA amount in MO/PF108 cubosomes, respectively. The cellular
internalization of MO/PF108 cubosomes caused a modiﬁcation of
the HeLa cell PL proﬁle, inducing a signiﬁcant synthesis of the PL
fraction incorporating OA (PL containing 18:1–18:1 and 18:1–
16:0). A signiﬁcant increase of polar lipids was also observed in
treated cells by NR measurements (red emission) at both
incubation times, indicating that the uptake of MO-based
cubosomes induced a signiﬁcant increase of cytoplasmic mem-
branes as a consequence of the endocytotic process. A good
negative correlation (correlation coefﬁcient r = 0.9239, with
r = Cov (X,Y)/sx  sy) was found between TC/PL ratio values and
values of NR-ﬂuorescent quantiﬁcation of cytoplasmic mem-
branes. The PL fatty acid modiﬁcation observed is physicochemi-
cally relevant. Plasma membrane and organelle membranes
consist of proteins embedded in a ﬂuid PL bilayer. PL, together
with membrane proteins and cholesterol, are involved in many cell
functions such as in the control of cell shape, compartmentaliza-
tion, storage of compounds, ion transport, metabolism, cell
signalling processes and cell fusion processes (Monteiro et al.,
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throughout the cell; each organelle has been found to have a
unique lipid composition allowing optimal functionality (Hagen
et al., 2010; Vance, 2014). As a matter of fact, alterations in cell
membrane lipid composition, like changes in the ratio between
saturated and monounsaturated fatty acid chains of the PL, can
directly inﬂuence the biophysical properties of biological mem-
branes (cytoplasmic and organelles' membranes), deeply altering
ﬂuidity, the lipid raft thermodynamic properties and microdomain
organization (Hagen et al., 2010; Ariyama et al., 2010). Therefore,
changes in lipid composition inﬂuence many cellular functions
such as signal transduction, cell adhesion, lipid trafﬁcking, ion
channel function, receptor mobility/interaction, and the biological
response to the drugs (Hagen et al., 2010).
In response to MO/PF108 nanoparticle treatments, our study
also evidenced a signiﬁcant increase of neutral lipids stored into
the lipid droplets observed in the cytoplasm of the cells. In turn,
as indicated by the good correlation coefﬁcient found between
TAG/neutral lipid values (r = 0.9668), the consequent accumula-
tion of the TAG fraction incorporating OA (OOO/OOP) was
ascertained. Here, it deserves noticing that intracellular LDs
basically accumulate when cells are cultured in the presence of
high concentrations of various exogenous lipids (Hsieh et al.,
2012). In many cell cultures of non-adipocytes, only a variable
number of LDs exist under normal conditions, but the addition of
unsaturated fatty acids such as OA to the medium induces
abundant TG-rich LDs, whereas the treatment with cholesterol
induces increased CE-rich LDs (Hsieh et al., 2012; Suzuki et al.,
2012). It is worth to note that no signiﬁcant changes in the cellular
levels of FC and CO were observed in cells treated with MO/
PF108 nanoparticles, indicating the activation of speciﬁc lipid
biosynthetic pathways in HeLa cells.
5. Conclusions
This study showed that exposure of HeLa cells to MO-based
cubosomes stabilized by Pluronic F108 (MO/PF108) can affect
the intracellular metabolism of lipids. Results evidenced that
MO/PF108 cubosome formulation was promptly taken up by the
Hela cells and inﬂuenced the cellular lipid proﬁle. Particularly, a
signiﬁcant synthesis of PL and TG rich in OA was observed along
with a marked increase in the synthesis of intracellular mem-
branes and accumulation of LDs. Given the importance of lipid
composition in membrane ﬂuidity, cell signaling modulation and
protein function, the data of the present study furnish evidence of
the impact of lipid-based cubosomes, at a low non-cytotoxic
concentration, on the biochemistry and physiology of cancer HeLa
cells. It should be largely taken into account when evaluating the in
vitro and in vivo biological response to encapsulated drugs.
Moreover, we highlight the potential role of lipid-based nano-
particles not only as simple carriers for in vivo drug delivery but
also as an in vivo platform to modulate the lipid biosynthetic
pathways of speciﬁc cell target. Further studies will be needed to
establish also the impact of lipid-based cubosomes on the lipid
proﬁle of normal cell.
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Abstract 
Herein we provided the first proof-of-principle for in vivo fluorescence optical 
imaging application using monoolein-based cubosomes in a healthy mouse animal 
model. This formulation, administred at a non cytotoxic concentration, was capable 
of providing both exogenous contrast for NIR fluorescence imaging with very high 
efficiency and chemospecific information upon lifetime analysis. Time-resolved 
measurements of fluorescence after the intravenous injection of cubosomes revealed 
that the dye rapidly accumulates mainly in the liver, while lifetimes profiles obtained 
in vivo allowed discriminating between the dye free or embedded within the 
cubosome nanostructure after injection. Plasmatic elimination of the dye-loaded 
cubosomes occurs following a pseudo first-order kinetic. 
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Introduction 
Spontaneous self-assembly of lipids in water allows formulation of liquid 
crystalline nanoparticles of the inverted type, showing inner nanostructure 
characterized by lipid bilayers wrapped on triply periodic minimal surfaces of 
cubic symmetry.1–4 Discovered in the eighties, such nanoparticles are 
universally known as cubosomes.5,6 They are considered an emerging 
platform for a wide range of nanomedicine applications by virtue of unique 
features.7 These include a high hydrophobic volume (higher than liposomes),8 
the possibility of simultaneously host both diagnostic agents and therapeutics 
(cubosomes are also proposed as theranostic tools),8–10 storage stability, and a 
viscosity of the formulation close to water, a fundamental characteristic for 
bolus delivery.11 Recently, their superior efficacy in the siRNA delivery 
(cuboplexes) with respect to traditional lipoplexes was also discussed.12 The 
necessary colloidal stability of cubosome formulations is typically achieved 
by using polyethylene oxide (PEO)-polypropylene oxide (PPO)-polyethylene 
oxide triblock copolymers (Pluronics) as stabilizing agents, although other 
kinds of stabilizers have been proposed.11–16 As a consequence, cubosomes are 
surrounded by a PEO corona that, similarly to stealth liposomes, should retard 
the clearance from the bloodstream of these nanoparticles via the mononuclear 
phagocytic system by inhibiting opsonization.17,18 Furthermore, their surface 
can be decorated with targeting residues to properly address cubosomes 
towards specific tissues.19,20 Despite their remarkable potential as 
nanocarriers, to the best of our knowledge, so far no papers have appeared 
describing the successful exploitation of cubosomes for in vivo imaging. 
Differently, several authors demonstrated that the hexagonal counterpart of 
cubosomes (namely, hexosomes) can be effectively labeled with radiotracers 
(such as 99Tc)21,22 or MRI contrast agents (paramagnetic nitroxide lipids),11,23 
providing valuable imaging tools for in vivo diagnostics. Compared with 
traditional structural and functional imaging modalities, fluorescence optical 
imaging (FOI) offers several advantages, requiring a relatively simple 
instrumental setup, and showing high signal-to-noise ratios in vivo, owing to 
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the development of novel synthetic fluorescent probes with high brightness 
and photostability in the near infra-red spectral region (NIR, 650-900 nm).24–27 
Therefore, innovative FOI methods hold promise as radiation-free, portable, 
and potentially cost-effective screening technology extremely useful in 
imaging studies in vivo.28 In particular, Time-Domain optical imaging (TD-
OI) technology allows for NIR fluorescence lifetime analysis, which is based 
both on the specificity of fluorescence probes and the sensitivity of their 
emission lifetime, related to environmental characteristics.29–34 In this context, 
here we provide the first proof-of-principle for FOI application using 
monoolein (MO)-based cubosomes in vivo in a healthy mouse animal model. 
 
Results and Discussion 
To favor its encapsulation within the MO bilayer, the fluorescent probe used, 
a Cyanine 5.5, was modified by adding a long hydrocarbon chain (Cy5.5-C14, 
see Supplementary Information for details). The fluorescent cubosome 
formulation was easily prepared by dispersing MO and Cy5.5-C14 in a 
Pluronic F108 (PF108) aqueous solution. The physicochemical 
characterization of the formulation was performed by dynamic light scattering 
(DLS), electron transmission microscopy at cryogenic temperature (cryo-
TEM), and small-angle x-ray scattering (SAXS). According to DLS results, 
the formulation was a homogenous dispersion (polydispersity index of 0.12) 
of nanoparticles characterized by a mean diameter of 144  1 nm and a -
potential of –21 mV. The nanoparticles morphology, as seen by cryo-TEM, 
revealed the co-existence of cubic shaped and quasi-spherical objects both 
displaying an inner structure made of a dark matrix and alternate bright spots 
(Supplementary Fig. S1a), as classically observed in liquid crystalline 
nanoparticles. It deserves noticing the complete absence of the vesicular 
material that is commonly found in this kind of formulations.35 The nature of 
the liquid crystalline phase was assessed by SAXS. The diffraction pattern 
was characterized by at least five Bragg peaks with relative positions 
√2:√3:2:√6:√8 (Supplementary Fig. S1b), confirming that the inner 
 5
nanostructure was made of a bicontinuous cubic double diamond phase (space 
group Pn3m), having a lattice parameter of 89.1  0.4 Å. Such a value is about 
ten percent smaller than that recorded in pristine cubosomes (not containing 
the fluorescent probe) obtained using the same components.19 This fact 
implicitly indicates that, although the nanostructure is retained, 
accommodation of Cy5.5-C14 within the lipid bilayer alters the MO effective 
packing parameter,36 inducing a slightly higher curvature at the MO/water 
interface, and a consequent decrease in the lattice parameter. The 
photophysical characterization of the dye and the cubosome formulation was 
performed by UV-Vis and fluorescence spectroscopy. As shown in 
Supplementary Fig. S2 and reported in Table S1, the free dye Cy5.5-C14 
showed, in EtOH, an absorption band centered at 685 nm (ε = 140000 M-1 cm-
1) with a shoulder at 650 nm (ε = 14000 M-1 cm-1). A strong emission at 709 
nm was observed (Φ = 0.27). Once encapsulated inside the cubosomes 
(Cy5.5-C14@cubosomes, aqueous dispersion), both the absorption (λabs = 696 
nm and 665 nm) and the emission bands (λemis  = 719 nm) of the dye were 
slightly red-shifted (Supplementary Fig. S3), probably due to the more apolar 
environment experienced by the fluorophore inside the nanoparticles with 
respect to EtOH. The differences in fluorescence anisotropy values (r = 0.008 
and r = 0.100 for Cy5.5-C14 and Cy5.5-C14@cubosomes, respectively) clearly 
confirmed the internalization of the fluorophore inside the nanoparticles. 
Before the evaluation in vivo as diagnostic tool, the formulation was tested in 
vitro for its toxicity. Indeed, several recent in vitro investigations drew 
attention to the potential cytotoxicity of cubosomes and, particularly, to their 
hemolytic properties.37,38 Accordingly, the proposed formulation was 
investigated for its cytotoxicity against 3T3 cells and erythrocytes. Although 
the cytotoxicity of cubosomes was found to be strongly dependent on the 
cellular line investigated, the lower concentration threshold was around 20 
g/mL of MO.9,39–41 The formulation here tested was found to induce no 
cytotoxicity in 3T3 cells up to 55 g/mL of MO (Fig. 1a). The incubation of 
Cy5.5-C14@cubosomes with human red blood cells evidenced the capacity to 
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induce direct lysis of erythrocytes in a dose-dependent manner modifying a 
standard hemolytic assay42 and using 109 erythrocytes (Fig. 1b).43,44 These 
results are in line with experiments previously reported,41,45  and evidenced 
that the cubosomes formulation here proposed did not show lysis of 
erythrocytes below 62 g/mL of monoolein. 
 
 
Figure 1. Evaluation of the formulation cytotoxicity. (a) Viability, expressed as % of the control, 
induced by incubation for 4 h with different concentrations of cubosomes (corresponding to 20-165 
g/mL of MO) in 3T3 fibroblasts by MTT assay. Data are expressed as a mean ± standard deviation (SD) 
of three independent experiments involving quadruplicate analyses for each sample; *** = p  0.001 versus 
Ctrl. (b) Hemolysis test of human red blood cells incubated with different amounts of cubosomes 
in a standard hemolytic assay using 10% erythrocytes. Data were expressed as % of lysis ± SD. 
 
Consequently, in vivo experiments were performed using a MO concentration of 
about 50 g per mL of plasma. After the in vivo injection of Cy5.5-C14@cubosomes 
into the tail vein (i.v.) of a healthy mouse, the distribution of the fluorophore was 
monitored using TD-OI. This technology helped understand the lifetime distribution, 
and provided a convenient route of analyzing the biodistribution and plasmatic 
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elimination of a fluorescent cubosomes formulation after intravenous administration 
in mice. Optical imaging was performed two times during the first day, then every 
24 hours for the next two days: the results showed that, following injection, Cy5.5-
C14@cubosomes were rapidly taken up by the liver (Fig. 2a). To further investigate 
the extent of Cy5.5-C14@cubosomes and/or free dye accumulation in the organs and 
tissues, mice were sacrificed at 48 hours after injection of the cubosomes for ex vivo 
TD-OI analysis of explanted organs (i.e., kidneys, thymus, heart, spleen, brain, 
lungs, stomach, intestine, and liver). This approach excludes any potential influence 
due to autofluorescence and scattering within the body and fur, thereby increasing 
both specificity and sensitivity of the probe detection. Ex vivo evaluation of organs 
at 48 hours post-injection showed that the highest fluorescence intensity was 
localized in the liver and stomach, emphasizing that Cy5.5-C14 is excreted through 
these organs (Fig. 2b). Cy5.5-C14@cubosome plasmatic elimination after single i.v. 
administration was investigated by analyzing the fluorescence signal of plasma 
samples at different times post-injection, which could be interpreted using a pseudo 
first-order kinetic (Supplementary Fig. S4). 
 
Figure 2. In vivo and ex vivo Time-Domain optical imaging experiments. (a) Whole body 
fluorescence intensity distribution of a representative healthy mouse that received an i.v. injection of 
cubosomes (1.5 L stock solution + 148.5 L PBS, corresponding to 0.4 nmol Cy5.5-C14 and 50 g 
MO), displayed in normalized counts (NC). Following injection, cubosomes were rapidly taken up by the 
liver. (b) In accordance to the in vivo results, ex vivo analysis clearly showed that the highest signal of 
fluorescence emission was associated with liver. A strong intensity specific signal was also detected in 
the stomach. 1. Lungs and heart; 2. Brain; 3. Thymus; 4. Stomach; 5. Intestine; 6. Kidney; 7. Liver; 8. 
Spleen. 
 
a b 
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Fluorescence lifetime information is complementary to intensity measurement and 
can be used to improve signal-to-background contrast and provide environment-
sensing capability. Some biological events not available from fluorescent intensity 
images can be monitored directly from the fluorescence lifetime map. The 
fluorescence decay of Cy5.5-C14@cubosomes and Cy5.5-C14 were measured in vitro 
and single-exponential models were appropriately fitted. Cy5.5-C14 clearly changed 
its fluorescence lifetime properties once loaded in the cubosomes formulation (Fig. 
3a). 
 
Figure 3. In vitro and in vivo fluorescence lifetime experiments. (a) In vitro fluorescence lifetime 
analysis with equimolar aliquots of the cubosomes preparative and the control NIR-dye. The samples 
were placed on a paper substrate before analysis of the lifetime. Fluorescence lifetime maps were created 
from temporal point-spread function (TPSF) data acquired using the time-domain diffuse optical imaging 
system. (b) In vivo fluorescence lifetime maps of whole body mice injected with cubosomes. The images 
were taken a few minutes and 6 hours after the injection. 
 
This provided the possibility to discriminate in vivo between the Cy5.5-
C14@cubosomes and the free dye based on distinct lifetime profiles. Whole body 
imaging analysis at a few minutes after i.v. injection revealed a diffuse distribution 
of cubosomes throughout the body of the mouse and, after the first 6 hours, a strong 
signal associated with the free dye was clearly detectable mainly in the liver and 
intestine, decreasing over time (Fig. 3b). 
To cross-validate the results obtained in vivo and ex vivo, the localization of Cy5.5-
C14 within the liver was confirmed by fluorescence microscopic examination of 
b a 
 tissue cryo-sections obtained from the explanted organ at 48 hours after Cy5.5
C14@cubosomes injection (Fig. 4). The close examination of the liver cryo
revealed the presence of several spherical fluorescent aggregates (indicated by the 
arrows) with size in the micrometer range, which could reasonably be identified as 
the lipid droplets (cytoplasmic organelles involved in neutral lipid storage) since the 
highly hydrophobic Cy5.5-C14 dye should preferentially stain structures of this kind 
in the cells. It deserves here noticing that MO
vesicles) are readily internalized after exposure to cells, causing growth in size and 
number of the lipid droplets.19,39,46 
Figure 4. Microscopic examination of liver cryo
sections obtained from liver explanted from the cubosomes
bright field and fluorescence mode under x63. DAPI staining was carried out to visualize cell nuclei, 
which appear in blue, while Cy5.5-C14 appears in red. The arrows indicate droplet structures in the 
hepatic parenchyma (bar = 15 m). 
 
Because of its high sensitivity, FOI has been increasingly applied
tissue pathology, such as in image-guided surgery, and for sentinel lymph node 
fluorescence mapping. In this respect, several intraoperative
systems are now available for pre-clinical and clinical studies and some of these 
systems have been approved by the FDA for use in humans.
imaging perspective, it was here not
potential in medicine as fluorescence and lifetime probes. 
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progresses of fluorescent cubosomes towards in vivo applications will depend on the 
introduction of targeting properties that will increase the specificity of the 
cubosomes to be used for both imaging and therapeutic applications. 
 
Methods 
Cubosomes preparation and characterization.  Cubosomes were prepared by 
dispersing melted monoolein (MO, 1-monooleoylglycerol, 98.1 wt%, kindly 
provided by Danisco A/S, DK-7200, Grinsted, Denmark) in an aqueous solution of 
Pluronic F108 (PF108, PEO132− PPO50−PEO132, Sigma-Aldrich) using an ultrasonic 
processor UP100H by Dr. Hielscher, cycle 0.9, amplitude 90%, for 10 min. To 
obtain fluorescent cubosomes, the fluorophore Cy5.5-C14 was dispersed in the 
melted MO with the help of an ultrasonic bath before dispersion in Pluronic F108. 
The typical sample volume was 4 mL with 96.39 wt % of water, 3.3 wt % of MO, 
and 0.31 wt % of Pluronic F108. The molar concentration of Cy5.5-C14 was 2.7 × 
10-4. Dynamic light scattering (DLS) measurements for the determination of the 
nanoparticles size and ζ-potential were performed at 25 °C using a ZetaSizer Nano 
ZSP (Malvern Instruments Ltd., Worcestershire, U.K.). DLS measurements were 
also performed after the cubosome formulation was passed through a 30G needle 
(the same used for cubosome i.v. administration for in vivo tests), to confirm that 
injection did not alter the physicochemical characteristics of the formulation. The 
characterization of the nanoparticles internal structure at 25 °C was carried out by 
small angle x-ray scattering (SAXS) using a Ganesha 300XL (SAXSLAB ApS, 
Skovlunde, Denmark). The morphology of the nanoparticles was observed at 120 kV 
acceleration voltage in an FEI Tecnai T12 G2 transmission electron microscope at 
about −175 °C in the low-dose imaging mode to minimize electron-beam radiation-
damage. Images were digitally recorded with a Gatan US1000 high-resolution CCD 
camera. 
 
Photophysical measurements. Cubosomes solutions were diluted with Milli-Q® 
water. UV-vis absorption spectra were recorded at 25 °C by means of a Perkin-
Elmer Lambda 45 spectrophotometer. Quartz cuvettes with optical path length of 1 
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cm were used. Corrected fluorescence emission and excitation spectra (450 W Xe 
lamp) were obtained with a modular UV-vis-NIR spectrofluorimeter Edinburgh 
Instruments FLS920 equipped with both a Hamamatsu R928P photomultiplier tube 
(for the 500-850 nm spectral range) and an Edinburgh Instruments Ge detector (for 
the 800-1600 nm spectral range). Luminescence quantum yields (uncertainty ± 15%) 
were recorded on air-equilibrated solutions and cyanine IR-125 (from Acros 
Organics) in Ethanol (Φ = 0.132).48 The same instrument connected to a PCS900 PC 
card was used for the TCSPC (Time-Correlated Single Photon Counting) 
experiments (excitation laser λ = 640 nm). Corrections for instrumental response, 
inner filter effects and phototube sensitivity were performed.49 Fluorescence 
anisotropy measurements were performed on an Edinburgh FLS920 equipped with 
Glan-Thompson polarizers. Anisotropy measurements were collected using an L-
format configuration, and data were corrected for polarization bias using the G-
factor. Four different spectra were acquired for each sample combining different 
orientation of the excitation and emission polarizers: IVV, IVH, IHH, IHV (where V 
stands for vertical and H for horizontal; the first subscript refers to the excitation 
polarizer and the second subscript refers to the emission one). The spectra were used 
to calculate the G-factor and the anisotropy r: G = IHV/IHH, r = (IVV - GIVH)/(IVV + 
2GIVH). 
 
Cytotoxicity experiments. Mouse 3T3 fibroblasts (ATCC collection) were grown at 
37 °C in phenol red-free Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, 
USA) with high glucose, supplemented with 10% (v/v) fetal bovine serum, 
penicillin (100 U mL−1), and streptomycin (100 μg mL−1) (Invitrogen) in a 5% CO2 
incubator at 37 °C. The cytotoxic effect of the nanoparticle formulation was 
evaluated in 3T3 fibroblasts by the MTT assay.50 3T3 cells were seeded in 96-well 
plates at a density of 2×103 cells/well in 100 µL of serum-containing media. 
Experiments were carried out two days after seeding when cells had reached 70% 
confluence. Cubosomes were added to the cells at different concentrations 
(corresponding to 20, 30, 40, 55, 83, and 165 g/mL of MO) in 100 µL of serum-
free medium, and incubated at 37 °C for 4 h. The cell culture medium was then 
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removed from each well of the 96-well plates; an 8 L portion of MTT solution (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (5 mg/mL in H2O) was 
added to cells in fresh medium and left for 2 h at 37 °C. The medium was aspirated, 
100 µL of DMSO was added to the wells, and color development was measured at 
570 nm with an Infinite 200 auto microplate reader (Infinite 200, Tecan, Austria). 
The absorbance is proportional to the number of viable cells. All measurements were 
performed in quadruplicate and repeated at least three times. Results are shown as 
percent of cell viability in comparison with non-treated control cells. Evaluation of 
statistical significance of differences was performed using Graph Pad INSTAT 
software (GraphPad software, San Diego, CA, USA). Comparison between groups 
was assessed by one–way analysis of variance (One–way ANOVA) followed by the 
Bonferroni Multiple Comparisons Test.  
 
Hemolytic assays. These assays were done as previously described.51 Briefly, 
hemolytic activity was performed by mixing different amount cubosomes in Veronal 
buffer with 50 μL of 10% human erythrocytes (EA) suspended in a final volume of 
250 μL. After incubation at 37 °C for 30 min, red cell lysis was calculated by 
measuring the OD415. Hemolytic activity was expressed as a percentage of lysis ± 
SD. 
 
Animal model and treatment. Pathogen-free female BALB/c mice (4- to 6-weeks 
old) were purchased from Harlan Laboratories (San Pietro al Natisone, Italy). Mice 
were housed in a controlled environment and maintained with ad libitum food and 
water. Mice were treated intravenously (i.v.) with 150 µL of cubosomes solution, 
corresponding to 0.4 nmol Cy5.5-C14 and 50 g MO. Mice were followed by 
optical imaging images acquisition over time to evaluate the probe biodistribution 
and accumulation in specific organs, and the animals were also subjected to blood 
samples for the plasma collection. 
 
In vivo and ex vivo time domain optical imaging analysis. Experimental animals 
were anesthetized with isoflurane at 1.8 - 2.0 volume %, shaved in the abdomen to 
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avoid laser scattering caused by fur, placed in the small animal time-domain Optix 
MX2 preclinical NIRF-imager (Advanced Research Technologies, Montreal, CA) 
and maintained under vaporized isoflurane for the entire imaging session. Two-
dimensional regions of interest were selected and laser power, integration time and 
scan step size were optimized according to the emitted signal. A blank image was 
acquired before i.v. administration of cubosomes to record background signal 
intensity and after i.v. treatment the animals were monitored at multiple time points. 
In all imaging experiments, a 670 nm pulsed laser diode with a repetition frequency 
of 80 MHz and a time resolution of 12 ps light pulse was used for excitation. 
Fluorescence emission was collected at 700 nm and optical imaging results were 
analysed by reporting fluorescence intensity values in normalized counts (NC) 
representing the photon count for unit excitation laser power and unit exposure time, 
allowing comparison among different images. The fluorescence lifetime results were 
obtained by fitting every fluorescence decay curve corresponding to each pixel 
measured by Optix using the Levenberg Marquet least squares method.52 For ex vivo 
imaging, the last in vivo whole body imaging session was followed by euthanasia of 
animals and the explanted organs were collected, washed in PBS and analysed with 
the same Optix system. Following, explanted organs were snap-frozen in isopentane 
and dry ice, and cooled at -80 °C for tissue analysis. 
 
Ex vivo tissue analyses. For fluorescence microscopy, sections of 7 and 12 µm 
thickness were cut from frozen organs with a cryostat at -20 °C. Glass slides were 
kept at 4 °C at dark and Vectashield Mounting Medium with DAPI (Vector 
Laboratories, Burlingame, CA), diluted 1:1 with PBS, was used to stain cell nuclei. 
Fluorescent images were acquired by using an inverted microscope with a CCD 
camera (DVC-1412AM monochrome digital camera QE > 62% at 550 nm) and the 
objectives lens 10X, 40X and 63X (NA 1.63) immersion oil. 
 
Ethical statement. All animal procedures were used to minimize animal pain and 
suffering. All the experimental procedures were performed in strict accordance with 
the recommendations in the Guide for the Care and Use of the Laboratory Animals 
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of the National Institutes of Health and in compliance with the European 
(86/609/EEC) and Italian (D.L.116/92) laws. The protocols for mice 
experimentation were approved by the Institutional Animal Care and Use 
Committee of the Cluster in Biomedicine (CBM) of the Area Science Park of Trieste 
and by the Italian Ministry of Health (DM 17/2001-A dd. 02/02/2011). 
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